drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.71k
| drug2_id
int64 1
1.71k
| drug1_name
stringlengths 4
31
| drug2_name
stringlengths 4
31
| drug1_desc
stringlengths 27
1.09k
⌀ | drug2_desc
stringlengths 27
1.06k
⌀ | label
stringlengths 58
191
| label_idx
int64 0
85
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
2.58k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00212
|
DB00774
| 672 | 1,072 |
Remikiren
|
Hydroflumethiazide
|
Remikiren is an orally active, high specificity renin inhibitor.
|
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
|
Remikiren may increase the hypotensive activities of Hydroflumethiazide.
| 59 |
[
[
[
672,
82,
1072
]
],
[
[
672,
82,
1049
],
[
1049,
82,
1072
]
],
[
[
672,
82,
1066
],
[
1066,
236,
1072
]
],
[
[
672,
82,
1045
],
[
1045,
1,
1072
]
],
[
[
672,
186,
702
],
[
702,
32,
1072
]
],
[
[
672,
249,
615
],
[
615,
32,
1072
]
],
[
[
672,
59,
230
],
[
230,
213,
1072
]
],
[
[
672,
236,
45
],
[
45,
225,
1072
]
],
[
[
672,
249,
438
],
[
438,
225,
1072
]
],
[
[
672,
249,
499
],
[
499,
71,
1072
]
]
] |
[
[
[
"Remikiren",
"{u} may increase the hypotensive activities of {v}",
"Hydroflumethiazide"
]
],
[
[
"Remikiren",
"{u} may increase the hypotensive activities of {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may increase the hypotensive activities of {v}",
"Hydroflumethiazide"
]
],
[
[
"Remikiren",
"{u} may increase the hypotensive activities of {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} may increase the hypotensive activities of {v}",
"Hydroflumethiazide"
]
],
[
[
"Remikiren",
"{u} may increase the hypotensive activities of {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
]
],
[
[
"Remikiren",
"{u} may increase the antihypertensive activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Hydroflumethiazide"
]
],
[
[
"Remikiren",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Hydroflumethiazide"
]
],
[
[
"Remikiren",
"{u} may decrease the antihypertensive activities of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensive activities of {v}",
"Hydroflumethiazide"
]
],
[
[
"Remikiren",
"{u} may increase the hypotensive activities of {v}",
"Mecamylamine"
],
[
"Mecamylamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydroflumethiazide"
]
],
[
[
"Remikiren",
"{u} may increase the serum concentration of {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydroflumethiazide"
]
],
[
[
"Remikiren",
"{u} may increase the serum concentration of {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydroflumethiazide"
]
]
] |
Remikiren may increase the hypotensive activities of Bendroflumethiazide and Bendroflumethiazide may increase the hypotensive activities of Hydroflumethiazide
Remikiren may increase the hypotensive activities of Polythiazide and Polythiazide may increase the hypotensive activities of Hydroflumethiazide
Remikiren may increase the hypotensive activities of Trichlormethiazide and Trichlormethiazide (Compound) resembles Hydroflumethiazide (Compound)
Remikiren may increase the antihypertensive activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Hydroflumethiazide
Remikiren may increase the serum concentration of Sildenafil and Sildenafil may increase the antihypertensive activities of Hydroflumethiazide
Remikiren may decrease the antihypertensive activities of Yohimbine and Yohimbine may decrease the antihypertensive activities of Hydroflumethiazide
Remikiren may increase the hypotensive activities of Mecamylamine and Mecamylamine may increase the severity of adverse effects when combined with Hydroflumethiazide
Remikiren may increase the serum concentration of Imipramine and Imipramine may increase the severity of adverse effects when combined with Hydroflumethiazide
Remikiren may increase the serum concentration of Clomipramine and Clomipramine may increase the severity of adverse effects when combined with Hydroflumethiazide
|
DB01179
|
DB00176
| 321 | 861 |
Podofilox
|
Fluvoxamine
|
A lignan found in podophyllin resin from the roots of podophyllum plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
|
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
|
The metabolism of Fluvoxamine can be decreased when combined with Podofilox.
| 46 |
[
[
[
321,
69,
861
]
],
[
[
321,
6,
4590
],
[
4590,
160,
861
]
],
[
[
321,
18,
6864
],
[
6864,
172,
861
]
],
[
[
321,
21,
28512
],
[
28512,
175,
861
]
],
[
[
321,
69,
55
],
[
55,
69,
861
]
],
[
[
321,
180,
171
],
[
171,
69,
861
]
],
[
[
321,
69,
1086
],
[
1086,
223,
861
]
],
[
[
321,
191,
243
],
[
243,
69,
861
]
],
[
[
321,
95,
1394
],
[
1394,
69,
861
]
],
[
[
321,
225,
292
],
[
292,
69,
861
]
]
] |
[
[
[
"Podofilox",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Podofilox",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fluvoxamine"
]
],
[
[
"Podofilox",
"{u} (Compound) downregulates {v} (Gene)",
"OXA1L"
],
[
"OXA1L",
"{u} (Gene) is downregulated by {v} (Compound)",
"Fluvoxamine"
]
],
[
[
"Podofilox",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fluvoxamine"
]
],
[
[
"Podofilox",
"{u} may decrease the metabolism of {v}",
"Moclobemide"
],
[
"Moclobemide",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Podofilox",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Podofilox",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Podofilox",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Podofilox",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Podofilox",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
]
] |
Podofilox (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fluvoxamine (Compound)
Podofilox (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Fluvoxamine (Compound)
Podofilox (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Fluvoxamine (Compound)
Podofilox may decrease the metabolism of Moclobemide and Moclobemide may decrease the metabolism of Fluvoxamine
Podofilox can increase the metabolism of Pentobarbital and Pentobarbital may decrease the metabolism of Fluvoxamine
Podofilox may decrease the metabolism of Clotrimazole and Clotrimazole may decrease the metabolism of Fluvoxamine
Podofilox may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may decrease the metabolism of Fluvoxamine
Podofilox may increase the serum concentration of Palbociclib and Palbociclib may decrease the metabolism of Fluvoxamine
Podofilox may increase the severity of adverse effects when combined with Paclitaxel and Paclitaxel may decrease the metabolism of Fluvoxamine
|
DB00455
|
DB00907
| 401 | 200 |
Loratadine
|
Cocaine
|
Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
|
An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.
|
The metabolism of Cocaine can be decreased when combined with Loratadine.
| 46 |
[
[
[
401,
69,
200
]
],
[
[
401,
6,
4590
],
[
4590,
160,
200
]
],
[
[
401,
21,
28395
],
[
28395,
175,
200
]
],
[
[
401,
180,
147
],
[
147,
26,
200
]
],
[
[
401,
192,
287
],
[
287,
38,
200
]
],
[
[
401,
38,
702
],
[
702,
192,
200
]
],
[
[
401,
54,
1046
],
[
1046,
208,
200
]
],
[
[
401,
69,
472
],
[
472,
223,
200
]
],
[
[
401,
225,
540
],
[
540,
69,
200
]
],
[
[
401,
69,
499
],
[
499,
69,
200
]
]
] |
[
[
[
"Loratadine",
"{u} may decrease the metabolism of {v}",
"Cocaine"
]
],
[
[
"Loratadine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cocaine"
]
],
[
[
"Loratadine",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cocaine"
]
],
[
[
"Loratadine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Cocaine"
]
],
[
[
"Loratadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Cocaine"
]
],
[
[
"Loratadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Cocaine"
]
],
[
[
"Loratadine",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Cocaine"
]
],
[
[
"Loratadine",
"{u} may decrease the metabolism of {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may decrease the metabolism of {v}",
"Cocaine"
]
],
[
[
"Loratadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
],
[
"Morphine",
"{u} may decrease the metabolism of {v}",
"Cocaine"
]
],
[
[
"Loratadine",
"{u} may decrease the metabolism of {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may decrease the metabolism of {v}",
"Cocaine"
]
]
] |
Loratadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cocaine (Compound)
Loratadine (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Cocaine (Compound)
Loratadine can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Cocaine
Loratadine may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Cocaine
Loratadine may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Cocaine
Loratadine may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Cocaine
Loratadine may decrease the metabolism of Isradipine and Isradipine may decrease the metabolism of Cocaine
Loratadine may increase the severity of adverse effects when combined with Morphine and Morphine may decrease the metabolism of Cocaine
Loratadine may decrease the metabolism of Clomipramine and Clomipramine may decrease the metabolism of Cocaine
|
DB06287
|
DB00912
| 513 | 423 |
Temsirolimus
|
Repaglinide
|
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
|
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia
|
The therapeutic efficacy of Repaglinide can be decreased when used in combination with Temsirolimus.
| 69 |
[
[
[
513,
92,
423
]
],
[
[
513,
6,
4590
],
[
4590,
160,
423
]
],
[
[
513,
7,
3146
],
[
3146,
172,
423
]
],
[
[
513,
21,
28463
],
[
28463,
175,
423
]
],
[
[
513,
251,
177
],
[
177,
26,
423
]
],
[
[
513,
180,
171
],
[
171,
26,
423
]
],
[
[
513,
92,
326
],
[
326,
31,
423
]
],
[
[
513,
92,
947
],
[
947,
185,
423
]
],
[
[
513,
225,
693
],
[
693,
185,
423
]
],
[
[
513,
69,
610
],
[
610,
223,
423
]
]
] |
[
[
[
"Temsirolimus",
"{u} may decrease the therapeutic efficacy of {v}",
"Repaglinide"
]
],
[
[
"Temsirolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Repaglinide"
]
],
[
[
"Temsirolimus",
"{u} (Compound) upregulates {v} (Gene)",
"DNMT3A"
],
[
"DNMT3A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Repaglinide"
]
],
[
[
"Temsirolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Repaglinide"
]
],
[
[
"Temsirolimus",
"{u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Repaglinide"
]
],
[
[
"Temsirolimus",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Repaglinide"
]
],
[
[
"Temsirolimus",
"{u} may decrease the therapeutic efficacy of {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may increase the hypoglycemic activities of {v}",
"Repaglinide"
]
],
[
[
"Temsirolimus",
"{u} may decrease the therapeutic efficacy of {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may increase the hypoglycemic activities of {v}",
"Repaglinide"
]
],
[
[
"Temsirolimus",
"{u} may increase the severity of adverse effects when combined with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} may increase the hypoglycemic activities of {v}",
"Repaglinide"
]
],
[
[
"Temsirolimus",
"{u} may decrease the metabolism of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may decrease the metabolism of {v}",
"Repaglinide"
]
]
] |
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Repaglinide (Compound)
Temsirolimus (Compound) upregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Repaglinide (Compound)
Temsirolimus (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Repaglinide (Compound)
Temsirolimus may decrease the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Repaglinide
Temsirolimus can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Repaglinide
Temsirolimus may decrease the therapeutic efficacy of Glipizide and Glipizide may increase the hypoglycemic activities of Repaglinide
Temsirolimus may decrease the therapeutic efficacy of Acarbose and Acarbose may increase the hypoglycemic activities of Repaglinide
Temsirolimus may increase the severity of adverse effects when combined with Linagliptin and Linagliptin may increase the hypoglycemic activities of Repaglinide
Temsirolimus may decrease the metabolism of Atomoxetine and Atomoxetine may decrease the metabolism of Repaglinide
|
DB09279
|
DB00350
| 1,363 | 1,065 |
Fimasartan
|
Minoxidil
|
Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name _Kanarb_ by Boryung Pharmaceuticals.
|
A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
|
The risk or severity of adverse effects can be increased when Fimasartan is combined with Minoxidil.
| 48 |
[
[
[
1363,
71,
1065
]
],
[
[
1363,
71,
702
],
[
702,
32,
1065
]
],
[
[
1363,
52,
968
],
[
968,
206,
1065
]
],
[
[
1363,
71,
642
],
[
642,
225,
1065
]
],
[
[
1363,
71,
1361
],
[
1361,
71,
1065
]
],
[
[
1363,
225,
531
],
[
531,
71,
1065
]
],
[
[
1363,
90,
306
],
[
306,
225,
1065
]
],
[
[
1363,
95,
198
],
[
198,
71,
1065
]
],
[
[
1363,
236,
171
],
[
171,
82,
1065
]
],
[
[
1363,
71,
56
],
[
56,
82,
1065
]
]
] |
[
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Minoxidil"
]
],
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Minoxidil"
]
],
[
[
"Fimasartan",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Minoxidil"
]
],
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benazepril"
],
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Minoxidil"
]
],
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levosimendan"
],
[
"Levosimendan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Minoxidil"
]
],
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Minoxidil"
]
],
[
[
"Fimasartan",
"{u} may increase the hyperkalemic activities of {v}",
"Aliskiren"
],
[
"Aliskiren",
"{u} may increase the severity of adverse effects when combined with {v}",
"Minoxidil"
]
],
[
[
"Fimasartan",
"{u} may increase the serum concentration of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Minoxidil"
]
],
[
[
"Fimasartan",
"{u} may increase the hypotensive activities of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may increase the hypotensive activities of {v}",
"Minoxidil"
]
],
[
[
"Fimasartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Rasagiline"
],
[
"Rasagiline",
"{u} may increase the hypotensive activities of {v}",
"Minoxidil"
]
]
] |
Fimasartan may increase the severity of adverse effects when combined with Brimonidine and Brimonidine may increase the antihypertensive activities of Minoxidil
Fimasartan may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Minoxidil
Fimasartan may increase the severity of adverse effects when combined with Benazepril and Benazepril may increase the severity of adverse effects when combined with Minoxidil
Fimasartan may increase the severity of adverse effects when combined with Levosimendan and Levosimendan may increase the severity of adverse effects when combined with Minoxidil
Fimasartan may increase the severity of adverse effects when combined with Conivaptan and Conivaptan may increase the severity of adverse effects when combined with Minoxidil
Fimasartan may increase the hyperkalemic activities of Aliskiren and Aliskiren may increase the severity of adverse effects when combined with Minoxidil
Fimasartan may increase the serum concentration of Cyclosporine and Cyclosporine may increase the severity of adverse effects when combined with Minoxidil
Fimasartan may increase the hypotensive activities of Pentobarbital and Pentobarbital may increase the hypotensive activities of Minoxidil
Fimasartan may increase the severity of adverse effects when combined with Rasagiline and Rasagiline may increase the hypotensive activities of Minoxidil
|
DB00498
|
DB00833
| 169 | 829 |
Phenindione
|
Cefaclor
|
An indandione that has been used as an anticoagulant. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)
|
Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.
|
Phenindione may increase the anticoagulant activities of Cefaclor.
| 5 |
[
[
[
169,
28,
829
]
],
[
[
169,
28,
858
],
[
858,
155,
829
]
],
[
[
169,
28,
741
],
[
741,
1,
829
]
],
[
[
169,
285,
384
],
[
384,
28,
829
]
],
[
[
169,
182,
342
],
[
342,
28,
829
]
],
[
[
169,
28,
498
],
[
498,
28,
829
]
],
[
[
169,
28,
858
],
[
858,
155,
866
],
[
866,
155,
829
]
],
[
[
169,
28,
741
],
[
741,
1,
1646
],
[
1646,
1,
829
]
],
[
[
169,
28,
888
],
[
888,
1,
812
],
[
812,
155,
829
]
],
[
[
169,
28,
880
],
[
880,
155,
1646
],
[
1646,
1,
829
]
]
] |
[
[
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Cefaclor"
]
],
[
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Cefonicid"
],
[
"Cefonicid",
"{u} (Compound) resembles {v} (Compound)",
"Cefaclor"
]
],
[
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Cefixime"
],
[
"Cefixime",
"{u} (Compound) resembles {v} (Compound)",
"Cefaclor"
]
],
[
[
"Phenindione",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Cefaclor"
]
],
[
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Cefaclor"
]
],
[
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Cefaclor"
]
],
[
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Cefonicid"
],
[
"Cefonicid",
"{u} (Compound) resembles {v} (Compound)",
"Cefradine"
],
[
"Cefradine",
"{u} (Compound) resembles {v} (Compound)",
"Cefaclor"
]
],
[
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Cefixime"
],
[
"Cefixime",
"{u} (Compound) resembles {v} (Compound)",
"Cefdinir"
],
[
"Cefdinir",
"{u} (Compound) resembles {v} (Compound)",
"Cefaclor"
]
],
[
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Azlocillin"
],
[
"Azlocillin",
"{u} (Compound) resembles {v} (Compound)",
"Oxacillin"
],
[
"Oxacillin",
"{u} (Compound) resembles {v} (Compound)",
"Cefaclor"
]
],
[
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Cefotaxime"
],
[
"Cefotaxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefdinir"
],
[
"Cefdinir",
"{u} (Compound) resembles {v} (Compound)",
"Cefaclor"
]
]
] |
Phenindione may increase the anticoagulant activities of Cefonicid and Cefonicid (Compound) resembles Cefaclor (Compound)
Phenindione may increase the anticoagulant activities of Cefixime and Cefixime (Compound) resembles Cefaclor (Compound)
Phenindione (Compound) resembles Phenprocoumon (Compound) and Phenindione may increase the anticoagulant activities of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Cefaclor
Phenindione may increase the anticoagulant activities of Acenocoumarol and Acenocoumarol may increase the anticoagulant activities of Cefaclor
Phenindione may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Cefaclor
Phenindione may increase the anticoagulant activities of Cefonicid and Cefonicid (Compound) resembles Cefradine (Compound) and Cefradine (Compound) resembles Cefaclor (Compound)
Phenindione may increase the anticoagulant activities of Cefixime and Cefixime (Compound) resembles Cefdinir (Compound) and Cefdinir (Compound) resembles Cefaclor (Compound)
Phenindione may increase the anticoagulant activities of Azlocillin and Azlocillin (Compound) resembles Oxacillin (Compound) and Oxacillin (Compound) resembles Cefaclor (Compound)
Phenindione may increase the anticoagulant activities of Cefotaxime and Cefotaxime (Compound) resembles Cefdinir (Compound) and Cefdinir (Compound) resembles Cefaclor (Compound)
|
DB00573
|
DB00288
| 745 | 114 |
Fenoprofen
|
Amcinonide
|
An anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.
|
Amcinonide is a corticosteroid.
|
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Amcinonide.
| 48 |
[
[
[
745,
71,
114
]
],
[
[
745,
71,
82
],
[
82,
155,
114
]
],
[
[
745,
71,
117
],
[
117,
1,
114
]
],
[
[
745,
21,
28633
],
[
28633,
175,
114
]
],
[
[
745,
182,
219
],
[
219,
28,
114
]
],
[
[
745,
225,
770
],
[
770,
71,
114
]
],
[
[
745,
116,
628
],
[
628,
71,
114
]
],
[
[
745,
71,
826
],
[
826,
71,
114
]
],
[
[
745,
182,
687
],
[
687,
71,
114
]
],
[
[
745,
1,
780
],
[
780,
71,
114
]
]
] |
[
[
[
"Fenoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
],
[
[
"Fenoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
]
],
[
[
"Fenoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Rimexolone"
],
[
"Rimexolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
]
],
[
[
"Fenoprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amcinonide"
]
],
[
[
"Fenoprofen",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Amcinonide"
]
],
[
[
"Fenoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Floctafenine"
],
[
"Floctafenine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
],
[
[
"Fenoprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Suprofen"
],
[
"Suprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
],
[
[
"Fenoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxyphenbutazone"
],
[
"Oxyphenbutazone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
],
[
[
"Fenoprofen",
"{u} may increase the anticoagulant activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
],
[
[
"Fenoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Nepafenac"
],
[
"Nepafenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
]
] |
Fenoprofen may increase the severity of adverse effects when combined with Prednisolone and Prednisolone (Compound) resembles Amcinonide (Compound)
Fenoprofen may increase the severity of adverse effects when combined with Rimexolone and Rimexolone (Compound) resembles Amcinonide (Compound)
Fenoprofen (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Amcinonide (Compound)
Fenoprofen may increase the anticoagulant activities of Warfarin and Warfarin may increase the anticoagulant activities of Amcinonide
Fenoprofen may increase the severity of adverse effects when combined with Floctafenine and Floctafenine may increase the severity of adverse effects when combined with Amcinonide
Fenoprofen (Compound) resembles Suprofen (Compound) and Fenoprofen may increase the severity of adverse effects when combined with Suprofen and Suprofen may increase the severity of adverse effects when combined with Amcinonide
Fenoprofen may increase the severity of adverse effects when combined with Oxyphenbutazone and Oxyphenbutazone may increase the severity of adverse effects when combined with Amcinonide
Fenoprofen may increase the anticoagulant activities of Nafamostat and Nafamostat may increase the severity of adverse effects when combined with Amcinonide
Fenoprofen (Compound) resembles Nepafenac (Compound) and Nepafenac may increase the severity of adverse effects when combined with Amcinonide
|
DB00870
|
DB01208
| 628 | 757 |
Suprofen
|
Sparfloxacin
|
An ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.
|
Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.
|
Suprofen may increase the neuroexcitatory activities of Sparfloxacin.
| 26 |
[
[
[
628,
49,
757
]
],
[
[
628,
49,
863
],
[
863,
1,
757
]
],
[
[
628,
18,
5353
],
[
5353,
172,
757
]
],
[
[
628,
21,
28943
],
[
28943,
175,
757
]
],
[
[
628,
182,
219
],
[
219,
28,
757
]
],
[
[
628,
69,
575
],
[
575,
31,
757
]
],
[
[
628,
95,
1019
],
[
1019,
31,
757
]
],
[
[
628,
225,
487
],
[
487,
49,
757
]
],
[
[
628,
71,
1351
],
[
1351,
49,
757
]
],
[
[
628,
69,
582
],
[
582,
49,
757
]
]
] |
[
[
[
"Suprofen",
"{u} may increase the neuroexcitatory activities of {v}",
"Sparfloxacin"
]
],
[
[
"Suprofen",
"{u} may increase the neuroexcitatory activities of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
]
],
[
[
"Suprofen",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sparfloxacin"
]
],
[
[
"Suprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Photophobia"
],
[
"Photophobia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sparfloxacin"
]
],
[
[
"Suprofen",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Sparfloxacin"
]
],
[
[
"Suprofen",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the hypoglycemic activities of {v}",
"Sparfloxacin"
]
],
[
[
"Suprofen",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the hypoglycemic activities of {v}",
"Sparfloxacin"
]
],
[
[
"Suprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zileuton"
],
[
"Zileuton",
"{u} may increase the neuroexcitatory activities of {v}",
"Sparfloxacin"
]
],
[
[
"Suprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Sparfloxacin"
]
],
[
[
"Suprofen",
"{u} may decrease the metabolism of {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may increase the neuroexcitatory activities of {v}",
"Sparfloxacin"
]
]
] |
Suprofen may increase the neuroexcitatory activities of Gemifloxacin and Gemifloxacin (Compound) resembles Sparfloxacin (Compound)
Suprofen (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Sparfloxacin (Compound)
Suprofen (Compound) causes Photophobia (Side Effect) and Photophobia (Side Effect) is caused by Sparfloxacin (Compound)
Suprofen may increase the anticoagulant activities of Warfarin and Warfarin may increase the anticoagulant activities of Sparfloxacin
Suprofen may decrease the metabolism of Sulfisoxazole and Sulfisoxazole may increase the hypoglycemic activities of Sparfloxacin
Suprofen may increase the serum concentration of Mifepristone and Mifepristone may increase the hypoglycemic activities of Sparfloxacin
Suprofen may increase the severity of adverse effects when combined with Zileuton and Zileuton may increase the neuroexcitatory activities of Sparfloxacin
Suprofen may increase the severity of adverse effects when combined with Acemetacin and Acemetacin may increase the neuroexcitatory activities of Sparfloxacin
Suprofen may decrease the metabolism of Leflunomide and Leflunomide may increase the neuroexcitatory activities of Sparfloxacin
|
DB01215
|
DB00208
| 275 | 613 |
Estazolam
|
Ticlopidine
|
A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
|
Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
|
The metabolism of Ticlopidine can be decreased when combined with Estazolam.
| 46 |
[
[
[
275,
69,
613
]
],
[
[
275,
6,
4590
],
[
4590,
160,
613
]
],
[
[
275,
21,
28521
],
[
28521,
175,
613
]
],
[
[
275,
180,
147
],
[
147,
26,
613
]
],
[
[
275,
95,
764
],
[
764,
182,
613
]
],
[
[
275,
69,
755
],
[
755,
223,
613
]
],
[
[
275,
192,
587
],
[
587,
69,
613
]
],
[
[
275,
225,
464
],
[
464,
69,
613
]
],
[
[
275,
246,
497
],
[
497,
69,
613
]
],
[
[
275,
71,
920
],
[
920,
69,
613
]
]
] |
[
[
[
"Estazolam",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Estazolam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ticlopidine"
]
],
[
[
"Estazolam",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ticlopidine"
]
],
[
[
"Estazolam",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Estazolam",
"{u} may increase the serum concentration of {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may increase the anticoagulant activities of {v}",
"Ticlopidine"
]
],
[
[
"Estazolam",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Estazolam",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Estazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meprobamate"
],
[
"Meprobamate",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Estazolam",
"{u} may decrease the therapeutic efficacy of {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Estazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Remoxipride"
],
[
"Remoxipride",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
]
] |
Estazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticlopidine (Compound)
Estazolam (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Ticlopidine (Compound)
Estazolam can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Ticlopidine
Estazolam may increase the serum concentration of Dasatinib and Dasatinib may increase the anticoagulant activities of Ticlopidine
Estazolam may decrease the metabolism of Doxycycline and Doxycycline may decrease the metabolism of Ticlopidine
Estazolam may increase the central nervous system depressant activities of Ethanol and Ethanol may decrease the metabolism of Ticlopidine
Estazolam may increase the severity of adverse effects when combined with Meprobamate and Meprobamate may decrease the metabolism of Ticlopidine
Estazolam may decrease the therapeutic efficacy of Theophylline and Theophylline may decrease the metabolism of Ticlopidine
Estazolam may increase the severity of adverse effects when combined with Remoxipride and Remoxipride may decrease the metabolism of Ticlopidine
|
DB00872
|
DB00208
| 531 | 613 |
Conivaptan
|
Ticlopidine
|
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
|
Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
|
The serum concentration of Ticlopidine can be increased when it is combined with Conivaptan.
| 72 |
[
[
[
531,
95,
613
]
],
[
[
531,
95,
597
],
[
597,
187,
613
]
],
[
[
531,
6,
4590
],
[
4590,
160,
613
]
],
[
[
531,
21,
28521
],
[
28521,
175,
613
]
],
[
[
531,
95,
147
],
[
147,
26,
613
]
],
[
[
531,
180,
171
],
[
171,
26,
613
]
],
[
[
531,
95,
560
],
[
560,
28,
613
]
],
[
[
531,
69,
755
],
[
755,
223,
613
]
],
[
[
531,
95,
480
],
[
480,
69,
613
]
],
[
[
531,
71,
1366
],
[
1366,
69,
613
]
]
] |
[
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Ticlopidine"
]
],
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Ticlopidine"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ticlopidine"
]
],
[
[
"Conivaptan",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ticlopidine"
]
],
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Conivaptan",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may increase the anticoagulant activities of {v}",
"Ticlopidine"
]
],
[
[
"Conivaptan",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Etizolam"
],
[
"Etizolam",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Conivaptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitric Oxide"
],
[
"Nitric Oxide",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
]
] |
Conivaptan may increase the serum concentration of Clopidogrel and Clopidogrel may reduce the serum concentration of the active metabolites of Ticlopidine
Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticlopidine (Compound)
Conivaptan (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Ticlopidine (Compound)
Conivaptan may increase the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Ticlopidine
Conivaptan can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Ticlopidine
Conivaptan may increase the serum concentration of Rivaroxaban and Rivaroxaban may increase the anticoagulant activities of Ticlopidine
Conivaptan may decrease the metabolism of Doxycycline and Doxycycline may decrease the metabolism of Ticlopidine
Conivaptan may increase the serum concentration of Etizolam and Etizolam may decrease the metabolism of Ticlopidine
Conivaptan may increase the severity of adverse effects when combined with Nitric Oxide and Nitric Oxide may decrease the metabolism of Ticlopidine
|
DB00641
|
DB00353
| 439 | 1,303 |
Simvastatin
|
Methylergometrine
|
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a
|
A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)
|
The serum concentration of Methylergometrine can be increased when it is combined with Simvastatin.
| 72 |
[
[
[
439,
95,
1303
]
],
[
[
439,
95,
376
],
[
376,
1,
1303
]
],
[
[
439,
225,
308
],
[
308,
71,
1303
]
],
[
[
439,
6,
4590
],
[
4590,
160,
1303
]
],
[
[
439,
7,
7956
],
[
7956,
161,
1303
]
],
[
[
439,
18,
7492
],
[
7492,
161,
1303
]
],
[
[
439,
18,
8687
],
[
8687,
172,
1303
]
],
[
[
439,
7,
5785
],
[
5785,
172,
1303
]
],
[
[
439,
21,
28440
],
[
28440,
175,
1303
]
],
[
[
439,
249,
576
],
[
576,
195,
1303
]
]
] |
[
[
[
"Simvastatin",
"{u} may increase the serum concentration of {v}",
"Methylergometrine"
]
],
[
[
"Simvastatin",
"{u} may increase the serum concentration of {v}",
"Ergometrine"
],
[
"Ergometrine",
"{u} (Compound) resembles {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Simvastatin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lisuride"
],
[
"Lisuride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylergometrine"
]
],
[
[
"Simvastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Simvastatin",
"{u} (Compound) upregulates {v} (Gene)",
"EDEM1"
],
[
"EDEM1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Simvastatin",
"{u} (Compound) downregulates {v} (Gene)",
"RRP8"
],
[
"RRP8",
"{u} (Gene) is upregulated by {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Simvastatin",
"{u} (Compound) downregulates {v} (Gene)",
"DNM1L"
],
[
"DNM1L",
"{u} (Gene) is downregulated by {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Simvastatin",
"{u} (Compound) upregulates {v} (Gene)",
"NPC1"
],
[
"NPC1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Simvastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Simvastatin",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may increase the vasoconstricting activities of {v}",
"Methylergometrine"
]
]
] |
Simvastatin may increase the serum concentration of Ergometrine and Ergometrine (Compound) resembles Methylergometrine (Compound)
Simvastatin may increase the severity of adverse effects when combined with Lisuride and Lisuride may increase the severity of adverse effects when combined with Methylergometrine
Simvastatin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methylergometrine (Compound)
Simvastatin (Compound) upregulates EDEM1 (Gene) and EDEM1 (Gene) is upregulated by Methylergometrine (Compound)
Simvastatin (Compound) downregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Methylergometrine (Compound)
Simvastatin (Compound) downregulates DNM1L (Gene) and DNM1L (Gene) is downregulated by Methylergometrine (Compound)
Simvastatin (Compound) upregulates NPC1 (Gene) and NPC1 (Gene) is downregulated by Methylergometrine (Compound)
Simvastatin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Methylergometrine (Compound)
Simvastatin may increase the serum concentration of Metoprolol and Metoprolol may increase the vasoconstricting activities of Methylergometrine
|
DB00312
|
DB09292
| 171 | 1,352 |
Pentobarbital
|
Sacubitril
|
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
|
Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It was approved by the FDA after being given the status of priority review for on July 7, 2015. Sacubitril's active metabolite, LBQ657 inhibits neprilysin, a neutral endopeptidase that would typically cleave natiuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP). ANP and BNP are released under atrial and ventricle stress, which activate downstream receptors leading to vasodilation, natriuresis and diuresis. Under normal conditions, neprilysin breaks down other vasodilating peptides and also v
|
Pentobarbital may increase the hypotensive activities of Sacubitril.
| 59 |
[
[
[
171,
82,
1352
]
],
[
[
171,
71,
968
],
[
968,
206,
1352
]
],
[
[
171,
26,
146
],
[
146,
71,
1352
]
],
[
[
171,
82,
1037
],
[
1037,
225,
1352
]
],
[
[
171,
71,
911
],
[
911,
71,
1352
]
],
[
[
171,
26,
172
],
[
172,
225,
1352
]
],
[
[
171,
97,
955
],
[
955,
225,
1352
]
],
[
[
171,
82,
56
],
[
56,
71,
1352
]
],
[
[
171,
52,
1326
],
[
1326,
225,
1352
]
],
[
[
171,
97,
227
],
[
227,
71,
1352
]
]
] |
[
[
[
"Pentobarbital",
"{u} may increase the hypotensive activities of {v}",
"Sacubitril"
]
],
[
[
"Pentobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Sacubitril"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Barnidipine"
],
[
"Barnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sacubitril"
]
],
[
[
"Pentobarbital",
"{u} may increase the hypotensive activities of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sacubitril"
]
],
[
[
"Pentobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sacubitril"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Tretinoin"
],
[
"Tretinoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sacubitril"
]
],
[
[
"Pentobarbital",
"{u} may decrease the serum concentration of {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sacubitril"
]
],
[
[
"Pentobarbital",
"{u} may increase the hypotensive activities of {v}",
"Rasagiline"
],
[
"Rasagiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sacubitril"
]
],
[
[
"Pentobarbital",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Methyclothiazide"
],
[
"Methyclothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sacubitril"
]
],
[
[
"Pentobarbital",
"{u} may decrease the serum concentration of {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sacubitril"
]
]
] |
Pentobarbital may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the orthostatic hypotensive activities of Sacubitril
Pentobarbital can increase the metabolism of Barnidipine and Barnidipine may increase the severity of adverse effects when combined with Sacubitril
Pentobarbital may increase the hypotensive activities of Betaxolol and Betaxolol may increase the severity of adverse effects when combined with Sacubitril
Pentobarbital may increase the severity of adverse effects when combined with Oxprenolol and Oxprenolol may increase the severity of adverse effects when combined with Sacubitril
Pentobarbital can increase the metabolism of Tretinoin and Tretinoin may increase the severity of adverse effects when combined with Sacubitril
Pentobarbital may decrease the serum concentration of Quetiapine and Quetiapine may increase the severity of adverse effects when combined with Sacubitril
Pentobarbital may increase the hypotensive activities of Rasagiline and Rasagiline may increase the severity of adverse effects when combined with Sacubitril
Pentobarbital may increase the orthostatic hypotensive activities of Methyclothiazide and Methyclothiazide may increase the severity of adverse effects when combined with Sacubitril
Pentobarbital may decrease the serum concentration of Bortezomib and Bortezomib may increase the severity of adverse effects when combined with Sacubitril
|
DB00281
|
DB01156
| 611 | 527 |
Lidocaine
|
Bupropion
|
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
|
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MA
|
The metabolism of Bupropion can be decreased when combined with Lidocaine.
| 46 |
[
[
[
611,
69,
527
]
],
[
[
611,
6,
18777
],
[
18777,
160,
527
]
],
[
[
611,
21,
28402
],
[
28402,
175,
527
]
],
[
[
611,
180,
142
],
[
142,
26,
527
]
],
[
[
611,
192,
1083
],
[
1083,
187,
527
]
],
[
[
611,
71,
224
],
[
224,
69,
527
]
],
[
[
611,
223,
992
],
[
992,
69,
527
]
],
[
[
611,
69,
422
],
[
422,
223,
527
]
],
[
[
611,
192,
491
],
[
491,
69,
527
]
],
[
[
611,
225,
955
],
[
955,
69,
527
]
]
] |
[
[
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Bupropion"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Bupropion"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bupropion"
]
],
[
[
"Lidocaine",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Bupropion"
]
],
[
[
"Lidocaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Bupropion"
]
],
[
[
"Lidocaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may decrease the metabolism of {v}",
"Bupropion"
]
],
[
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may decrease the metabolism of {v}",
"Bupropion"
]
],
[
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may decrease the metabolism of {v}",
"Bupropion"
]
],
[
[
"Lidocaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may decrease the metabolism of {v}",
"Bupropion"
]
],
[
[
"Lidocaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may decrease the metabolism of {v}",
"Bupropion"
]
]
] |
Lidocaine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bupropion (Compound)
Lidocaine (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Bupropion (Compound)
Lidocaine can increase the metabolism of Phenytoin and Phenytoin can increase the metabolism of Bupropion
Lidocaine may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may reduce the serum concentration of the active metabolites of Bupropion
Lidocaine may increase the severity of adverse effects when combined with Amoxapine and Amoxapine may decrease the metabolism of Bupropion
Lidocaine may decrease the metabolism of Olanzapine and Olanzapine may decrease the metabolism of Bupropion
Lidocaine may decrease the metabolism of Midostaurin and Midostaurin may decrease the metabolism of Bupropion
Lidocaine may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may decrease the metabolism of Bupropion
Lidocaine may increase the severity of adverse effects when combined with Quetiapine and Quetiapine may decrease the metabolism of Bupropion
|
DB00842
|
DB00283
| 229 | 41 |
Oxazepam
|
Clemastine
|
Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. It is an active metabolite of both [diazepam] and [temazepam] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions.
|
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
|
The metabolism of Clemastine can be decreased when combined with Oxazepam.
| 46 |
[
[
[
229,
69,
41
]
],
[
[
229,
71,
990
],
[
990,
69,
41
]
],
[
[
229,
6,
4590
],
[
4590,
160,
41
]
],
[
[
229,
21,
28684
],
[
28684,
175,
41
]
],
[
[
229,
71,
63
],
[
63,
178,
41
]
],
[
[
229,
184,
674
],
[
674,
30,
41
]
],
[
[
229,
38,
1264
],
[
1264,
192,
41
]
],
[
[
229,
192,
543
],
[
543,
38,
41
]
],
[
[
229,
54,
471
],
[
471,
208,
41
]
],
[
[
229,
225,
254
],
[
254,
69,
41
]
]
] |
[
[
[
"Oxazepam",
"{u} may decrease the metabolism of {v}",
"Clemastine"
]
],
[
[
"Oxazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mesoridazine"
],
[
"Mesoridazine",
"{u} may decrease the metabolism of {v}",
"Clemastine"
]
],
[
[
"Oxazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clemastine"
]
],
[
[
"Oxazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Euphoric mood"
],
[
"Euphoric mood",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clemastine"
]
],
[
[
"Oxazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may increase the anticholinergic activities of {v}",
"Clemastine"
]
],
[
[
"Oxazepam",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Clemastine"
]
],
[
[
"Oxazepam",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Clemastine"
]
],
[
[
"Oxazepam",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Clemastine"
]
],
[
[
"Oxazepam",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Clemastine"
]
],
[
[
"Oxazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Buspirone"
],
[
"Buspirone",
"{u} may decrease the metabolism of {v}",
"Clemastine"
]
]
] |
Oxazepam may increase the severity of adverse effects when combined with Mesoridazine and Mesoridazine may decrease the metabolism of Clemastine
Oxazepam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clemastine (Compound)
Oxazepam (Compound) causes Euphoric mood (Side Effect) and Euphoric mood (Side Effect) is caused by Clemastine (Compound)
Oxazepam may increase the severity of adverse effects when combined with Tranylcypromine and Tranylcypromine may increase the anticholinergic activities of Clemastine
Oxazepam can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Clemastine
Oxazepam may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Clemastine
Oxazepam may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Clemastine
Oxazepam may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Clemastine
Oxazepam may increase the severity of adverse effects when combined with Buspirone and Buspirone may decrease the metabolism of Clemastine
|
DB00679
|
DB09065
| 653 | 1,095 |
Thioridazine
|
Cobicistat
|
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
|
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
|
The serum concentration of Cobicistat can be increased when it is combined with Thioridazine.
| 72 |
[
[
[
653,
95,
1095
]
],
[
[
653,
95,
795
],
[
795,
187,
1095
]
],
[
[
653,
209,
589
],
[
589,
69,
1095
]
],
[
[
653,
225,
312
],
[
312,
69,
1095
]
],
[
[
653,
71,
442
],
[
442,
69,
1095
]
],
[
[
653,
95,
385
],
[
385,
69,
1095
]
],
[
[
653,
38,
1257
],
[
1257,
69,
1095
]
],
[
[
653,
42,
143
],
[
143,
69,
1095
]
],
[
[
653,
69,
566
],
[
566,
69,
1095
]
],
[
[
653,
192,
587
],
[
587,
69,
1095
]
]
] |
[
[
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Cobicistat"
]
],
[
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Cobicistat"
]
],
[
[
"Thioridazine",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may decrease the metabolism of {v}",
"Cobicistat"
]
],
[
[
"Thioridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Temazepam"
],
[
"Temazepam",
"{u} may decrease the metabolism of {v}",
"Cobicistat"
]
],
[
[
"Thioridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrazepam"
],
[
"Nitrazepam",
"{u} may decrease the metabolism of {v}",
"Cobicistat"
]
],
[
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Amlodipine"
],
[
"Amlodipine",
"{u} may decrease the metabolism of {v}",
"Cobicistat"
]
],
[
[
"Thioridazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may decrease the metabolism of {v}",
"Cobicistat"
]
],
[
[
"Thioridazine",
"{u} may increase the QTc prolonging activities of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may decrease the metabolism of {v}",
"Cobicistat"
]
],
[
[
"Thioridazine",
"{u} may decrease the metabolism of {v}",
"Gemfibrozil"
],
[
"Gemfibrozil",
"{u} may decrease the metabolism of {v}",
"Cobicistat"
]
],
[
[
"Thioridazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may decrease the metabolism of {v}",
"Cobicistat"
]
]
] |
Thioridazine may increase the serum concentration of Ticagrelor and Ticagrelor may reduce the serum concentration of the active metabolites of Cobicistat
Thioridazine may increase the severity of QTc prolonging effects when combined with Disopyramide and Disopyramide may decrease the metabolism of Cobicistat
Thioridazine may increase the severity of adverse effects when combined with Temazepam and Temazepam may decrease the metabolism of Cobicistat
Thioridazine may increase the severity of adverse effects when combined with Nitrazepam and Nitrazepam may decrease the metabolism of Cobicistat
Thioridazine may increase the serum concentration of Amlodipine and Amlodipine may decrease the metabolism of Cobicistat
Thioridazine may increase the central nervous system depressant activities of Perampanel and Perampanel may decrease the metabolism of Cobicistat
Thioridazine may increase the QTc prolonging activities of Erythromycin and Erythromycin may decrease the metabolism of Cobicistat
Thioridazine may decrease the metabolism of Gemfibrozil and Gemfibrozil may decrease the metabolism of Cobicistat
Thioridazine may increase the central nervous system depressant activities of Ethanol and Ethanol may decrease the metabolism of Cobicistat
|
DB06212
|
DB00976
| 1,437 | 528 |
Tolvaptan
|
Telithromycin
|
Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
|
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
|
The serum concentration of Telithromycin can be increased when it is combined with Tolvaptan.
| 72 |
[
[
[
1437,
95,
528
]
],
[
[
1437,
95,
1088
],
[
1088,
42,
528
]
],
[
[
1437,
6,
4590
],
[
4590,
160,
528
]
],
[
[
1437,
21,
28375
],
[
28375,
175,
528
]
],
[
[
1437,
251,
173
],
[
173,
26,
528
]
],
[
[
1437,
95,
680
],
[
680,
187,
528
]
],
[
[
1437,
95,
575
],
[
575,
196,
528
]
],
[
[
1437,
244,
650
],
[
650,
196,
528
]
],
[
[
1437,
95,
648
],
[
648,
69,
528
]
],
[
[
1437,
225,
289
],
[
289,
69,
528
]
]
] |
[
[
[
"Tolvaptan",
"{u} may increase the serum concentration of {v}",
"Telithromycin"
]
],
[
[
"Tolvaptan",
"{u} may increase the serum concentration of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Tolvaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Tolvaptan",
"{u} (Compound) causes {v} (Side Effect)",
"Urine output increased"
],
[
"Urine output increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Tolvaptan",
"{u} may decrease the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Tolvaptan",
"{u} may increase the serum concentration of {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Telithromycin"
]
],
[
[
"Tolvaptan",
"{u} may increase the serum concentration of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Tolvaptan",
"{u} may increase the hyperkalemic activities of {v}",
"Moexipril"
],
[
"Moexipril",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Tolvaptan",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Tolvaptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may decrease the metabolism of {v}",
"Telithromycin"
]
]
] |
Tolvaptan may increase the serum concentration of Clarithromycin and Clarithromycin may increase the QTc prolonging activities of Telithromycin
Tolvaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Telithromycin (Compound)
Tolvaptan (Compound) causes Urine output increased (Side Effect) and Urine output increased (Side Effect) is caused by Telithromycin (Compound)
Tolvaptan may decrease the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Telithromycin
Tolvaptan may increase the serum concentration of Ifosfamide and Ifosfamide may reduce the serum concentration of the active metabolites of Telithromycin
Tolvaptan may increase the serum concentration of Sulfisoxazole and Sulfisoxazole may increase the QTc prolonging activities of Telithromycin
Tolvaptan may increase the hyperkalemic activities of Moexipril and Moexipril may increase the QTc prolonging activities of Telithromycin
Tolvaptan may increase the serum concentration of Nefazodone and Nefazodone may decrease the metabolism of Telithromycin
Tolvaptan may increase the severity of adverse effects when combined with Levacetylmethadol and Levacetylmethadol may decrease the metabolism of Telithromycin
|
DB01426
|
DB00608
| 1,328 | 588 |
Ajmaline
|
Chloroquine
|
An alkaloid found in the root of Rauwolfia serpentina, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials. Ajmaline produces potent sodium channel blocking effects and a very short half-life which makes it a very useful drug for acute intravenous treatments. The drug has been very popular in some countries for the treatment of atrial fibrillation in patients with the Wolff–Parkinson–White syndrome and in well tolerated monomorphic ventricular tachycardias. It has also been used for many years as a drug to challenge the conduction system of the heart in cases of bundle branch block and syncope. In these cases, abnormal prolongation of the HV interval has been taken as a proof for infrahisian conduction defects tributary for permanent pacemaker implantation.
|
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine]. Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis. **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.** Chloroquine was granted FDA Approval on 31 October 1949.
|
The metabolism of Chloroquine can be decreased when combined with Ajmaline.
| 46 |
[
[
[
1328,
69,
588
]
],
[
[
1328,
6,
18777
],
[
18777,
160,
588
]
],
[
[
1328,
69,
173
],
[
173,
26,
588
]
],
[
[
1328,
69,
681
],
[
681,
196,
588
]
],
[
[
1328,
69,
539
],
[
539,
209,
588
]
],
[
[
1328,
69,
396
],
[
396,
223,
588
]
],
[
[
1328,
69,
381
],
[
381,
69,
588
]
],
[
[
1328,
104,
1318
],
[
1318,
249,
588
]
],
[
[
1328,
69,
1269
],
[
1269,
249,
588
]
],
[
[
1328,
249,
653
],
[
653,
95,
588
]
]
] |
[
[
[
"Ajmaline",
"{u} may decrease the metabolism of {v}",
"Chloroquine"
]
],
[
[
"Ajmaline",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Chloroquine"
]
],
[
[
"Ajmaline",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Chloroquine"
]
],
[
[
"Ajmaline",
"{u} may decrease the metabolism of {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may increase the QTc prolonging activities of {v}",
"Chloroquine"
]
],
[
[
"Ajmaline",
"{u} may decrease the metabolism of {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Chloroquine"
]
],
[
[
"Ajmaline",
"{u} may decrease the metabolism of {v}",
"Terbinafine"
],
[
"Terbinafine",
"{u} may decrease the metabolism of {v}",
"Chloroquine"
]
],
[
[
"Ajmaline",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may decrease the metabolism of {v}",
"Chloroquine"
]
],
[
[
"Ajmaline",
"{u} may increase the arrhythmogenic activities of {v}",
"Propafenone"
],
[
"Propafenone",
"{u} may increase the serum concentration of {v}",
"Chloroquine"
]
],
[
[
"Ajmaline",
"{u} may decrease the metabolism of {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may increase the serum concentration of {v}",
"Chloroquine"
]
],
[
[
"Ajmaline",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Chloroquine"
]
]
] |
Ajmaline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Chloroquine (Compound)
Ajmaline may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Chloroquine
Ajmaline may decrease the metabolism of Clozapine and Clozapine may increase the QTc prolonging activities of Chloroquine
Ajmaline may decrease the metabolism of Artemether and Artemether may increase the severity of QTc prolonging effects when combined with Chloroquine
Ajmaline may decrease the metabolism of Terbinafine and Terbinafine may decrease the metabolism of Chloroquine
Ajmaline may decrease the metabolism of Rucaparib and Rucaparib may decrease the metabolism of Chloroquine
Ajmaline may increase the arrhythmogenic activities of Propafenone and Propafenone may increase the serum concentration of Chloroquine
Ajmaline may decrease the metabolism of Stiripentol and Stiripentol may increase the serum concentration of Chloroquine
Ajmaline may increase the serum concentration of Thioridazine and Thioridazine may increase the serum concentration of Chloroquine
|
DB01418
|
DB13873
| 342 | 841 |
Acenocoumarol
|
Fenofibric acid
|
Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation. Hematocrit, hemoglobin, international normalized ratio and liver panel should be monitored. Patients on acenocoumarol are prohibited from giving blood.
|
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed for improved solubility, gastrointestinal absorption, and bioavailability, and more convenient administration.[A32038,A193362]
|
Acenocoumarol may increase the anticoagulant activities of Fenofibric acid.
| 5 |
[
[
[
342,
28,
841
]
],
[
[
342,
131,
498
],
[
498,
28,
841
]
],
[
[
342,
155,
219
],
[
219,
28,
841
]
],
[
[
342,
28,
169
],
[
169,
28,
841
]
],
[
[
342,
28,
526
],
[
526,
31,
841
]
],
[
[
342,
69,
297
],
[
297,
31,
841
]
],
[
[
342,
69,
198
],
[
198,
233,
841
]
],
[
[
342,
131,
498
],
[
498,
285,
219
],
[
219,
28,
841
]
],
[
[
342,
155,
219
],
[
219,
131,
498
],
[
498,
28,
841
]
],
[
[
342,
28,
169
],
[
169,
28,
498
],
[
498,
28,
841
]
]
] |
[
[
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Fenofibric acid"
]
],
[
[
"Acenocoumarol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Fenofibric acid"
]
],
[
[
"Acenocoumarol",
"{u} (Compound) resembles {v} (Compound)",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Fenofibric acid"
]
],
[
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Fenofibric acid"
]
],
[
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Glyburide"
],
[
"Glyburide",
"{u} may increase the hypoglycemic activities of {v}",
"Fenofibric acid"
]
],
[
[
"Acenocoumarol",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Fenofibric acid"
]
],
[
[
"Acenocoumarol",
"{u} may decrease the metabolism of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the nephrotoxic activities of {v}",
"Fenofibric acid"
]
],
[
[
"Acenocoumarol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Fenofibric acid"
]
],
[
[
"Acenocoumarol",
"{u} (Compound) resembles {v} (Compound)",
"Warfarin"
],
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Fenofibric acid"
]
],
[
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Fenofibric acid"
]
]
] |
Acenocoumarol (Compound) resembles Dicoumarol (Compound) and Acenocoumarol may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Fenofibric acid
Acenocoumarol (Compound) resembles Warfarin (Compound) and Warfarin may increase the anticoagulant activities of Fenofibric acid
Acenocoumarol may increase the anticoagulant activities of Phenindione and Phenindione may increase the anticoagulant activities of Fenofibric acid
Acenocoumarol may increase the anticoagulant activities of Glyburide and Glyburide may increase the hypoglycemic activities of Fenofibric acid
Acenocoumarol may decrease the metabolism of Tolbutamide and Tolbutamide may increase the hypoglycemic activities of Fenofibric acid
Acenocoumarol may decrease the metabolism of Cyclosporine and Cyclosporine may increase the nephrotoxic activities of Fenofibric acid
Acenocoumarol (Compound) resembles Dicoumarol (Compound) and Acenocoumarol may increase the anticoagulant activities of Dicoumarol and Dicoumarol (Compound) resembles Warfarin (Compound) and Dicoumarol may increase the anticoagulant activities of Warfarin and Warfarin may increase the anticoagulant activities of Fenofibric acid
Acenocoumarol (Compound) resembles Warfarin (Compound) and Warfarin (Compound) resembles Dicoumarol (Compound) and Warfarin may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Fenofibric acid
Acenocoumarol may increase the anticoagulant activities of Phenindione and Phenindione may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Fenofibric acid
|
DB00212
|
DB00275
| 672 | 1,054 |
Remikiren
|
Olmesartan
|
Remikiren is an orally active, high specificity renin inhibitor.
|
Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS
|
Remikiren may increase the hypotensive activities of Olmesartan.
| 59 |
[
[
[
672,
82,
1054
]
],
[
[
672,
82,
1071
],
[
1071,
225,
1054
]
],
[
[
672,
82,
567
],
[
567,
155,
1054
]
],
[
[
672,
236,
239
],
[
239,
71,
1054
]
],
[
[
672,
186,
1040
],
[
1040,
32,
1054
]
],
[
[
672,
249,
615
],
[
615,
32,
1054
]
],
[
[
672,
59,
230
],
[
230,
213,
1054
]
],
[
[
672,
236,
678
],
[
678,
225,
1054
]
],
[
[
672,
223,
461
],
[
461,
225,
1054
]
],
[
[
672,
249,
438
],
[
438,
71,
1054
]
]
] |
[
[
[
"Remikiren",
"{u} may increase the hypotensive activities of {v}",
"Olmesartan"
]
],
[
[
"Remikiren",
"{u} may increase the hypotensive activities of {v}",
"Telmisartan"
],
[
"Telmisartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Remikiren",
"{u} may increase the hypotensive activities of {v}",
"Losartan"
],
[
"Losartan",
"{u} (Compound) resembles {v} (Compound)",
"Olmesartan"
]
],
[
[
"Remikiren",
"{u} may increase the hypotensive activities of {v}",
"Valsartan"
],
[
"Valsartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Remikiren",
"{u} may increase the antihypertensive activities of {v}",
"Tadalafil"
],
[
"Tadalafil",
"{u} may increase the antihypertensive activities of {v}",
"Olmesartan"
]
],
[
[
"Remikiren",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Olmesartan"
]
],
[
[
"Remikiren",
"{u} may decrease the antihypertensive activities of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensive activities of {v}",
"Olmesartan"
]
],
[
[
"Remikiren",
"{u} may increase the hypotensive activities of {v}",
"Doxazosin"
],
[
"Doxazosin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Remikiren",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Remikiren",
"{u} may increase the serum concentration of {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
]
] |
Remikiren may increase the hypotensive activities of Telmisartan and Telmisartan may increase the severity of adverse effects when combined with Olmesartan
Remikiren may increase the hypotensive activities of Losartan and Losartan (Compound) resembles Olmesartan (Compound)
Remikiren may increase the hypotensive activities of Valsartan and Valsartan may increase the severity of adverse effects when combined with Olmesartan
Remikiren may increase the antihypertensive activities of Tadalafil and Tadalafil may increase the antihypertensive activities of Olmesartan
Remikiren may increase the serum concentration of Sildenafil and Sildenafil may increase the antihypertensive activities of Olmesartan
Remikiren may decrease the antihypertensive activities of Yohimbine and Yohimbine may decrease the antihypertensive activities of Olmesartan
Remikiren may increase the hypotensive activities of Doxazosin and Doxazosin may increase the severity of adverse effects when combined with Olmesartan
Remikiren may decrease the metabolism of Diltiazem and Diltiazem may increase the severity of adverse effects when combined with Olmesartan
Remikiren may increase the serum concentration of Imipramine and Imipramine may increase the severity of adverse effects when combined with Olmesartan
|
DB01218
|
DB08933
| 272 | 1,114 |
Halofantrine
|
Luliconazole
|
Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
|
Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
|
The serum concentration of Luliconazole can be increased when it is combined with Halofantrine.
| 72 |
[
[
[
272,
95,
1114
]
],
[
[
272,
6,
4590
],
[
4590,
160,
1114
]
],
[
[
272,
95,
1113
],
[
1113,
95,
1114
]
],
[
[
272,
69,
422
],
[
422,
95,
1114
]
],
[
[
272,
180,
147
],
[
147,
95,
1114
]
],
[
[
272,
225,
640
],
[
640,
95,
1114
]
],
[
[
272,
249,
270
],
[
270,
95,
1114
]
],
[
[
272,
251,
225
],
[
225,
95,
1114
]
],
[
[
272,
55,
539
],
[
539,
95,
1114
]
],
[
[
272,
99,
35
],
[
35,
95,
1114
]
]
] |
[
[
[
"Halofantrine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Halofantrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Luliconazole"
]
],
[
[
"Halofantrine",
"{u} may increase the serum concentration of {v}",
"Boceprevir"
],
[
"Boceprevir",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Halofantrine",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Halofantrine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Halofantrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Halofantrine",
"{u} may increase the serum concentration of {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Halofantrine",
"{u} may decrease the serum concentration of {v}",
"Bosentan"
],
[
"Bosentan",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Halofantrine",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Halofantrine",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Fesoterodine"
],
[
"Fesoterodine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
]
] |
Halofantrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Luliconazole (Compound)
Halofantrine may increase the serum concentration of Boceprevir and Boceprevir may increase the serum concentration of Luliconazole
Halofantrine may decrease the metabolism of Midostaurin and Midostaurin may increase the serum concentration of Luliconazole
Halofantrine can increase the metabolism of Rifampicin and Rifampicin may increase the serum concentration of Luliconazole
Halofantrine may increase the severity of adverse effects when combined with Quinine and Quinine may increase the serum concentration of Luliconazole
Halofantrine may increase the serum concentration of Prochlorperazine and Prochlorperazine may increase the serum concentration of Luliconazole
Halofantrine may decrease the serum concentration of Bosentan and Bosentan may increase the serum concentration of Luliconazole
Halofantrine may increase the severity of QTc prolonging effects when combined with Artemether and Artemether may increase the serum concentration of Luliconazole
Halofantrine may increase the serum concentration of the active metabolites of Fesoterodine and Fesoterodine may increase the serum concentration of Luliconazole
|
DB00980
|
DB00208
| 250 | 613 |
Ramelteon
|
Ticlopidine
|
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
|
Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
|
The metabolism of Ticlopidine can be decreased when combined with Ramelteon.
| 46 |
[
[
[
250,
69,
613
]
],
[
[
250,
6,
12128
],
[
12128,
160,
613
]
],
[
[
250,
21,
28440
],
[
28440,
175,
613
]
],
[
[
250,
180,
147
],
[
147,
26,
613
]
],
[
[
250,
95,
764
],
[
764,
182,
613
]
],
[
[
250,
69,
755
],
[
755,
223,
613
]
],
[
[
250,
225,
480
],
[
480,
69,
613
]
],
[
[
250,
95,
233
],
[
233,
69,
613
]
],
[
[
250,
69,
497
],
[
497,
69,
613
]
],
[
[
250,
71,
968
],
[
968,
69,
613
]
]
] |
[
[
[
"Ramelteon",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Ramelteon",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Ticlopidine"
]
],
[
[
"Ramelteon",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ticlopidine"
]
],
[
[
"Ramelteon",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Ramelteon",
"{u} may increase the serum concentration of {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may increase the anticoagulant activities of {v}",
"Ticlopidine"
]
],
[
[
"Ramelteon",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Ramelteon",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etizolam"
],
[
"Etizolam",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Ramelteon",
"{u} may increase the serum concentration of {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Ramelteon",
"{u} may decrease the metabolism of {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Ramelteon",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
]
] |
Ramelteon (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ticlopidine (Compound)
Ramelteon (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Ticlopidine (Compound)
Ramelteon can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Ticlopidine
Ramelteon may increase the serum concentration of Dasatinib and Dasatinib may increase the anticoagulant activities of Ticlopidine
Ramelteon may decrease the metabolism of Doxycycline and Doxycycline may decrease the metabolism of Ticlopidine
Ramelteon may increase the severity of adverse effects when combined with Etizolam and Etizolam may decrease the metabolism of Ticlopidine
Ramelteon may increase the serum concentration of Fluorouracil and Fluorouracil may decrease the metabolism of Ticlopidine
Ramelteon may decrease the metabolism of Theophylline and Theophylline may decrease the metabolism of Ticlopidine
Ramelteon may increase the severity of adverse effects when combined with Levodopa and Levodopa may decrease the metabolism of Ticlopidine
|
DB00409
|
DB00588
| 920 | 84 |
Remoxipride
|
Fluticasone propionate
|
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
|
Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990.
|
The risk or severity of adverse effects can be increased when Remoxipride is combined with Fluticasone propionate.
| 48 |
[
[
[
920,
71,
84
]
],
[
[
920,
7,
4471
],
[
4471,
161,
84
]
],
[
[
920,
69,
173
],
[
173,
26,
84
]
],
[
[
920,
71,
161
],
[
161,
26,
84
]
],
[
[
920,
225,
156
],
[
156,
26,
84
]
],
[
[
920,
184,
674
],
[
674,
30,
84
]
],
[
[
920,
38,
1257
],
[
1257,
192,
84
]
],
[
[
920,
192,
491
],
[
491,
38,
84
]
],
[
[
920,
54,
1365
],
[
1365,
208,
84
]
],
[
[
920,
225,
530
],
[
530,
223,
84
]
]
] |
[
[
[
"Remoxipride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluticasone propionate"
]
],
[
[
"Remoxipride",
"{u} (Compound) upregulates {v} (Gene)",
"RGS2"
],
[
"RGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Fluticasone propionate"
]
],
[
[
"Remoxipride",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Fluticasone propionate"
]
],
[
[
"Remoxipride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Fluticasone propionate"
]
],
[
[
"Remoxipride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Fluticasone propionate"
]
],
[
[
"Remoxipride",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Fluticasone propionate"
]
],
[
[
"Remoxipride",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluticasone propionate"
]
],
[
[
"Remoxipride",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluticasone propionate"
]
],
[
[
"Remoxipride",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Fluticasone propionate"
]
],
[
[
"Remoxipride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may decrease the metabolism of {v}",
"Fluticasone propionate"
]
]
] |
Remoxipride (Compound) upregulates RGS2 (Gene) and RGS2 (Gene) is upregulated by Fluticasone propionate (Compound)
Remoxipride may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Fluticasone propionate
Remoxipride may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Fluticasone propionate
Remoxipride may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Fluticasone propionate
Remoxipride can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Fluticasone propionate
Remoxipride may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Fluticasone propionate
Remoxipride may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Fluticasone propionate
Remoxipride may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Fluticasone propionate
Remoxipride may increase the severity of adverse effects when combined with Dihydroergotamine and Dihydroergotamine may decrease the metabolism of Fluticasone propionate
|
DB01626
|
DB00571
| 75 | 504 |
Pargyline
|
Propranolol
|
Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
|
Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.
|
Pargyline may increase the hypotensive activities of Propranolol.
| 59 |
[
[
[
75,
82,
504
]
],
[
[
75,
82,
576
],
[
576,
95,
504
]
],
[
[
75,
82,
1026
],
[
1026,
155,
504
]
],
[
[
75,
82,
1037
],
[
1037,
71,
504
]
],
[
[
75,
225,
156
],
[
156,
26,
504
]
],
[
[
75,
185,
473
],
[
473,
31,
504
]
],
[
[
75,
186,
615
],
[
615,
32,
504
]
],
[
[
75,
247,
1344
],
[
1344,
47,
504
]
],
[
[
75,
82,
1053
],
[
1053,
47,
504
]
],
[
[
75,
223,
369
],
[
369,
47,
504
]
]
] |
[
[
[
"Pargyline",
"{u} may increase the hypotensive activities of {v}",
"Propranolol"
]
],
[
[
"Pargyline",
"{u} may increase the hypotensive activities of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may increase the serum concentration of {v}",
"Propranolol"
]
],
[
[
"Pargyline",
"{u} may increase the hypotensive activities of {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Propranolol"
]
],
[
[
"Pargyline",
"{u} may increase the hypotensive activities of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
]
],
[
[
"Pargyline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Propranolol"
]
],
[
[
"Pargyline",
"{u} may increase the hypoglycemic activities of {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may increase the hypoglycemic activities of {v}",
"Propranolol"
]
],
[
[
"Pargyline",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Propranolol"
]
],
[
[
"Pargyline",
"{u} may increase the hypertensive activities of {v}",
"Levonordefrin"
],
[
"Levonordefrin",
"{u} may increase the atrioventricular blocking activities of {v}",
"Propranolol"
]
],
[
[
"Pargyline",
"{u} may increase the hypotensive activities of {v}",
"Moxonidine"
],
[
"Moxonidine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Propranolol"
]
],
[
[
"Pargyline",
"{u} may decrease the metabolism of {v}",
"Pergolide"
],
[
"Pergolide",
"{u} may increase the atrioventricular blocking activities of {v}",
"Propranolol"
]
]
] |
Pargyline may increase the hypotensive activities of Metoprolol and Metoprolol may increase the serum concentration of Propranolol
Pargyline may increase the hypotensive activities of Acebutolol and Acebutolol (Compound) resembles Propranolol (Compound)
Pargyline may increase the hypotensive activities of Betaxolol and Betaxolol may increase the severity of adverse effects when combined with Propranolol
Pargyline may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Propranolol
Pargyline may increase the hypoglycemic activities of Glimepiride and Glimepiride may increase the hypoglycemic activities of Propranolol
Pargyline may increase the antihypertensive activities of Sildenafil and Sildenafil may increase the antihypertensive activities of Propranolol
Pargyline may increase the hypertensive activities of Levonordefrin and Levonordefrin may increase the atrioventricular blocking activities of Propranolol
Pargyline may increase the hypotensive activities of Moxonidine and Moxonidine may increase the atrioventricular blocking activities of Propranolol
Pargyline may decrease the metabolism of Pergolide and Pergolide may increase the atrioventricular blocking activities of Propranolol
|
DB06772
|
DB01092
| 152 | 1,348 |
Cabazitaxel
|
Ouabain
|
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
|
A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase.
|
Cabazitaxel may decrease the cardiotoxic activities of Ouabain.
| 57 |
[
[
[
152,
80,
1348
]
],
[
[
152,
80,
232
],
[
232,
155,
1348
]
],
[
[
152,
80,
1347
],
[
1347,
1,
1348
]
],
[
[
152,
6,
18803
],
[
18803,
160,
1348
]
],
[
[
152,
6,
4070
],
[
4070,
172,
1348
]
],
[
[
152,
69,
461
],
[
461,
47,
1348
]
],
[
[
152,
71,
1213
],
[
1213,
80,
1348
]
],
[
[
152,
251,
1080
],
[
1080,
80,
1348
]
],
[
[
152,
225,
357
],
[
357,
80,
1348
]
],
[
[
152,
191,
243
],
[
243,
80,
1348
]
]
] |
[
[
[
"Cabazitaxel",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
],
[
[
"Cabazitaxel",
"{u} may decrease the cardiotoxic activities of {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Ouabain"
]
],
[
[
"Cabazitaxel",
"{u} may decrease the cardiotoxic activities of {v}",
"Acetyldigitoxin"
],
[
"Acetyldigitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Ouabain"
]
],
[
[
"Cabazitaxel",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound)",
"Ouabain"
]
],
[
[
"Cabazitaxel",
"{u} (Compound) binds {v} (Gene)",
"TUBB6"
],
[
"TUBB6",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ouabain"
]
],
[
[
"Cabazitaxel",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the atrioventricular blocking activities of {v}",
"Ouabain"
]
],
[
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
],
[
[
"Cabazitaxel",
"{u} may decrease the serum concentration of {v}",
"Mitotane"
],
[
"Mitotane",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
],
[
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Docetaxel"
],
[
"Docetaxel",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
],
[
[
"Cabazitaxel",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
]
] |
Cabazitaxel may decrease the cardiotoxic activities of Digitoxin and Digitoxin (Compound) resembles Ouabain (Compound)
Cabazitaxel may decrease the cardiotoxic activities of Acetyldigitoxin and Acetyldigitoxin (Compound) resembles Ouabain (Compound)
Cabazitaxel (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Ouabain (Compound)
Cabazitaxel (Compound) binds TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Ouabain (Compound)
Cabazitaxel may decrease the metabolism of Diltiazem and Diltiazem may increase the atrioventricular blocking activities of Ouabain
Cabazitaxel may increase the severity of adverse effects when combined with Fludarabine and Fludarabine may decrease the cardiotoxic activities of Ouabain
Cabazitaxel may decrease the serum concentration of Mitotane and Mitotane may decrease the cardiotoxic activities of Ouabain
Cabazitaxel may increase the severity of adverse effects when combined with Docetaxel and Docetaxel may decrease the cardiotoxic activities of Ouabain
Cabazitaxel may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may decrease the cardiotoxic activities of Ouabain
|
DB00323
|
DB00715
| 975 | 878 |
Tolcapone
|
Paroxetine
|
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
|
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
|
The risk or severity of adverse effects can be increased when Tolcapone is combined with Paroxetine.
| 48 |
[
[
[
975,
71,
878
]
],
[
[
975,
6,
7128
],
[
7128,
160,
878
]
],
[
[
975,
21,
29114
],
[
29114,
175,
878
]
],
[
[
975,
71,
953
],
[
953,
31,
878
]
],
[
[
975,
71,
556
],
[
556,
42,
878
]
],
[
[
975,
225,
1208
],
[
1208,
42,
878
]
],
[
[
975,
225,
280
],
[
280,
69,
878
]
],
[
[
975,
71,
504
],
[
504,
69,
878
]
],
[
[
975,
192,
287
],
[
287,
69,
878
]
],
[
[
975,
71,
1269
],
[
1269,
223,
878
]
]
] |
[
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paroxetine"
]
],
[
[
"Tolcapone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Paroxetine"
]
],
[
[
"Tolcapone",
"{u} (Compound) causes {v} (Side Effect)",
"Pulmonary embolism"
],
[
"Pulmonary embolism",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paroxetine"
]
],
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may increase the hypoglycemic activities of {v}",
"Paroxetine"
]
],
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may increase the QTc prolonging activities of {v}",
"Paroxetine"
]
],
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may increase the QTc prolonging activities of {v}",
"Paroxetine"
]
],
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propofol"
],
[
"Propofol",
"{u} may decrease the metabolism of {v}",
"Paroxetine"
]
],
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may decrease the metabolism of {v}",
"Paroxetine"
]
],
[
[
"Tolcapone",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may decrease the metabolism of {v}",
"Paroxetine"
]
],
[
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may decrease the metabolism of {v}",
"Paroxetine"
]
]
] |
Tolcapone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Paroxetine (Compound)
Tolcapone (Compound) causes Pulmonary embolism (Side Effect) and Pulmonary embolism (Side Effect) is caused by Paroxetine (Compound)
Tolcapone may increase the severity of adverse effects when combined with Empagliflozin and Empagliflozin may increase the hypoglycemic activities of Paroxetine
Tolcapone may increase the severity of adverse effects when combined with Citalopram and Citalopram may increase the QTc prolonging activities of Paroxetine
Tolcapone may increase the severity of adverse effects when combined with Arsenic trioxide and Arsenic trioxide may increase the QTc prolonging activities of Paroxetine
Tolcapone may increase the severity of adverse effects when combined with Propofol and Propofol may decrease the metabolism of Paroxetine
Tolcapone may increase the severity of adverse effects when combined with Propranolol and Propranolol may decrease the metabolism of Paroxetine
Tolcapone may increase the central nervous system depressant activities of Zolpidem and Zolpidem may decrease the metabolism of Paroxetine
Tolcapone may increase the severity of adverse effects when combined with Stiripentol and Stiripentol may decrease the metabolism of Paroxetine
|
DB01081
|
DB08815
| 942 | 1,003 |
Diphenoxylate
|
Lurasidone
|
A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II.
|
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
|
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lurasidone.
| 48 |
[
[
[
942,
71,
1003
]
],
[
[
942,
184,
674
],
[
674,
30,
1003
]
],
[
[
942,
38,
1257
],
[
1257,
192,
1003
]
],
[
[
942,
192,
543
],
[
543,
38,
1003
]
],
[
[
942,
225,
59
],
[
59,
42,
1003
]
],
[
[
942,
54,
1046
],
[
1046,
208,
1003
]
],
[
[
942,
71,
18
],
[
18,
58,
1003
]
],
[
[
942,
240,
324
],
[
324,
71,
1003
]
],
[
[
942,
71,
978
],
[
978,
225,
1003
]
],
[
[
942,
71,
413
],
[
413,
71,
1003
]
]
] |
[
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lurasidone"
]
],
[
[
"Diphenoxylate",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Lurasidone"
]
],
[
[
"Diphenoxylate",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Lurasidone"
]
],
[
[
"Diphenoxylate",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Lurasidone"
]
],
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may increase the QTc prolonging activities of {v}",
"Lurasidone"
]
],
[
[
"Diphenoxylate",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Lurasidone"
]
],
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may increase the antipsychotic activities of {v}",
"Lurasidone"
]
],
[
[
"Diphenoxylate",
"{u} may increase the serotonergic activities of {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lurasidone"
]
],
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fospropofol"
],
[
"Fospropofol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lurasidone"
]
],
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lurasidone"
]
]
] |
Diphenoxylate can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Lurasidone
Diphenoxylate may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Lurasidone
Diphenoxylate may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Lurasidone
Diphenoxylate may increase the severity of adverse effects when combined with Quinidine and Quinidine may increase the QTc prolonging activities of Lurasidone
Diphenoxylate may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Lurasidone
Diphenoxylate may increase the severity of adverse effects when combined with Sulpiride and Sulpiride may increase the antipsychotic activities of Lurasidone
Diphenoxylate may increase the serotonergic activities of Escitalopram and Escitalopram may increase the severity of adverse effects when combined with Lurasidone
Diphenoxylate may increase the severity of adverse effects when combined with Fospropofol and Fospropofol may increase the severity of adverse effects when combined with Lurasidone
Diphenoxylate may increase the severity of adverse effects when combined with Pimozide and Pimozide may increase the severity of adverse effects when combined with Lurasidone
|
DB01224
|
DB00980
| 955 | 250 |
Quetiapine
|
Ramelteon
|
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].
|
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
|
The risk or severity of adverse effects can be increased when Quetiapine is combined with Ramelteon.
| 48 |
[
[
[
955,
71,
250
]
],
[
[
955,
6,
10999
],
[
10999,
160,
250
]
],
[
[
955,
21,
28575
],
[
28575,
175,
250
]
],
[
[
955,
251,
164
],
[
164,
26,
250
]
],
[
[
955,
192,
72
],
[
72,
38,
250
]
],
[
[
955,
38,
1257
],
[
1257,
192,
250
]
],
[
[
955,
54,
471
],
[
471,
208,
250
]
],
[
[
955,
69,
1077
],
[
1077,
223,
250
]
],
[
[
955,
95,
379
],
[
379,
223,
250
]
],
[
[
955,
225,
461
],
[
461,
223,
250
]
]
] |
[
[
[
"Quetiapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ramelteon"
]
],
[
[
"Quetiapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Quetiapine",
"{u} (Compound) causes {v} (Side Effect)",
"Influenza"
],
[
"Influenza",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Quetiapine",
"{u} may decrease the serum concentration of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Quetiapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Ramelteon"
]
],
[
[
"Quetiapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Ramelteon"
]
],
[
[
"Quetiapine",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Ramelteon"
]
],
[
[
"Quetiapine",
"{u} may decrease the metabolism of {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may decrease the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Quetiapine",
"{u} may increase the serum concentration of {v}",
"Ranolazine"
],
[
"Ranolazine",
"{u} may decrease the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Quetiapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may decrease the metabolism of {v}",
"Ramelteon"
]
]
] |
Quetiapine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ramelteon (Compound)
Quetiapine (Compound) causes Influenza (Side Effect) and Influenza (Side Effect) is caused by Ramelteon (Compound)
Quetiapine may decrease the serum concentration of Phenobarbital and Phenobarbital can increase the metabolism of Ramelteon
Quetiapine may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Ramelteon
Quetiapine may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Ramelteon
Quetiapine may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Ramelteon
Quetiapine may decrease the metabolism of Isavuconazonium and Isavuconazonium may decrease the metabolism of Ramelteon
Quetiapine may increase the serum concentration of Ranolazine and Ranolazine may decrease the metabolism of Ramelteon
Quetiapine may increase the severity of adverse effects when combined with Diltiazem and Diltiazem may decrease the metabolism of Ramelteon
|
DB01182
|
DB00203
| 1,318 | 615 |
Propafenone
|
Sildenafil
|
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
|
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
|
The serum concentration of Sildenafil can be increased when it is combined with Propafenone.
| 72 |
[
[
[
1318,
95,
615
]
],
[
[
1318,
42,
154
],
[
154,
69,
615
]
],
[
[
1318,
6,
18777
],
[
18777,
160,
615
]
],
[
[
1318,
21,
28396
],
[
28396,
175,
615
]
],
[
[
1318,
249,
173
],
[
173,
26,
615
]
],
[
[
1318,
251,
150
],
[
150,
26,
615
]
],
[
[
1318,
249,
519
],
[
519,
186,
615
]
],
[
[
1318,
42,
689
],
[
689,
186,
615
]
],
[
[
1318,
230,
643
],
[
643,
186,
615
]
],
[
[
1318,
273,
504
],
[
504,
186,
615
]
]
] |
[
[
[
"Propafenone",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
]
],
[
[
"Propafenone",
"{u} may increase the QTc prolonging activities of {v}",
"Vardenafil"
],
[
"Vardenafil",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
]
],
[
[
"Propafenone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Sildenafil"
]
],
[
[
"Propafenone",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sildenafil"
]
],
[
[
"Propafenone",
"{u} may increase the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Sildenafil"
]
],
[
[
"Propafenone",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Sildenafil"
]
],
[
[
"Propafenone",
"{u} may increase the serum concentration of {v}",
"Celiprolol"
],
[
"Celiprolol",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
],
[
[
"Propafenone",
"{u} may increase the QTc prolonging activities of {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
],
[
[
"Propafenone",
"{u} may increase the bradycardic activities of {v}",
"Guanfacine"
],
[
"Guanfacine",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
],
[
[
"Propafenone",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the serum concentration of {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
]
] |
Propafenone may increase the QTc prolonging activities of Vardenafil and Vardenafil may decrease the metabolism of Sildenafil
Propafenone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Sildenafil (Compound)
Propafenone (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Sildenafil (Compound)
Propafenone may increase the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Sildenafil
Propafenone may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Sildenafil
Propafenone may increase the serum concentration of Celiprolol and Celiprolol may increase the antihypertensive activities of Sildenafil
Propafenone may increase the QTc prolonging activities of Treprostinil and Treprostinil may increase the antihypertensive activities of Sildenafil
Propafenone may increase the bradycardic activities of Guanfacine and Guanfacine may increase the antihypertensive activities of Sildenafil
Propafenone (Compound) resembles Propranolol (Compound) and Propafenone may increase the serum concentration of Propranolol and Propranolol may increase the antihypertensive activities of Sildenafil
|
DB01054
|
DB00196
| 329 | 1,076 |
Nitrendipine
|
Fluconazole
|
Nitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
|
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
|
The serum concentration of Fluconazole can be increased when it is combined with Nitrendipine.
| 72 |
[
[
[
329,
95,
1076
]
],
[
[
329,
69,
657
],
[
657,
155,
1076
]
],
[
[
329,
6,
4590
],
[
4590,
160,
1076
]
],
[
[
329,
92,
597
],
[
597,
187,
1076
]
],
[
[
329,
69,
143
],
[
143,
42,
1076
]
],
[
[
329,
225,
539
],
[
539,
42,
1076
]
],
[
[
329,
236,
640
],
[
640,
42,
1076
]
],
[
[
329,
95,
1019
],
[
1019,
196,
1076
]
],
[
[
329,
71,
1027
],
[
1027,
42,
1076
]
],
[
[
329,
251,
495
],
[
495,
55,
1076
]
]
] |
[
[
[
"Nitrendipine",
"{u} may increase the serum concentration of {v}",
"Fluconazole"
]
],
[
[
"Nitrendipine",
"{u} may decrease the metabolism of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} (Compound) resembles {v} (Compound)",
"Fluconazole"
]
],
[
[
"Nitrendipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fluconazole"
]
],
[
[
"Nitrendipine",
"{u} may decrease the therapeutic efficacy of {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Fluconazole"
]
],
[
[
"Nitrendipine",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Nitrendipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Nitrendipine",
"{u} may increase the hypotensive activities of {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Nitrendipine",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Nitrendipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Nitrendipine",
"{u} may decrease the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Fluconazole"
]
]
] |
Nitrendipine may decrease the metabolism of Voriconazole and Voriconazole (Compound) resembles Fluconazole (Compound)
Nitrendipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fluconazole (Compound)
Nitrendipine may decrease the therapeutic efficacy of Clopidogrel and Clopidogrel may reduce the serum concentration of the active metabolites of Fluconazole
Nitrendipine may decrease the metabolism of Erythromycin and Erythromycin may increase the QTc prolonging activities of Fluconazole
Nitrendipine may increase the severity of adverse effects when combined with Artemether and Artemether may increase the QTc prolonging activities of Fluconazole
Nitrendipine may increase the hypotensive activities of Quinine and Quinine may increase the QTc prolonging activities of Fluconazole
Nitrendipine may increase the serum concentration of Mifepristone and Mifepristone may increase the QTc prolonging activities of Fluconazole
Nitrendipine may increase the severity of adverse effects when combined with Sotalol and Sotalol may increase the QTc prolonging activities of Fluconazole
Nitrendipine may decrease the serum concentration of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Fluconazole
|
DB08881
|
DB06699
| 495 | 1,232 |
Vemurafenib
|
Degarelix
|
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
|
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
|
Vemurafenib may increase the QTc-prolonging activities of Degarelix.
| 19 |
[
[
[
495,
42,
1232
]
],
[
[
495,
42,
1187
],
[
1187,
1,
1232
]
],
[
[
495,
21,
28613
],
[
28613,
175,
1232
]
],
[
[
495,
97,
243
],
[
243,
37,
1232
]
],
[
[
495,
97,
645
],
[
645,
42,
1232
]
],
[
[
495,
249,
1208
],
[
1208,
42,
1232
]
],
[
[
495,
95,
1088
],
[
1088,
42,
1232
]
],
[
[
495,
55,
863
],
[
863,
42,
1232
]
],
[
[
495,
42,
1210
],
[
1210,
42,
1232
]
],
[
[
495,
209,
956
],
[
956,
42,
1232
]
]
] |
[
[
[
"Vemurafenib",
"{u} may increase the QTc prolonging activities of {v}",
"Degarelix"
]
],
[
[
"Vemurafenib",
"{u} may increase the QTc prolonging activities of {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
]
],
[
[
"Vemurafenib",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Degarelix"
]
],
[
[
"Vemurafenib",
"{u} may decrease the serum concentration of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Degarelix"
]
],
[
[
"Vemurafenib",
"{u} may decrease the serum concentration of {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Degarelix"
]
],
[
[
"Vemurafenib",
"{u} may increase the serum concentration of {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may increase the QTc prolonging activities of {v}",
"Degarelix"
]
],
[
[
"Vemurafenib",
"{u} may increase the serum concentration of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Degarelix"
]
],
[
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Degarelix"
]
],
[
[
"Vemurafenib",
"{u} may increase the QTc prolonging activities of {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Degarelix"
]
],
[
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may increase the QTc prolonging activities of {v}",
"Degarelix"
]
]
] |
Vemurafenib may increase the QTc prolonging activities of Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Vemurafenib (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Degarelix (Compound)
Vemurafenib may decrease the serum concentration of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Degarelix
Vemurafenib may decrease the serum concentration of Azithromycin and Azithromycin may increase the QTc prolonging activities of Degarelix
Vemurafenib may increase the serum concentration of Arsenic trioxide and Arsenic trioxide may increase the QTc prolonging activities of Degarelix
Vemurafenib may increase the serum concentration of Clarithromycin and Clarithromycin may increase the QTc prolonging activities of Degarelix
Vemurafenib may increase the severity of QTc prolonging effects when combined with Gemifloxacin and Gemifloxacin may increase the QTc prolonging activities of Degarelix
Vemurafenib may increase the QTc prolonging activities of Ofloxacin and Ofloxacin may increase the QTc prolonging activities of Degarelix
Vemurafenib may increase the severity of QTc prolonging effects when combined with Tetrabenazine and Tetrabenazine may increase the QTc prolonging activities of Degarelix
|
DB00860
|
DB09269
| 82 | 1,217 |
Prednisolone
|
Phenylacetic acid
|
Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955.
|
Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor. Because it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China.
|
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Prednisolone.
| 69 |
[
[
[
82,
92,
1217
]
],
[
[
82,
191,
243
],
[
243,
37,
1217
]
],
[
[
82,
225,
357
],
[
357,
71,
1217
]
],
[
[
82,
80,
1348
],
[
1348,
234,
1217
]
],
[
[
82,
155,
103
],
[
103,
92,
1217
]
],
[
[
82,
1,
128
],
[
128,
92,
1217
]
],
[
[
82,
191,
243
],
[
243,
37,
292
],
[
292,
71,
1217
]
],
[
[
82,
225,
357
],
[
357,
225,
292
],
[
292,
71,
1217
]
],
[
[
82,
225,
292
],
[
292,
191,
243
],
[
243,
37,
1217
]
],
[
[
82,
80,
1348
],
[
1348,
234,
243
],
[
243,
37,
1217
]
]
] |
[
[
[
"Prednisolone",
"{u} may decrease the therapeutic efficacy of {v}",
"Phenylacetic acid"
]
],
[
[
"Prednisolone",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Phenylacetic acid"
]
],
[
[
"Prednisolone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Docetaxel"
],
[
"Docetaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylacetic acid"
]
],
[
[
"Prednisolone",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
],
[
"Ouabain",
"{u} may decrease the cardiotoxic activities of {v}",
"Phenylacetic acid"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may decrease the therapeutic efficacy of {v}",
"Phenylacetic acid"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Cortisone acetate"
],
[
"Cortisone acetate",
"{u} may decrease the therapeutic efficacy of {v}",
"Phenylacetic acid"
]
],
[
[
"Prednisolone",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylacetic acid"
]
],
[
[
"Prednisolone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Docetaxel"
],
[
"Docetaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylacetic acid"
]
],
[
[
"Prednisolone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Phenylacetic acid"
]
],
[
[
"Prednisolone",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
],
[
"Ouabain",
"{u} may decrease the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Phenylacetic acid"
]
]
] |
Prednisolone may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Phenylacetic acid
Prednisolone may increase the severity of adverse effects when combined with Docetaxel and Docetaxel may increase the severity of adverse effects when combined with Phenylacetic acid
Prednisolone may decrease the cardiotoxic activities of Ouabain and Ouabain may decrease the cardiotoxic activities of Phenylacetic acid
Prednisolone (Compound) resembles Betamethasone (Compound) and Betamethasone may decrease the therapeutic efficacy of Phenylacetic acid
Prednisolone (Compound) resembles Cortisone acetate (Compound) and Cortisone acetate may decrease the therapeutic efficacy of Phenylacetic acid
Prednisolone may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Paclitaxel and Paclitaxel may increase the severity of adverse effects when combined with Phenylacetic acid
Prednisolone may increase the severity of adverse effects when combined with Docetaxel and Docetaxel may increase the severity of adverse effects when combined with Paclitaxel and Paclitaxel may increase the severity of adverse effects when combined with Phenylacetic acid
Prednisolone may increase the severity of adverse effects when combined with Paclitaxel and Paclitaxel may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Phenylacetic acid
Prednisolone may decrease the cardiotoxic activities of Ouabain and Ouabain may decrease the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Phenylacetic acid
|
DB00390
|
DB09054
| 457 | 1,099 |
Digoxin
|
Idelalisib
|
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.
|
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth
|
The metabolism of Idelalisib can be decreased when combined with Digoxin.
| 46 |
[
[
[
457,
69,
1099
]
],
[
[
457,
234,
680
],
[
680,
187,
1099
]
],
[
[
457,
234,
243
],
[
243,
37,
1099
]
],
[
[
457,
76,
340
],
[
340,
210,
1099
]
],
[
[
457,
69,
482
],
[
482,
69,
1099
]
],
[
[
457,
234,
1018
],
[
1018,
69,
1099
]
],
[
[
457,
230,
519
],
[
519,
69,
1099
]
],
[
[
457,
95,
198
],
[
198,
69,
1099
]
],
[
[
457,
76,
248
],
[
248,
69,
1099
]
],
[
[
457,
1,
232
],
[
232,
69,
1099
]
]
] |
[
[
[
"Digoxin",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Digoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Idelalisib"
]
],
[
[
"Digoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Idelalisib"
]
],
[
[
"Digoxin",
"{u} may increase the bradycardic activities of {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may increase the immunosuppressive activities of {v}",
"Idelalisib"
]
],
[
[
"Digoxin",
"{u} may decrease the metabolism of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Digoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Digoxin",
"{u} may increase the bradycardic activities of {v}",
"Celiprolol"
],
[
"Celiprolol",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Digoxin",
"{u} may increase the serum concentration of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Digoxin",
"{u} may increase the bradycardic activities of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Digoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digitoxin"
],
[
"Digitoxin",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
]
] |
Digoxin may decrease the cardiotoxic activities of Ifosfamide and Ifosfamide may reduce the serum concentration of the active metabolites of Idelalisib
Digoxin may decrease the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Idelalisib
Digoxin may increase the bradycardic activities of Fingolimod and Fingolimod may increase the immunosuppressive activities of Idelalisib
Digoxin may decrease the metabolism of Verapamil and Verapamil may decrease the metabolism of Idelalisib
Digoxin may decrease the cardiotoxic activities of Sunitinib and Sunitinib may decrease the metabolism of Idelalisib
Digoxin may increase the bradycardic activities of Celiprolol and Celiprolol may decrease the metabolism of Idelalisib
Digoxin may increase the serum concentration of Cyclosporine and Cyclosporine may decrease the metabolism of Idelalisib
Digoxin may increase the bradycardic activities of Carvedilol and Carvedilol may decrease the metabolism of Idelalisib
Digoxin (Compound) resembles Digitoxin (Compound) and Digitoxin may decrease the metabolism of Idelalisib
|
DB00177
|
DB01244
| 239 | 190 |
Valsartan
|
Bepridil
|
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [olmesartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, valsartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via
|
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).
|
Valsartan may increase the hypotensive activities of Bepridil.
| 59 |
[
[
[
239,
82,
190
]
],
[
[
239,
236,
17
],
[
17,
82,
190
]
],
[
[
239,
82,
355
],
[
355,
82,
190
]
],
[
[
239,
5,
17090
],
[
17090,
159,
190
]
],
[
[
239,
21,
28446
],
[
28446,
175,
190
]
],
[
[
239,
236,
197
],
[
197,
26,
190
]
],
[
[
239,
223,
298
],
[
298,
26,
190
]
],
[
[
239,
180,
161
],
[
161,
26,
190
]
],
[
[
239,
186,
702
],
[
702,
32,
190
]
],
[
[
239,
223,
633
],
[
633,
196,
190
]
]
] |
[
[
[
"Valsartan",
"{u} may increase the hypotensive activities of {v}",
"Bepridil"
]
],
[
[
"Valsartan",
"{u} may increase the hypotensive activities of {v}",
"Trimethaphan"
],
[
"Trimethaphan",
"{u} may increase the hypotensive activities of {v}",
"Bepridil"
]
],
[
[
"Valsartan",
"{u} may increase the hypotensive activities of {v}",
"Phenoxybenzamine"
],
[
"Phenoxybenzamine",
"{u} may increase the hypotensive activities of {v}",
"Bepridil"
]
],
[
[
"Valsartan",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Bepridil"
]
],
[
[
"Valsartan",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bepridil"
]
],
[
[
"Valsartan",
"{u} may increase the hypotensive activities of {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} can increase the metabolism of {v}",
"Bepridil"
]
],
[
[
"Valsartan",
"{u} may decrease the metabolism of {v}",
"Hexobarbital"
],
[
"Hexobarbital",
"{u} can increase the metabolism of {v}",
"Bepridil"
]
],
[
[
"Valsartan",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Bepridil"
]
],
[
[
"Valsartan",
"{u} may increase the antihypertensive activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Bepridil"
]
],
[
[
"Valsartan",
"{u} may decrease the metabolism of {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may increase the QTc prolonging activities of {v}",
"Bepridil"
]
]
] |
Valsartan may increase the hypotensive activities of Trimethaphan and Trimethaphan may increase the hypotensive activities of Bepridil
Valsartan may increase the hypotensive activities of Phenoxybenzamine and Phenoxybenzamine may increase the hypotensive activities of Bepridil
Valsartan (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Bepridil (Compound)
Valsartan (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Bepridil (Compound)
Valsartan may increase the hypotensive activities of Amobarbital and Amobarbital can increase the metabolism of Bepridil
Valsartan may decrease the metabolism of Hexobarbital and Hexobarbital can increase the metabolism of Bepridil
Valsartan can increase the metabolism of Primidone and Primidone can increase the metabolism of Bepridil
Valsartan may increase the antihypertensive activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Bepridil
Valsartan may decrease the metabolism of Cisapride and Cisapride may increase the QTc prolonging activities of Bepridil
|
DB12161
|
DB00199
| 399 | 143 |
Deutetrabenazine
|
Erythromycin
|
Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated. The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound. This allows less frequent dosing and a lower daily dose with improvement in tolerability. Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine. Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction,
|
Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of [Azithromycin], [Clarithromycin], [Spiramycin] and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria.[L5245,L7261] It is available for administration in various forms, including intravenous, topical, and eye drop preparations.
|
The metabolism of Erythromycin can be decreased when combined with Deutetrabenazine.
| 46 |
[
[
[
399,
69,
143
]
],
[
[
399,
69,
645
],
[
645,
42,
143
]
],
[
[
399,
180,
147
],
[
147,
26,
143
]
],
[
[
399,
69,
438
],
[
438,
196,
143
]
],
[
[
399,
69,
611
],
[
611,
69,
143
]
],
[
[
399,
95,
1095
],
[
1095,
223,
143
]
],
[
[
399,
69,
496
],
[
496,
223,
143
]
],
[
[
399,
180,
156
],
[
156,
69,
143
]
],
[
[
399,
95,
476
],
[
476,
249,
143
]
],
[
[
399,
69,
530
],
[
530,
95,
143
]
]
] |
[
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Erythromycin"
]
],
[
[
"Deutetrabenazine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Erythromycin"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may increase the QTc prolonging activities of {v}",
"Erythromycin"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
]
],
[
[
"Deutetrabenazine",
"{u} may increase the serum concentration of {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
],
[
"Ketoconazole",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
]
],
[
[
"Deutetrabenazine",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
]
],
[
[
"Deutetrabenazine",
"{u} may increase the serum concentration of {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may increase the serum concentration of {v}",
"Erythromycin"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may increase the serum concentration of {v}",
"Erythromycin"
]
]
] |
Deutetrabenazine may decrease the metabolism of Azithromycin and Azithromycin may increase the QTc prolonging activities of Erythromycin
Deutetrabenazine can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Erythromycin
Deutetrabenazine may decrease the metabolism of Imipramine and Imipramine may increase the QTc prolonging activities of Erythromycin
Deutetrabenazine may decrease the metabolism of Lidocaine and Lidocaine may decrease the metabolism of Erythromycin
Deutetrabenazine may increase the serum concentration of Cobicistat and Cobicistat may decrease the metabolism of Erythromycin
Deutetrabenazine may decrease the metabolism of Ketoconazole and Ketoconazole may decrease the metabolism of Erythromycin
Deutetrabenazine can increase the metabolism of Carbamazepine and Carbamazepine may decrease the metabolism of Erythromycin
Deutetrabenazine may increase the serum concentration of Netupitant and Netupitant may increase the serum concentration of Erythromycin
Deutetrabenazine may decrease the metabolism of Dihydroergotamine and Dihydroergotamine may increase the serum concentration of Erythromycin
|
DB06288
|
DB00206
| 980 | 925 |
Amisulpride
|
Reserpine
|
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea
|
An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. The FDA withdrew its approval for the use of all oral dosage form drug products containing more than 1 mg of reserpine.
|
Amisulpride may increase the antipsychotic activities of Reserpine.
| 35 |
[
[
[
980,
58,
925
]
],
[
[
980,
21,
28512
],
[
28512,
175,
925
]
],
[
[
980,
184,
674
],
[
674,
30,
925
]
],
[
[
980,
192,
1083
],
[
1083,
38,
925
]
],
[
[
980,
38,
1265
],
[
1265,
192,
925
]
],
[
[
980,
225,
828
],
[
828,
206,
925
]
],
[
[
980,
54,
1365
],
[
1365,
208,
925
]
],
[
[
980,
211,
997
],
[
997,
57,
925
]
],
[
[
980,
71,
18
],
[
18,
58,
925
]
],
[
[
980,
225,
440
],
[
440,
71,
925
]
]
] |
[
[
[
"Amisulpride",
"{u} may increase the antipsychotic activities of {v}",
"Reserpine"
]
],
[
[
"Amisulpride",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Reserpine"
]
],
[
[
"Amisulpride",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Reserpine"
]
],
[
[
"Amisulpride",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Reserpine"
]
],
[
[
"Amisulpride",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Reserpine"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Reserpine"
]
],
[
[
"Amisulpride",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Reserpine"
]
],
[
[
"Amisulpride",
"{u} may increase the neurotoxic activities of {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Reserpine"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may increase the antipsychotic activities of {v}",
"Reserpine"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Reserpine"
]
]
] |
Amisulpride (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Reserpine (Compound)
Amisulpride can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Reserpine
Amisulpride may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Reserpine
Amisulpride may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Reserpine
Amisulpride may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Reserpine
Amisulpride may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Reserpine
Amisulpride may increase the neurotoxic activities of Lithium cation and Lithium cation may increase the neurotoxic activities of Reserpine
Amisulpride may increase the severity of adverse effects when combined with Sulpiride and Sulpiride may increase the antipsychotic activities of Reserpine
Amisulpride may increase the severity of adverse effects when combined with Dextromethorphan and Dextromethorphan may increase the severity of adverse effects when combined with Reserpine
|
DB01045
|
DB00458
| 147 | 438 |
Rifampicin
|
Imipramine
|
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
|
Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also block histamine H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic
|
The metabolism of Imipramine can be increased when combined with Rifampicin.
| 3 |
[
[
[
147,
26,
438
]
],
[
[
147,
26,
392
],
[
392,
1,
438
]
],
[
[
147,
26,
221
],
[
221,
225,
438
]
],
[
[
147,
6,
8682
],
[
8682,
160,
438
]
],
[
[
147,
180,
164
],
[
164,
26,
438
]
],
[
[
147,
26,
194
],
[
194,
26,
438
]
],
[
[
147,
97,
150
],
[
150,
26,
438
]
],
[
[
147,
26,
342
],
[
342,
28,
438
]
],
[
[
147,
26,
568
],
[
568,
187,
438
]
],
[
[
147,
97,
1083
],
[
1083,
38,
438
]
]
] |
[
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Imipramine"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Imipramine"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Imipramine"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"CYP2B6"
],
[
"CYP2B6",
"{u} (Gene) is bound by {v} (Compound)",
"Imipramine"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Imipramine"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Methylphenobarbital"
],
[
"Methylphenobarbital",
"{u} can increase the metabolism of {v}",
"Imipramine"
]
],
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Imipramine"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Imipramine"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Imipramine"
]
],
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Imipramine"
]
]
] |
Rifampicin can increase the metabolism of Chlorpromazine and Chlorpromazine (Compound) resembles Imipramine (Compound)
Rifampicin can increase the metabolism of Nortriptyline and Nortriptyline may increase the severity of adverse effects when combined with Imipramine
Rifampicin (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Imipramine (Compound)
Rifampicin can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Imipramine
Rifampicin can increase the metabolism of Methylphenobarbital and Methylphenobarbital can increase the metabolism of Imipramine
Rifampicin may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Imipramine
Rifampicin can increase the metabolism of Acenocoumarol and Acenocoumarol may increase the anticoagulant activities of Imipramine
Rifampicin can increase the metabolism of Tamoxifen and Tamoxifen may reduce the serum concentration of the active metabolites of Imipramine
Rifampicin may decrease the serum concentration of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Imipramine
|
DB06237
|
DB01029
| 506 | 535 |
Avanafil
|
Irbesartan
|
Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual disturbances associated with off-target PDE6 inhibition. It first received FDA approval on April 27, 2012, with subsequent EMA approval in June 2013.
|
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy.[L7456,L7459] It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.[L7456,L7459] Irbesartan was granted FDA approval on 30 September 1997.[L7456,L7459]
|
Avanafil may increase the antihypertensive activities of Irbesartan.
| 9 |
[
[
[
506,
32,
535
]
],
[
[
506,
32,
304
],
[
304,
71,
535
]
],
[
[
506,
32,
567
],
[
567,
1,
535
]
],
[
[
506,
6,
4590
],
[
4590,
160,
535
]
],
[
[
506,
21,
28784
],
[
28784,
175,
535
]
],
[
[
506,
95,
191
],
[
191,
26,
535
]
],
[
[
506,
180,
150
],
[
150,
26,
535
]
],
[
[
506,
225,
154
],
[
154,
32,
535
]
],
[
[
506,
95,
266
],
[
266,
223,
535
]
],
[
[
506,
32,
689
],
[
689,
69,
535
]
]
] |
[
[
[
"Avanafil",
"{u} may increase the antihypertensive activities of {v}",
"Irbesartan"
]
],
[
[
"Avanafil",
"{u} may increase the antihypertensive activities of {v}",
"Candesartan cilexetil"
],
[
"Candesartan cilexetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Irbesartan"
]
],
[
[
"Avanafil",
"{u} may increase the antihypertensive activities of {v}",
"Losartan"
],
[
"Losartan",
"{u} (Compound) resembles {v} (Compound)",
"Irbesartan"
]
],
[
[
"Avanafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Irbesartan"
]
],
[
[
"Avanafil",
"{u} (Compound) causes {v} (Side Effect)",
"Angina pectoris"
],
[
"Angina pectoris",
"{u} (Side Effect) is caused by {v} (Compound)",
"Irbesartan"
]
],
[
[
"Avanafil",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} can increase the metabolism of {v}",
"Irbesartan"
]
],
[
[
"Avanafil",
"{u} can increase the metabolism of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Irbesartan"
]
],
[
[
"Avanafil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vardenafil"
],
[
"Vardenafil",
"{u} may increase the antihypertensive activities of {v}",
"Irbesartan"
]
],
[
[
"Avanafil",
"{u} may increase the serum concentration of {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may decrease the metabolism of {v}",
"Irbesartan"
]
],
[
[
"Avanafil",
"{u} may increase the antihypertensive activities of {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may decrease the metabolism of {v}",
"Irbesartan"
]
]
] |
Avanafil may increase the antihypertensive activities of Candesartan cilexetil and Candesartan cilexetil may increase the severity of adverse effects when combined with Irbesartan
Avanafil may increase the antihypertensive activities of Losartan and Losartan (Compound) resembles Irbesartan (Compound)
Avanafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Irbesartan (Compound)
Avanafil (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Irbesartan (Compound)
Avanafil may increase the serum concentration of Aprepitant and Aprepitant can increase the metabolism of Irbesartan
Avanafil can increase the metabolism of Fosphenytoin and Fosphenytoin can increase the metabolism of Irbesartan
Avanafil may increase the severity of adverse effects when combined with Vardenafil and Vardenafil may increase the antihypertensive activities of Irbesartan
Avanafil may increase the serum concentration of Indinavir and Indinavir may decrease the metabolism of Irbesartan
Avanafil may increase the antihypertensive activities of Treprostinil and Treprostinil may decrease the metabolism of Irbesartan
|
DB01297
|
DB08880
| 1,016 | 814 |
Practolol
|
Teriflunomide
|
A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.
|
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
|
Practolol may decrease the antihypertensive activities of Teriflunomide.
| 36 |
[
[
[
1016,
59,
814
]
],
[
[
1016,
1,
139
],
[
139,
59,
814
]
],
[
[
1016,
155,
1027
],
[
1027,
59,
814
]
],
[
[
1016,
251,
147
],
[
147,
69,
814
]
],
[
[
1016,
95,
193
],
[
193,
69,
814
]
],
[
[
1016,
59,
375
],
[
375,
69,
814
]
],
[
[
1016,
69,
588
],
[
588,
69,
814
]
],
[
[
1016,
59,
826
],
[
826,
71,
814
]
],
[
[
1016,
59,
789
],
[
789,
225,
814
]
],
[
[
1016,
59,
768
],
[
768,
79,
814
]
]
] |
[
[
[
"Practolol",
"{u} may decrease the antihypertensive activities of {v}",
"Teriflunomide"
]
],
[
[
"Practolol",
"{u} (Compound) resembles {v} (Compound)",
"Atenolol"
],
[
"Atenolol",
"{u} may decrease the antihypertensive activities of {v}",
"Teriflunomide"
]
],
[
[
"Practolol",
"{u} (Compound) resembles {v} (Compound)",
"Sotalol"
],
[
"Sotalol",
"{u} may decrease the antihypertensive activities of {v}",
"Teriflunomide"
]
],
[
[
"Practolol",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may decrease the metabolism of {v}",
"Teriflunomide"
]
],
[
[
"Practolol",
"{u} may increase the serum concentration of {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may decrease the metabolism of {v}",
"Teriflunomide"
]
],
[
[
"Practolol",
"{u} may decrease the antihypertensive activities of {v}",
"Mefenamic acid"
],
[
"Mefenamic acid",
"{u} may decrease the metabolism of {v}",
"Teriflunomide"
]
],
[
[
"Practolol",
"{u} may decrease the metabolism of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may decrease the metabolism of {v}",
"Teriflunomide"
]
],
[
[
"Practolol",
"{u} may decrease the antihypertensive activities of {v}",
"Oxyphenbutazone"
],
[
"Oxyphenbutazone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Teriflunomide"
]
],
[
[
"Practolol",
"{u} may decrease the antihypertensive activities of {v}",
"Benzydamine"
],
[
"Benzydamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Teriflunomide"
]
],
[
[
"Practolol",
"{u} may decrease the antihypertensive activities of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the nephrotoxic activities of {v}",
"Teriflunomide"
]
]
] |
Practolol (Compound) resembles Atenolol (Compound) and Atenolol may decrease the antihypertensive activities of Teriflunomide
Practolol (Compound) resembles Sotalol (Compound) and Sotalol may decrease the antihypertensive activities of Teriflunomide
Practolol may decrease the serum concentration of Rifampicin and Rifampicin may decrease the metabolism of Teriflunomide
Practolol may increase the serum concentration of Levomilnacipran and Levomilnacipran may decrease the metabolism of Teriflunomide
Practolol may decrease the antihypertensive activities of Mefenamic acid and Mefenamic acid may decrease the metabolism of Teriflunomide
Practolol may decrease the metabolism of Chloroquine and Chloroquine may decrease the metabolism of Teriflunomide
Practolol may decrease the antihypertensive activities of Oxyphenbutazone and Oxyphenbutazone may increase the severity of adverse effects when combined with Teriflunomide
Practolol may decrease the antihypertensive activities of Benzydamine and Benzydamine may increase the severity of adverse effects when combined with Teriflunomide
Practolol may decrease the antihypertensive activities of Olsalazine and Olsalazine may increase the nephrotoxic activities of Teriflunomide
|
DB00275
|
DB01050
| 1,054 | 334 |
Olmesartan
|
Ibuprofen
|
Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS
|
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than
|
The risk or severity of adverse effects can be increased when Olmesartan is combined with Ibuprofen.
| 48 |
[
[
[
1054,
71,
334
]
],
[
[
1054,
236,
23
],
[
23,
1,
334
]
],
[
[
1054,
82,
1046
],
[
1046,
155,
334
]
],
[
[
1054,
21,
29196
],
[
29196,
175,
334
]
],
[
[
1054,
236,
164
],
[
164,
26,
334
]
],
[
[
1054,
71,
687
],
[
687,
28,
334
]
],
[
[
1054,
225,
557
],
[
557,
205,
334
]
],
[
[
1054,
225,
1037
],
[
1037,
59,
334
]
],
[
[
1054,
71,
248
],
[
248,
59,
334
]
],
[
[
1054,
90,
306
],
[
306,
59,
334
]
]
] |
[
[
[
"Olmesartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ibuprofen"
]
],
[
[
"Olmesartan",
"{u} may increase the hypotensive activities of {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} (Compound) resembles {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Olmesartan",
"{u} may increase the hypotensive activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} (Compound) resembles {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Olmesartan",
"{u} (Compound) causes {v} (Side Effect)",
"Tubulointerstitial nephritis"
],
[
"Tubulointerstitial nephritis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Olmesartan",
"{u} may increase the hypotensive activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Ibuprofen"
]
],
[
[
"Olmesartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Ibuprofen"
]
],
[
[
"Olmesartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may decrease the diuretic activities of {v}",
"Ibuprofen"
]
],
[
[
"Olmesartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may decrease the antihypertensive activities of {v}",
"Ibuprofen"
]
],
[
[
"Olmesartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may decrease the antihypertensive activities of {v}",
"Ibuprofen"
]
],
[
[
"Olmesartan",
"{u} may increase the hyperkalemic activities of {v}",
"Aliskiren"
],
[
"Aliskiren",
"{u} may decrease the antihypertensive activities of {v}",
"Ibuprofen"
]
]
] |
Olmesartan may increase the hypotensive activities of Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Olmesartan may increase the hypotensive activities of Metyrosine and Metyrosine (Compound) resembles Ibuprofen (Compound)
Olmesartan (Compound) causes Tubulointerstitial nephritis (Side Effect) and Tubulointerstitial nephritis (Side Effect) is caused by Ibuprofen (Compound)
Olmesartan may increase the hypotensive activities of Phenobarbital and Phenobarbital can increase the metabolism of Ibuprofen
Olmesartan may increase the severity of adverse effects when combined with Nafamostat and Nafamostat may increase the anticoagulant activities of Ibuprofen
Olmesartan may increase the severity of adverse effects when combined with Torasemide and Torasemide may decrease the diuretic activities of Ibuprofen
Olmesartan may increase the severity of adverse effects when combined with Betaxolol and Betaxolol may decrease the antihypertensive activities of Ibuprofen
Olmesartan may increase the severity of adverse effects when combined with Carvedilol and Carvedilol may decrease the antihypertensive activities of Ibuprofen
Olmesartan may increase the hyperkalemic activities of Aliskiren and Aliskiren may decrease the antihypertensive activities of Ibuprofen
|
DB01104
|
DB00208
| 411 | 613 |
Sertraline
|
Ticlopidine
|
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.[A1846,A187075,T28]
|
Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
|
The metabolism of Ticlopidine can be decreased when combined with Sertraline.
| 46 |
[
[
[
411,
69,
613
]
],
[
[
411,
33,
597
],
[
597,
187,
613
]
],
[
[
411,
6,
12128
],
[
12128,
160,
613
]
],
[
[
411,
21,
28521
],
[
28521,
175,
613
]
],
[
[
411,
180,
161
],
[
161,
26,
613
]
],
[
[
411,
223,
156
],
[
156,
26,
613
]
],
[
[
411,
182,
169
],
[
169,
28,
613
]
],
[
[
411,
99,
677
],
[
677,
28,
613
]
],
[
[
411,
69,
755
],
[
755,
223,
613
]
],
[
[
411,
225,
480
],
[
480,
69,
613
]
]
] |
[
[
[
"Sertraline",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Sertraline",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Ticlopidine"
]
],
[
[
"Sertraline",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Ticlopidine"
]
],
[
[
"Sertraline",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ticlopidine"
]
],
[
[
"Sertraline",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Sertraline",
"{u} may decrease the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Sertraline",
"{u} may increase the anticoagulant activities of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Ticlopidine"
]
],
[
[
"Sertraline",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Dabigatran etexilate"
],
[
"Dabigatran etexilate",
"{u} may increase the anticoagulant activities of {v}",
"Ticlopidine"
]
],
[
[
"Sertraline",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
],
[
[
"Sertraline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etizolam"
],
[
"Etizolam",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
]
]
] |
Sertraline may reduce the serum concentration of the active metabolites of Clopidogrel and Clopidogrel may reduce the serum concentration of the active metabolites of Ticlopidine
Sertraline (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ticlopidine (Compound)
Sertraline (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Ticlopidine (Compound)
Sertraline can increase the metabolism of Primidone and Primidone can increase the metabolism of Ticlopidine
Sertraline may decrease the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Ticlopidine
Sertraline may increase the anticoagulant activities of Phenindione and Phenindione may increase the anticoagulant activities of Ticlopidine
Sertraline may increase the serum concentration of the active metabolites of Dabigatran etexilate and Dabigatran etexilate may increase the anticoagulant activities of Ticlopidine
Sertraline may decrease the metabolism of Doxycycline and Doxycycline may decrease the metabolism of Ticlopidine
Sertraline may increase the severity of adverse effects when combined with Etizolam and Etizolam may decrease the metabolism of Ticlopidine
|
DB00296
|
DB01263
| 541 | 479 |
Ropivacaine
|
Posaconazole
|
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
|
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
|
The metabolism of Posaconazole can be decreased when combined with Ropivacaine.
| 46 |
[
[
[
541,
69,
479
]
],
[
[
541,
69,
496
],
[
496,
223,
479
]
],
[
[
541,
6,
4590
],
[
4590,
160,
479
]
],
[
[
541,
21,
28899
],
[
28899,
175,
479
]
],
[
[
541,
180,
161
],
[
161,
26,
479
]
],
[
[
541,
225,
1007
],
[
1007,
42,
479
]
],
[
[
541,
71,
956
],
[
956,
42,
479
]
],
[
[
541,
69,
575
],
[
575,
42,
479
]
],
[
[
541,
95,
1019
],
[
1019,
196,
479
]
],
[
[
541,
71,
336
],
[
336,
69,
479
]
]
] |
[
[
[
"Ropivacaine",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
]
],
[
[
"Ropivacaine",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
],
[
"Ketoconazole",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
]
],
[
[
"Ropivacaine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Posaconazole"
]
],
[
[
"Ropivacaine",
"{u} (Compound) causes {v} (Side Effect)",
"Neuropathy"
],
[
"Neuropathy",
"{u} (Side Effect) is caused by {v} (Compound)",
"Posaconazole"
]
],
[
[
"Ropivacaine",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Posaconazole"
]
],
[
[
"Ropivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Posaconazole"
]
],
[
[
"Ropivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may increase the QTc prolonging activities of {v}",
"Posaconazole"
]
],
[
[
"Ropivacaine",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the QTc prolonging activities of {v}",
"Posaconazole"
]
],
[
[
"Ropivacaine",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Posaconazole"
]
],
[
[
"Ropivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prazepam"
],
[
"Prazepam",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
]
]
] |
Ropivacaine may decrease the metabolism of Ketoconazole and Ketoconazole may decrease the metabolism of Posaconazole
Ropivacaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Ropivacaine (Compound) causes Neuropathy (Side Effect) and Neuropathy (Side Effect) is caused by Posaconazole (Compound)
Ropivacaine can increase the metabolism of Primidone and Primidone can increase the metabolism of Posaconazole
Ropivacaine may increase the severity of adverse effects when combined with Paliperidone and Paliperidone may increase the QTc prolonging activities of Posaconazole
Ropivacaine may increase the severity of adverse effects when combined with Tetrabenazine and Tetrabenazine may increase the QTc prolonging activities of Posaconazole
Ropivacaine may decrease the metabolism of Sulfisoxazole and Sulfisoxazole may increase the QTc prolonging activities of Posaconazole
Ropivacaine may increase the serum concentration of Mifepristone and Mifepristone may increase the QTc prolonging activities of Posaconazole
Ropivacaine may increase the severity of adverse effects when combined with Prazepam and Prazepam may decrease the metabolism of Posaconazole
|
DB00835
|
DB06595
| 165 | 422 |
Brompheniramine
|
Midostaurin
|
Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
|
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
|
The metabolism of Midostaurin can be decreased when combined with Brompheniramine.
| 46 |
[
[
[
165,
69,
422
]
],
[
[
165,
180,
147
],
[
147,
26,
422
]
],
[
[
165,
192,
1083
],
[
1083,
187,
422
]
],
[
[
165,
69,
527
],
[
527,
69,
422
]
],
[
[
165,
69,
1085
],
[
1085,
223,
422
]
],
[
[
165,
192,
287
],
[
287,
69,
422
]
],
[
[
165,
225,
940
],
[
940,
69,
422
]
],
[
[
165,
155,
44
],
[
44,
69,
422
]
],
[
[
165,
71,
193
],
[
193,
69,
422
]
],
[
[
165,
252,
718
],
[
718,
69,
422
]
]
] |
[
[
[
"Brompheniramine",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
]
],
[
[
"Brompheniramine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Midostaurin"
]
],
[
[
"Brompheniramine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Midostaurin"
]
],
[
[
"Brompheniramine",
"{u} may decrease the metabolism of {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
]
],
[
[
"Brompheniramine",
"{u} may decrease the metabolism of {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
]
],
[
[
"Brompheniramine",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
]
],
[
[
"Brompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
]
],
[
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Tolterodine"
],
[
"Tolterodine",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
]
],
[
[
"Brompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
]
],
[
[
"Brompheniramine",
"{u} may decrease the sedative activities of {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
]
]
] |
Brompheniramine can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Midostaurin
Brompheniramine may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may reduce the serum concentration of the active metabolites of Midostaurin
Brompheniramine may decrease the metabolism of Bupropion and Bupropion may decrease the metabolism of Midostaurin
Brompheniramine may decrease the metabolism of Olaparib and Olaparib may decrease the metabolism of Midostaurin
Brompheniramine may increase the central nervous system depressant activities of Zolpidem and Zolpidem may decrease the metabolism of Midostaurin
Brompheniramine may increase the severity of adverse effects when combined with Trifluoperazine and Trifluoperazine may decrease the metabolism of Midostaurin
Brompheniramine (Compound) resembles Tolterodine (Compound) and Tolterodine may decrease the metabolism of Midostaurin
Brompheniramine may increase the severity of adverse effects when combined with Levomilnacipran and Levomilnacipran may decrease the metabolism of Midostaurin
Brompheniramine may decrease the sedative activities of Pseudoephedrine and Pseudoephedrine may decrease the metabolism of Midostaurin
|
DB01236
|
DB00275
| 354 | 1,054 |
Sevoflurane
|
Olmesartan
|
Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.
|
Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS
|
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Olmesartan.
| 48 |
[
[
[
354,
71,
1054
]
],
[
[
354,
71,
1071
],
[
1071,
225,
1054
]
],
[
[
354,
71,
567
],
[
567,
155,
1054
]
],
[
[
354,
71,
239
],
[
239,
71,
1054
]
],
[
[
354,
21,
28990
],
[
28990,
175,
1054
]
],
[
[
354,
69,
615
],
[
615,
32,
1054
]
],
[
[
354,
52,
828
],
[
828,
206,
1054
]
],
[
[
354,
225,
1352
],
[
1352,
71,
1054
]
],
[
[
354,
69,
461
],
[
461,
225,
1054
]
],
[
[
354,
38,
1265
],
[
1265,
71,
1054
]
]
] |
[
[
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Telmisartan"
],
[
"Telmisartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Losartan"
],
[
"Losartan",
"{u} (Compound) resembles {v} (Compound)",
"Olmesartan"
]
],
[
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valsartan"
],
[
"Valsartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Sevoflurane",
"{u} (Compound) causes {v} (Side Effect)",
"Glycosuria"
],
[
"Glycosuria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Olmesartan"
]
],
[
[
"Sevoflurane",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Olmesartan"
]
],
[
[
"Sevoflurane",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Olmesartan"
]
],
[
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sacubitril"
],
[
"Sacubitril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Sevoflurane",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
],
[
[
"Sevoflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
]
]
] |
Sevoflurane may increase the severity of adverse effects when combined with Telmisartan and Telmisartan may increase the severity of adverse effects when combined with Olmesartan
Sevoflurane may increase the severity of adverse effects when combined with Losartan and Losartan (Compound) resembles Olmesartan (Compound)
Sevoflurane may increase the severity of adverse effects when combined with Valsartan and Valsartan may increase the severity of adverse effects when combined with Olmesartan
Sevoflurane (Compound) causes Glycosuria (Side Effect) and Glycosuria (Side Effect) is caused by Olmesartan (Compound)
Sevoflurane may decrease the metabolism of Sildenafil and Sildenafil may increase the antihypertensive activities of Olmesartan
Sevoflurane may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Olmesartan
Sevoflurane may increase the severity of adverse effects when combined with Sacubitril and Sacubitril may increase the severity of adverse effects when combined with Olmesartan
Sevoflurane may decrease the metabolism of Diltiazem and Diltiazem may increase the severity of adverse effects when combined with Olmesartan
Sevoflurane may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the severity of adverse effects when combined with Olmesartan
|
DB01041
|
DB00690
| 679 | 565 |
Thalidomide
|
Flurazepam
|
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
|
A benzodiazepine derivative used mainly as a hypnotic.
|
Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
| 15 |
[
[
[
679,
38,
565
]
],
[
[
679,
38,
499
],
[
499,
225,
565
]
],
[
[
679,
38,
1267
],
[
1267,
71,
565
]
],
[
[
679,
38,
275
],
[
275,
1,
565
]
],
[
[
679,
6,
13066
],
[
13066,
160,
565
]
],
[
[
679,
21,
28921
],
[
28921,
175,
565
]
],
[
[
679,
38,
164
],
[
164,
26,
565
]
],
[
[
679,
69,
173
],
[
173,
26,
565
]
],
[
[
679,
180,
147
],
[
147,
26,
565
]
],
[
[
679,
184,
674
],
[
674,
30,
565
]
]
] |
[
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Flurazepam"
]
],
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flurazepam"
]
],
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Lorazepam"
],
[
"Lorazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flurazepam"
]
],
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Estazolam"
],
[
"Estazolam",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
]
],
[
[
"Thalidomide",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)",
"Flurazepam"
]
],
[
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {v} (Compound)",
"Flurazepam"
]
],
[
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Flurazepam"
]
],
[
[
"Thalidomide",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Flurazepam"
]
],
[
[
"Thalidomide",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Flurazepam"
]
],
[
[
"Thalidomide",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Flurazepam"
]
]
] |
Thalidomide may increase the central nervous system depressant activities of Clomipramine and Clomipramine may increase the severity of adverse effects when combined with Flurazepam
Thalidomide may increase the central nervous system depressant activities of Lorazepam and Lorazepam may increase the severity of adverse effects when combined with Flurazepam
Thalidomide may increase the central nervous system depressant activities of Estazolam and Estazolam (Compound) resembles Flurazepam (Compound)
Thalidomide (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Flurazepam (Compound)
Thalidomide (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Flurazepam (Compound)
Thalidomide may increase the central nervous system depressant activities of Phenobarbital and Phenobarbital can increase the metabolism of Flurazepam
Thalidomide may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Flurazepam
Thalidomide can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Flurazepam
Thalidomide can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Flurazepam
|
DB01708
|
DB00176
| 126 | 861 |
Prasterone
|
Fluvoxamine
|
Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (DHEA) can be converted to testosterone; androstenedione; estradiol; and estrone. Most of DHEA is sulfated (dehydroepiandrosterone sulfate) before secretion. In the United States, DHEA or DHEAS have been advertised with claims that they may be beneficial for a wide variety of ailments. DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements. In November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (
|
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
|
The metabolism of Fluvoxamine can be decreased when combined with Prasterone.
| 46 |
[
[
[
126,
69,
861
]
],
[
[
126,
95,
1269
],
[
1269,
223,
861
]
],
[
[
126,
225,
478
],
[
478,
69,
861
]
],
[
[
126,
180,
171
],
[
171,
69,
861
]
],
[
[
126,
69,
657
],
[
657,
69,
861
]
],
[
[
126,
105,
557
],
[
557,
69,
861
]
],
[
[
126,
69,
1086
],
[
1086,
223,
861
]
],
[
[
126,
71,
651
],
[
651,
69,
861
]
],
[
[
126,
182,
219
],
[
219,
69,
861
]
],
[
[
126,
97,
1092
],
[
1092,
69,
861
]
]
] |
[
[
[
"Prasterone",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Prasterone",
"{u} may increase the serum concentration of {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Prasterone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olopatadine"
],
[
"Olopatadine",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Prasterone",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Prasterone",
"{u} may decrease the metabolism of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Prasterone",
"{u} may increase the hypokalemic activities of {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Prasterone",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Prasterone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Malathion"
],
[
"Malathion",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Prasterone",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
],
[
[
"Prasterone",
"{u} may decrease the serum concentration of {v}",
"Telaprevir"
],
[
"Telaprevir",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
]
]
] |
Prasterone may increase the serum concentration of Stiripentol and Stiripentol may decrease the metabolism of Fluvoxamine
Prasterone may increase the severity of adverse effects when combined with Olopatadine and Olopatadine may decrease the metabolism of Fluvoxamine
Prasterone can increase the metabolism of Pentobarbital and Pentobarbital may decrease the metabolism of Fluvoxamine
Prasterone may decrease the metabolism of Voriconazole and Voriconazole may decrease the metabolism of Fluvoxamine
Prasterone may increase the hypokalemic activities of Torasemide and Torasemide may decrease the metabolism of Fluvoxamine
Prasterone may decrease the metabolism of Clotrimazole and Clotrimazole may decrease the metabolism of Fluvoxamine
Prasterone may increase the severity of adverse effects when combined with Malathion and Malathion may decrease the metabolism of Fluvoxamine
Prasterone may increase the anticoagulant activities of Warfarin and Warfarin may decrease the metabolism of Fluvoxamine
Prasterone may decrease the serum concentration of Telaprevir and Telaprevir may decrease the metabolism of Fluvoxamine
|
DB01124
|
DB00187
| 297 | 1,034 |
Tolbutamide
|
Esmolol
|
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to
|
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.
|
Tolbutamide may increase the hypoglycemic activities of Esmolol.
| 8 |
[
[
[
297,
31,
1034
]
],
[
[
297,
31,
1027
],
[
1027,
225,
1034
]
],
[
[
297,
31,
911
],
[
911,
1,
1034
]
],
[
[
297,
223,
334
],
[
334,
155,
1034
]
],
[
[
297,
21,
28549
],
[
28549,
175,
1034
]
],
[
[
297,
223,
526
],
[
526,
31,
1034
]
],
[
[
297,
31,
874
],
[
874,
31,
1034
]
],
[
[
297,
1,
792
],
[
792,
31,
1034
]
],
[
[
297,
31,
519
],
[
519,
190,
1034
]
],
[
[
297,
223,
638
],
[
638,
190,
1034
]
]
] |
[
[
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Esmolol"
]
],
[
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Esmolol"
]
],
[
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} (Compound) resembles {v} (Compound)",
"Esmolol"
]
],
[
[
"Tolbutamide",
"{u} may decrease the metabolism of {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} (Compound) resembles {v} (Compound)",
"Esmolol"
]
],
[
[
"Tolbutamide",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Esmolol"
]
],
[
[
"Tolbutamide",
"{u} may decrease the metabolism of {v}",
"Glyburide"
],
[
"Glyburide",
"{u} may increase the hypoglycemic activities of {v}",
"Esmolol"
]
],
[
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Tolazamide"
],
[
"Tolazamide",
"{u} may increase the hypoglycemic activities of {v}",
"Esmolol"
]
],
[
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glisoxepide"
],
[
"Glisoxepide",
"{u} may increase the hypoglycemic activities of {v}",
"Esmolol"
]
],
[
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Celiprolol"
],
[
"Celiprolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Esmolol"
]
],
[
[
"Tolbutamide",
"{u} may decrease the metabolism of {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may decrease the bronchodilatory activities of {v}",
"Esmolol"
]
]
] |
Tolbutamide may increase the hypoglycemic activities of Sotalol and Sotalol may increase the severity of adverse effects when combined with Esmolol
Tolbutamide may increase the hypoglycemic activities of Oxprenolol and Oxprenolol (Compound) resembles Esmolol (Compound)
Tolbutamide may decrease the metabolism of Ibuprofen and Ibuprofen (Compound) resembles Esmolol (Compound)
Tolbutamide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Esmolol (Compound)
Tolbutamide may decrease the metabolism of Glyburide and Glyburide may increase the hypoglycemic activities of Esmolol
Tolbutamide may increase the hypoglycemic activities of Tolazamide and Tolazamide may increase the hypoglycemic activities of Esmolol
Tolbutamide (Compound) resembles Glisoxepide (Compound) and Glisoxepide may increase the hypoglycemic activities of Esmolol
Tolbutamide may increase the hypoglycemic activities of Celiprolol and Celiprolol may decrease the bronchodilatory activities of Esmolol
Tolbutamide may decrease the metabolism of Olodaterol and Olodaterol may decrease the bronchodilatory activities of Esmolol
|
DB01590
|
DB00455
| 1,392 | 401 |
Everolimus
|
Loratadine
|
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
|
Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
|
The serum concentration of Loratadine can be increased when it is combined with Everolimus.
| 72 |
[
[
[
1392,
95,
401
]
],
[
[
1392,
6,
4590
],
[
4590,
160,
401
]
],
[
[
1392,
7,
3107
],
[
3107,
161,
401
]
],
[
[
1392,
21,
28614
],
[
28614,
175,
401
]
],
[
[
1392,
251,
161
],
[
161,
26,
401
]
],
[
[
1392,
95,
147
],
[
147,
26,
401
]
],
[
[
1392,
95,
491
],
[
491,
38,
401
]
],
[
[
1392,
95,
640
],
[
640,
223,
401
]
],
[
[
1392,
92,
297
],
[
297,
223,
401
]
],
[
[
1392,
95,
563
],
[
563,
71,
401
]
]
] |
[
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Loratadine"
]
],
[
[
"Everolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Loratadine"
]
],
[
[
"Everolimus",
"{u} (Compound) upregulates {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Loratadine"
]
],
[
[
"Everolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Loratadine"
]
],
[
[
"Everolimus",
"{u} may decrease the serum concentration of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Loratadine"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Loratadine"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Loratadine"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Quinine"
],
[
"Quinine",
"{u} may decrease the metabolism of {v}",
"Loratadine"
]
],
[
[
"Everolimus",
"{u} may decrease the therapeutic efficacy of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may decrease the metabolism of {v}",
"Loratadine"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Ergotamine"
],
[
"Ergotamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Loratadine"
]
]
] |
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Loratadine (Compound)
Everolimus (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Loratadine (Compound)
Everolimus (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Loratadine (Compound)
Everolimus may decrease the serum concentration of Primidone and Primidone can increase the metabolism of Loratadine
Everolimus may increase the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Loratadine
Everolimus may increase the serum concentration of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Loratadine
Everolimus may increase the serum concentration of Quinine and Quinine may decrease the metabolism of Loratadine
Everolimus may decrease the therapeutic efficacy of Tolbutamide and Tolbutamide may decrease the metabolism of Loratadine
Everolimus may increase the serum concentration of Ergotamine and Ergotamine may increase the severity of adverse effects when combined with Loratadine
|
DB00974
|
DB01283
| 749 | 349 |
Edetic acid
|
Lumiracoxib
|
A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
|
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.
|
Edetic acid may increase the anticoagulant activities of Lumiracoxib.
| 5 |
[
[
[
749,
28,
349
]
],
[
[
749,
6,
12128
],
[
12128,
160,
349
]
],
[
[
749,
28,
744
],
[
744,
28,
349
]
],
[
[
749,
182,
794
],
[
794,
28,
349
]
],
[
[
749,
28,
613
],
[
613,
223,
349
]
],
[
[
749,
28,
808
],
[
808,
225,
349
]
],
[
[
749,
28,
11
],
[
11,
71,
349
]
],
[
[
749,
88,
1351
],
[
1351,
225,
349
]
],
[
[
749,
28,
768
],
[
768,
79,
349
]
],
[
[
749,
28,
814
],
[
814,
97,
349
]
]
] |
[
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Lumiracoxib"
]
],
[
[
"Edetic acid",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Lumiracoxib"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may increase the anticoagulant activities of {v}",
"Lumiracoxib"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Protocatechualdehyde"
],
[
"Protocatechualdehyde",
"{u} may increase the anticoagulant activities of {v}",
"Lumiracoxib"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may decrease the metabolism of {v}",
"Lumiracoxib"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Magnesium salicylate"
],
[
"Magnesium salicylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lumiracoxib"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Carprofen"
],
[
"Carprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lumiracoxib"
]
],
[
[
"Edetic acid",
"{u} may increase bleeding risks when combined with {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lumiracoxib"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the nephrotoxic activities of {v}",
"Lumiracoxib"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may decrease the serum concentration of {v}",
"Lumiracoxib"
]
]
] |
Edetic acid (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lumiracoxib (Compound)
Edetic acid may increase the anticoagulant activities of Edoxaban and Edoxaban may increase the anticoagulant activities of Lumiracoxib
Edetic acid may increase the anticoagulant activities of Protocatechualdehyde and Protocatechualdehyde may increase the anticoagulant activities of Lumiracoxib
Edetic acid may increase the anticoagulant activities of Ticlopidine and Ticlopidine may decrease the metabolism of Lumiracoxib
Edetic acid may increase the anticoagulant activities of Magnesium salicylate and Magnesium salicylate may increase the severity of adverse effects when combined with Lumiracoxib
Edetic acid may increase the anticoagulant activities of Carprofen and Carprofen may increase the severity of adverse effects when combined with Lumiracoxib
Edetic acid may increase bleeding risks when combined with Acemetacin and Acemetacin may increase the severity of adverse effects when combined with Lumiracoxib
Edetic acid may increase the anticoagulant activities of Olsalazine and Olsalazine may increase the nephrotoxic activities of Lumiracoxib
Edetic acid may increase the anticoagulant activities of Teriflunomide and Teriflunomide may decrease the serum concentration of Lumiracoxib
|
DB01349
|
DB00203
| 174 | 615 |
Tasosartan
|
Sildenafil
|
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
|
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
|
The metabolism of Sildenafil can be decreased when combined with Tasosartan.
| 46 |
[
[
[
174,
69,
615
]
],
[
[
174,
6,
4590
],
[
4590,
160,
615
]
],
[
[
174,
180,
147
],
[
147,
26,
615
]
],
[
[
174,
155,
567
],
[
567,
186,
615
]
],
[
[
174,
90,
1073
],
[
1073,
186,
615
]
],
[
[
174,
69,
472
],
[
472,
186,
615
]
],
[
[
174,
69,
267
],
[
267,
223,
615
]
],
[
[
174,
71,
584
],
[
584,
69,
615
]
],
[
[
174,
69,
1079
],
[
1079,
69,
615
]
],
[
[
174,
244,
198
],
[
198,
69,
615
]
]
] |
[
[
[
"Tasosartan",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
]
],
[
[
"Tasosartan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sildenafil"
]
],
[
[
"Tasosartan",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Sildenafil"
]
],
[
[
"Tasosartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
],
[
"Losartan",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
],
[
[
"Tasosartan",
"{u} may increase the hyperkalemic activities of {v}",
"Nicorandil"
],
[
"Nicorandil",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
],
[
[
"Tasosartan",
"{u} may decrease the metabolism of {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may increase the antihypertensive activities of {v}",
"Sildenafil"
]
],
[
[
"Tasosartan",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
]
],
[
[
"Tasosartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tenoxicam"
],
[
"Tenoxicam",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
]
],
[
[
"Tasosartan",
"{u} may decrease the metabolism of {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
]
],
[
[
"Tasosartan",
"{u} may increase the hyperkalemic activities of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
]
]
] |
Tasosartan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sildenafil (Compound)
Tasosartan can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Sildenafil
Tasosartan (Compound) resembles Losartan (Compound) and Losartan may increase the antihypertensive activities of Sildenafil
Tasosartan may increase the hyperkalemic activities of Nicorandil and Nicorandil may increase the antihypertensive activities of Sildenafil
Tasosartan may decrease the metabolism of Isradipine and Isradipine may increase the antihypertensive activities of Sildenafil
Tasosartan may decrease the metabolism of Lovastatin and Lovastatin may decrease the metabolism of Sildenafil
Tasosartan may increase the severity of adverse effects when combined with Tenoxicam and Tenoxicam may decrease the metabolism of Sildenafil
Tasosartan may decrease the metabolism of Crizotinib and Crizotinib may decrease the metabolism of Sildenafil
Tasosartan may increase the hyperkalemic activities of Cyclosporine and Cyclosporine may decrease the metabolism of Sildenafil
|
DB00483
|
DB01090
| 60 | 21 |
Gallamine triethiodide
|
Pentolinium
|
A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)
|
Pentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.
|
The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Pentolinium.
| 48 |
[
[
[
60,
71,
21
]
],
[
[
60,
178,
26
],
[
26,
24,
21
]
],
[
[
60,
61,
1400
],
[
1400,
215,
21
]
],
[
[
60,
225,
70
],
[
70,
71,
21
]
],
[
[
60,
71,
46
],
[
46,
225,
21
]
],
[
[
60,
71,
44
],
[
44,
71,
21
]
],
[
[
60,
76,
1026
],
[
1026,
236,
21
]
],
[
[
60,
76,
504
],
[
504,
82,
21
]
],
[
[
60,
43,
640
],
[
640,
82,
21
]
],
[
[
60,
193,
557
],
[
557,
82,
21
]
]
] |
[
[
[
"Gallamine triethiodide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentolinium"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the anticholinergic activities of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} may increase the anticholinergic activities of {v}",
"Pentolinium"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the constipating activities of {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may increase the constipating activities of {v}",
"Pentolinium"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tropicamide"
],
[
"Tropicamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentolinium"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Solifenacin"
],
[
"Solifenacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentolinium"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentolinium"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the bradycardic activities of {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may increase the hypotensive activities of {v}",
"Pentolinium"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the bradycardic activities of {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may increase the hypotensive activities of {v}",
"Pentolinium"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the neuromuscular blocking activities of {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the hypotensive activities of {v}",
"Pentolinium"
]
],
[
[
"Gallamine triethiodide",
"{u} may decrease the neuromuscular blocking activities of {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may increase the hypotensive activities of {v}",
"Pentolinium"
]
]
] |
Gallamine triethiodide may increase the anticholinergic activities of Tiotropium and Tiotropium may increase the anticholinergic activities of Pentolinium
Gallamine triethiodide may increase the constipating activities of Eluxadoline and Eluxadoline may increase the constipating activities of Pentolinium
Gallamine triethiodide may increase the severity of adverse effects when combined with Tropicamide and Tropicamide may increase the severity of adverse effects when combined with Pentolinium
Gallamine triethiodide may increase the severity of adverse effects when combined with Solifenacin and Solifenacin may increase the severity of adverse effects when combined with Pentolinium
Gallamine triethiodide may increase the severity of adverse effects when combined with Tolterodine and Tolterodine may increase the severity of adverse effects when combined with Pentolinium
Gallamine triethiodide may increase the bradycardic activities of Acebutolol and Acebutolol may increase the hypotensive activities of Pentolinium
Gallamine triethiodide may increase the bradycardic activities of Propranolol and Propranolol may increase the hypotensive activities of Pentolinium
Gallamine triethiodide may increase the neuromuscular blocking activities of Quinine and Quinine may increase the hypotensive activities of Pentolinium
Gallamine triethiodide may decrease the neuromuscular blocking activities of Torasemide and Torasemide may increase the hypotensive activities of Pentolinium
|
DB00530
|
DB00976
| 600 | 528 |
Erlotinib
|
Telithromycin
|
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer
|
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
|
The serum concentration of Telithromycin can be increased when it is combined with Erlotinib.
| 72 |
[
[
[
600,
95,
528
]
],
[
[
600,
95,
1088
],
[
1088,
42,
528
]
],
[
[
600,
6,
4590
],
[
4590,
160,
528
]
],
[
[
600,
21,
28714
],
[
28714,
175,
528
]
],
[
[
600,
251,
147
],
[
147,
26,
528
]
],
[
[
600,
69,
588
],
[
588,
196,
528
]
],
[
[
600,
251,
992
],
[
992,
196,
528
]
],
[
[
600,
69,
438
],
[
438,
69,
528
]
],
[
[
600,
69,
1122
],
[
1122,
223,
528
]
],
[
[
600,
95,
648
],
[
648,
69,
528
]
]
] |
[
[
[
"Erlotinib",
"{u} may increase the serum concentration of {v}",
"Telithromycin"
]
],
[
[
"Erlotinib",
"{u} may increase the serum concentration of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Erlotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Erlotinib",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Erlotinib",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Erlotinib",
"{u} may decrease the metabolism of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Erlotinib",
"{u} may decrease the serum concentration of {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Erlotinib",
"{u} may decrease the metabolism of {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may decrease the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Erlotinib",
"{u} may decrease the metabolism of {v}",
"Lobeglitazone"
],
[
"Lobeglitazone",
"{u} may decrease the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Erlotinib",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Telithromycin"
]
]
] |
Erlotinib may increase the serum concentration of Clarithromycin and Clarithromycin may increase the QTc prolonging activities of Telithromycin
Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Telithromycin (Compound)
Erlotinib (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Telithromycin (Compound)
Erlotinib may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Telithromycin
Erlotinib may decrease the metabolism of Chloroquine and Chloroquine may increase the QTc prolonging activities of Telithromycin
Erlotinib may decrease the serum concentration of Olanzapine and Olanzapine may increase the QTc prolonging activities of Telithromycin
Erlotinib may decrease the metabolism of Imipramine and Imipramine may decrease the metabolism of Telithromycin
Erlotinib may decrease the metabolism of Lobeglitazone and Lobeglitazone may decrease the metabolism of Telithromycin
Erlotinib may increase the serum concentration of Nefazodone and Nefazodone may decrease the metabolism of Telithromycin
|
DB04846
|
DB05676
| 519 | 743 |
Celiprolol
|
Apremilast
|
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome. This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial rupture in which the layers of the vessel separate prior to complete failure of the artery wall). Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.
|
Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation.
|
Celiprolol may decrease the antihypertensive activities of Apremilast.
| 36 |
[
[
[
519,
59,
743
]
],
[
[
519,
59,
687
],
[
687,
28,
743
]
],
[
[
519,
105,
894
],
[
894,
205,
743
]
],
[
[
519,
76,
340
],
[
340,
210,
743
]
],
[
[
519,
52,
248
],
[
248,
59,
743
]
],
[
[
519,
190,
576
],
[
576,
59,
743
]
],
[
[
519,
236,
504
],
[
504,
59,
743
]
],
[
[
519,
82,
306
],
[
306,
59,
743
]
],
[
[
519,
230,
1091
],
[
1091,
223,
743
]
],
[
[
519,
93,
610
],
[
610,
223,
743
]
]
] |
[
[
[
"Celiprolol",
"{u} may decrease the antihypertensive activities of {v}",
"Apremilast"
]
],
[
[
"Celiprolol",
"{u} may decrease the antihypertensive activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Apremilast"
]
],
[
[
"Celiprolol",
"{u} may increase the hypokalemic activities of {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may decrease the diuretic activities of {v}",
"Apremilast"
]
],
[
[
"Celiprolol",
"{u} may increase the bradycardic activities of {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may increase the immunosuppressive activities of {v}",
"Apremilast"
]
],
[
[
"Celiprolol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may decrease the antihypertensive activities of {v}",
"Apremilast"
]
],
[
[
"Celiprolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may decrease the antihypertensive activities of {v}",
"Apremilast"
]
],
[
[
"Celiprolol",
"{u} may increase the hypotensive activities of {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may decrease the antihypertensive activities of {v}",
"Apremilast"
]
],
[
[
"Celiprolol",
"{u} may increase the hypotensive activities of {v}",
"Aliskiren"
],
[
"Aliskiren",
"{u} may decrease the antihypertensive activities of {v}",
"Apremilast"
]
],
[
[
"Celiprolol",
"{u} may increase the bradycardic activities of {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may decrease the metabolism of {v}",
"Apremilast"
]
],
[
[
"Celiprolol",
"{u} may increase the hypertensive activities of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may decrease the metabolism of {v}",
"Apremilast"
]
]
] |
Celiprolol may decrease the antihypertensive activities of Nafamostat and Nafamostat may increase the anticoagulant activities of Apremilast
Celiprolol may increase the hypokalemic activities of Furosemide and Furosemide may decrease the diuretic activities of Apremilast
Celiprolol may increase the bradycardic activities of Fingolimod and Fingolimod may increase the immunosuppressive activities of Apremilast
Celiprolol may increase the orthostatic hypotensive activities of Carvedilol and Carvedilol may decrease the antihypertensive activities of Apremilast
Celiprolol may decrease the bronchodilatory activities of Metoprolol and Metoprolol may decrease the antihypertensive activities of Apremilast
Celiprolol may increase the hypotensive activities of Propranolol and Propranolol may decrease the antihypertensive activities of Apremilast
Celiprolol may increase the hypotensive activities of Aliskiren and Aliskiren may decrease the antihypertensive activities of Apremilast
Celiprolol may increase the bradycardic activities of Dronedarone and Dronedarone may decrease the metabolism of Apremilast
Celiprolol may increase the hypertensive activities of Atomoxetine and Atomoxetine may decrease the metabolism of Apremilast
|
DB00343
|
DB00571
| 461 | 504 |
Diltiazem
|
Propranolol
|
Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization. Compared to dihydropyridine drugs, such as [nifedipine], that preferentially act on vascular smooth muscle and [verapamil] that directly acts on the heart muscle, diltiazem displays an intermediate specificity to target both the cardiac and vascular smooth muscle. Being a potent vasodilator, diltiazem is used clinically as an antihypertensive, anti-arrhythmic, and as an anti-anginal agent for the management of cardiovascular conditions such as hypertension, chronic stable angina, atrial fibrillation,
|
Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.
|
The risk or severity of adverse effects can be increased when Diltiazem is combined with Propranolol.
| 48 |
[
[
[
461,
71,
504
]
],
[
[
461,
71,
1026
],
[
1026,
155,
504
]
],
[
[
461,
225,
1037
],
[
1037,
71,
504
]
],
[
[
461,
82,
1031
],
[
1031,
155,
504
]
],
[
[
461,
249,
379
],
[
379,
95,
504
]
],
[
[
461,
71,
1035
],
[
1035,
71,
504
]
],
[
[
461,
5,
17090
],
[
17090,
159,
504
]
],
[
[
461,
6,
18777
],
[
18777,
160,
504
]
],
[
[
461,
21,
28440
],
[
28440,
175,
504
]
],
[
[
461,
180,
164
],
[
164,
26,
504
]
]
] |
[
[
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
]
],
[
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Propranolol"
]
],
[
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
]
],
[
[
"Diltiazem",
"{u} may increase the hypotensive activities of {v}",
"Bevantolol"
],
[
"Bevantolol",
"{u} (Compound) resembles {v} (Compound)",
"Propranolol"
]
],
[
[
"Diltiazem",
"{u} may increase the serum concentration of {v}",
"Ranolazine"
],
[
"Ranolazine",
"{u} may increase the serum concentration of {v}",
"Propranolol"
]
],
[
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carteolol"
],
[
"Carteolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
]
],
[
[
"Diltiazem",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Propranolol"
]
],
[
[
"Diltiazem",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Propranolol"
]
],
[
[
"Diltiazem",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Propranolol"
]
],
[
[
"Diltiazem",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Propranolol"
]
]
] |
Diltiazem may increase the severity of adverse effects when combined with Acebutolol and Acebutolol (Compound) resembles Propranolol (Compound)
Diltiazem may increase the severity of adverse effects when combined with Betaxolol and Betaxolol may increase the severity of adverse effects when combined with Propranolol
Diltiazem may increase the hypotensive activities of Bevantolol and Bevantolol (Compound) resembles Propranolol (Compound)
Diltiazem may increase the serum concentration of Ranolazine and Ranolazine may increase the serum concentration of Propranolol
Diltiazem may increase the severity of adverse effects when combined with Carteolol and Carteolol may increase the severity of adverse effects when combined with Propranolol
Diltiazem (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Propranolol (Compound)
Diltiazem (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Propranolol (Compound)
Diltiazem (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Propranolol (Compound)
Diltiazem can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Propranolol
|
DB09049
|
DB01229
| 1,475 | 292 |
Naloxegol
|
Paclitaxel
|
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier.
|
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
|
The serum concentration of Paclitaxel can be increased when it is combined with Naloxegol.
| 72 |
[
[
[
1475,
95,
292
]
],
[
[
1475,
95,
152
],
[
152,
225,
292
]
],
[
[
1475,
251,
164
],
[
164,
26,
292
]
],
[
[
1475,
95,
173
],
[
173,
26,
292
]
],
[
[
1475,
95,
243
],
[
243,
37,
292
]
],
[
[
1475,
95,
305
],
[
305,
211,
292
]
],
[
[
1475,
95,
269
],
[
269,
223,
292
]
],
[
[
1475,
95,
376
],
[
376,
71,
292
]
],
[
[
1475,
249,
653
],
[
653,
225,
292
]
],
[
[
1475,
95,
457
],
[
457,
234,
292
]
]
] |
[
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Paclitaxel"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
]
],
[
[
"Naloxegol",
"{u} may decrease the serum concentration of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Paclitaxel"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Paclitaxel"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Paclitaxel"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may increase the neurotoxic activities of {v}",
"Paclitaxel"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may decrease the metabolism of {v}",
"Paclitaxel"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Ergometrine"
],
[
"Ergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may decrease the cardiotoxic activities of {v}",
"Paclitaxel"
]
]
] |
Naloxegol may increase the serum concentration of Cabazitaxel and Cabazitaxel may increase the severity of adverse effects when combined with Paclitaxel
Naloxegol may decrease the serum concentration of Phenobarbital and Phenobarbital can increase the metabolism of Paclitaxel
Naloxegol may increase the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Paclitaxel
Naloxegol may increase the serum concentration of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Paclitaxel
Naloxegol may increase the serum concentration of Vinorelbine and Vinorelbine may increase the neurotoxic activities of Paclitaxel
Naloxegol may increase the serum concentration of Nelfinavir and Nelfinavir may decrease the metabolism of Paclitaxel
Naloxegol may increase the serum concentration of Ergometrine and Ergometrine may increase the severity of adverse effects when combined with Paclitaxel
Naloxegol may increase the serum concentration of Thioridazine and Thioridazine may increase the severity of adverse effects when combined with Paclitaxel
Naloxegol may increase the serum concentration of Digoxin and Digoxin may decrease the cardiotoxic activities of Paclitaxel
|
DB00925
|
DB01054
| 355 | 329 |
Phenoxybenzamine
|
Nitrendipine
|
An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.
|
Nitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
|
Phenoxybenzamine may increase the hypotensive activities of Nitrendipine.
| 59 |
[
[
[
355,
82,
329
]
],
[
[
355,
82,
435
],
[
435,
1,
329
]
],
[
[
355,
236,
158
],
[
158,
1,
329
]
],
[
[
355,
6,
4590
],
[
4590,
160,
329
]
],
[
[
355,
180,
164
],
[
164,
26,
329
]
],
[
[
355,
236,
197
],
[
197,
26,
329
]
],
[
[
355,
186,
344
],
[
344,
32,
329
]
],
[
[
355,
52,
968
],
[
968,
206,
329
]
],
[
[
355,
59,
230
],
[
230,
213,
329
]
],
[
[
355,
69,
1092
],
[
1092,
223,
329
]
]
] |
[
[
[
"Phenoxybenzamine",
"{u} may increase the hypotensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the hypotensive activities of {v}",
"Nilvadipine"
],
[
"Nilvadipine",
"{u} (Compound) resembles {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the hypotensive activities of {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Phenoxybenzamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Nitrendipine"
]
],
[
[
"Phenoxybenzamine",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Nitrendipine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the hypotensive activities of {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} can increase the metabolism of {v}",
"Nitrendipine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the antihypertensive activities of {v}",
"Udenafil"
],
[
"Udenafil",
"{u} may increase the antihypertensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Phenoxybenzamine",
"{u} may decrease the antihypertensive activities of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensive activities of {v}",
"Nitrendipine"
]
],
[
[
"Phenoxybenzamine",
"{u} may decrease the metabolism of {v}",
"Telaprevir"
],
[
"Telaprevir",
"{u} may decrease the metabolism of {v}",
"Nitrendipine"
]
]
] |
Phenoxybenzamine may increase the hypotensive activities of Nilvadipine and Nilvadipine (Compound) resembles Nitrendipine (Compound)
Phenoxybenzamine may increase the hypotensive activities of Nicardipine and Nicardipine (Compound) resembles Nitrendipine (Compound)
Phenoxybenzamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nitrendipine (Compound)
Phenoxybenzamine can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Nitrendipine
Phenoxybenzamine may increase the hypotensive activities of Amobarbital and Amobarbital can increase the metabolism of Nitrendipine
Phenoxybenzamine may increase the antihypertensive activities of Udenafil and Udenafil may increase the antihypertensive activities of Nitrendipine
Phenoxybenzamine may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Nitrendipine
Phenoxybenzamine may decrease the antihypertensive activities of Yohimbine and Yohimbine may decrease the antihypertensive activities of Nitrendipine
Phenoxybenzamine may decrease the metabolism of Telaprevir and Telaprevir may decrease the metabolism of Nitrendipine
|
DB00543
|
DB00701
| 224 | 431 |
Amoxapine
|
Amprenavir
|
Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block
|
Amprenavir is a protease inhibitor used to treat HIV infection.
|
The serum concentration of Amprenavir can be increased when it is combined with Amoxapine.
| 72 |
[
[
[
224,
95,
431
]
],
[
[
224,
6,
18777
],
[
18777,
160,
431
]
],
[
[
224,
21,
28501
],
[
28501,
175,
431
]
],
[
[
224,
180,
171
],
[
171,
26,
431
]
],
[
[
224,
225,
142
],
[
142,
26,
431
]
],
[
[
224,
71,
150
],
[
150,
26,
431
]
],
[
[
224,
69,
173
],
[
173,
26,
431
]
],
[
[
224,
69,
422
],
[
422,
223,
431
]
],
[
[
224,
1,
681
],
[
681,
223,
431
]
],
[
[
224,
196,
575
],
[
575,
223,
431
]
]
] |
[
[
[
"Amoxapine",
"{u} may increase the serum concentration of {v}",
"Amprenavir"
]
],
[
[
"Amoxapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Amprenavir"
]
],
[
[
"Amoxapine",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amprenavir"
]
],
[
[
"Amoxapine",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Amoxapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Amoxapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Amoxapine",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Amoxapine",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may decrease the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Amoxapine",
"{u} (Compound) resembles {v} (Compound)",
"Clozapine"
],
[
"Clozapine",
"{u} may decrease the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Amoxapine",
"{u} may increase the QTc prolonging activities of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may decrease the metabolism of {v}",
"Amprenavir"
]
]
] |
Amoxapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Amprenavir (Compound)
Amoxapine (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Amprenavir (Compound)
Amoxapine can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Amprenavir
Amoxapine may increase the severity of adverse effects when combined with Phenytoin and Phenytoin can increase the metabolism of Amprenavir
Amoxapine may increase the severity of adverse effects when combined with Fosphenytoin and Fosphenytoin can increase the metabolism of Amprenavir
Amoxapine may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Amprenavir
Amoxapine may decrease the metabolism of Midostaurin and Midostaurin may decrease the metabolism of Amprenavir
Amoxapine (Compound) resembles Clozapine (Compound) and Clozapine may decrease the metabolism of Amprenavir
Amoxapine may increase the QTc prolonging activities of Sulfisoxazole and Sulfisoxazole may decrease the metabolism of Amprenavir
|
DB00604
|
DB01149
| 633 | 648 |
Cisapride
|
Nefazodone
|
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
|
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
|
The serum concentration of Nefazodone can be increased when it is combined with Cisapride.
| 72 |
[
[
[
633,
95,
648
]
],
[
[
633,
55,
370
],
[
370,
95,
648
]
],
[
[
633,
42,
1262
],
[
1262,
71,
648
]
],
[
[
633,
42,
175
],
[
175,
69,
648
]
],
[
[
633,
42,
932
],
[
932,
95,
648
]
],
[
[
633,
6,
8607
],
[
8607,
160,
648
]
],
[
[
633,
180,
173
],
[
173,
26,
648
]
],
[
[
633,
69,
297
],
[
297,
31,
648
]
],
[
[
633,
69,
795
],
[
795,
187,
648
]
],
[
[
633,
69,
556
],
[
556,
69,
648
]
]
] |
[
[
[
"Cisapride",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
]
],
[
[
"Cisapride",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Domperidone"
],
[
"Domperidone",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
]
],
[
[
"Cisapride",
"{u} may increase the QTc prolonging activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nefazodone"
]
],
[
[
"Cisapride",
"{u} may increase the QTc prolonging activities of {v}",
"Trazodone"
],
[
"Trazodone",
"{u} may decrease the metabolism of {v}",
"Nefazodone"
]
],
[
[
"Cisapride",
"{u} may increase the QTc prolonging activities of {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may increase the serum concentration of {v}",
"Nefazodone"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Nefazodone"
]
],
[
[
"Cisapride",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Nefazodone"
]
],
[
[
"Cisapride",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Nefazodone"
]
],
[
[
"Cisapride",
"{u} may decrease the metabolism of {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Nefazodone"
]
],
[
[
"Cisapride",
"{u} may decrease the metabolism of {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may decrease the metabolism of {v}",
"Nefazodone"
]
]
] |
Cisapride may increase the severity of QTc prolonging effects when combined with Domperidone and Domperidone may increase the serum concentration of Nefazodone
Cisapride may increase the QTc prolonging activities of Hydroxyzine and Hydroxyzine may increase the severity of adverse effects when combined with Nefazodone
Cisapride may increase the QTc prolonging activities of Trazodone and Trazodone may decrease the metabolism of Nefazodone
Cisapride may increase the QTc prolonging activities of Aripiprazole and Aripiprazole may increase the serum concentration of Nefazodone
Cisapride (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Nefazodone (Compound)
Cisapride can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Nefazodone
Cisapride may decrease the metabolism of Tolbutamide and Tolbutamide may increase the hypoglycemic activities of Nefazodone
Cisapride may decrease the metabolism of Ticagrelor and Ticagrelor may reduce the serum concentration of the active metabolites of Nefazodone
Cisapride may decrease the metabolism of Citalopram and Citalopram may decrease the metabolism of Nefazodone
|
DB06288
|
DB00413
| 980 | 1,365 |
Amisulpride
|
Pramipexole
|
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea
|
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients, leading to increased difficulty in performing activities of daily living due to symptoms that progress over time. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016. This increase may be attributed to an aging population along with other contributing factors. In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (
|
Amisulpride may increase the sedative activities of Pramipexole.
| 31 |
[
[
[
980,
54,
1365
]
],
[
[
980,
6,
7869
],
[
7869,
160,
1365
]
],
[
[
980,
21,
28515
],
[
28515,
175,
1365
]
],
[
[
980,
225,
828
],
[
828,
206,
1365
]
],
[
[
980,
225,
962
],
[
962,
54,
1365
]
],
[
[
980,
71,
959
],
[
959,
54,
1365
]
],
[
[
980,
192,
587
],
[
587,
54,
1365
]
],
[
[
980,
58,
973
],
[
973,
54,
1365
]
],
[
[
980,
246,
968
],
[
968,
54,
1365
]
],
[
[
980,
38,
702
],
[
702,
54,
1365
]
]
] |
[
[
[
"Amisulpride",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Amisulpride",
"{u} (Compound) binds {v} (Gene)",
"HTR2B"
],
[
"HTR2B",
"{u} (Gene) is bound by {v} (Compound)",
"Pramipexole"
]
],
[
[
"Amisulpride",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pramipexole"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Pramipexole"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mepivacaine"
],
[
"Mepivacaine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Amisulpride",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Amisulpride",
"{u} may increase the antipsychotic activities of {v}",
"Aceprometazine"
],
[
"Aceprometazine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Amisulpride",
"{u} may decrease the therapeutic efficacy of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Amisulpride",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
]
] |
Amisulpride (Compound) binds HTR2B (Gene) and HTR2B (Gene) is bound by Pramipexole (Compound)
Amisulpride (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Pramipexole (Compound)
Amisulpride may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Pramipexole
Amisulpride may increase the severity of adverse effects when combined with Mepivacaine and Mepivacaine may increase the sedative activities of Pramipexole
Amisulpride may increase the severity of adverse effects when combined with Fexofenadine and Fexofenadine may increase the sedative activities of Pramipexole
Amisulpride may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the sedative activities of Pramipexole
Amisulpride may increase the antipsychotic activities of Aceprometazine and Aceprometazine may increase the sedative activities of Pramipexole
Amisulpride may decrease the therapeutic efficacy of Levodopa and Levodopa may increase the sedative activities of Pramipexole
Amisulpride may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the sedative activities of Pramipexole
|
DB00645
|
DB01202
| 982 | 1,271 |
Dyclonine
|
Levetiracetam
|
Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It may also be found in some Cepacol sore throat spray products.
|
Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions.
|
The risk or severity of adverse effects can be increased when Dyclonine is combined with Levetiracetam.
| 48 |
[
[
[
982,
71,
1271
]
],
[
[
982,
38,
702
],
[
702,
192,
1271
]
],
[
[
982,
192,
1083
],
[
1083,
38,
1271
]
],
[
[
982,
54,
1365
],
[
1365,
208,
1271
]
],
[
[
982,
71,
257
],
[
257,
71,
1271
]
],
[
[
982,
71,
963
],
[
963,
225,
1271
]
],
[
[
982,
225,
442
],
[
442,
71,
1271
]
],
[
[
982,
155,
245
],
[
245,
71,
1271
]
],
[
[
982,
184,
674
],
[
674,
92,
1271
]
],
[
[
982,
38,
702
],
[
702,
21,
28479
],
[
28479,
175,
1271
]
]
] |
[
[
[
"Dyclonine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levetiracetam"
]
],
[
[
"Dyclonine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Levetiracetam"
]
],
[
[
"Dyclonine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Levetiracetam"
]
],
[
[
"Dyclonine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Levetiracetam"
]
],
[
[
"Dyclonine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sertindole"
],
[
"Sertindole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levetiracetam"
]
],
[
[
"Dyclonine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gabapentin enacarbil"
],
[
"Gabapentin enacarbil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levetiracetam"
]
],
[
[
"Dyclonine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrazepam"
],
[
"Nitrazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levetiracetam"
]
],
[
[
"Dyclonine",
"{u} (Compound) resembles {v} (Compound)",
"Haloperidol"
],
[
"Haloperidol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levetiracetam"
]
],
[
[
"Dyclonine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} may decrease the therapeutic efficacy of {v}",
"Levetiracetam"
]
],
[
[
"Dyclonine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} (Compound) causes {v} (Side Effect)",
"Bronchitis"
],
[
"Bronchitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levetiracetam"
]
]
] |
Dyclonine may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Levetiracetam
Dyclonine may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Levetiracetam
Dyclonine may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Levetiracetam
Dyclonine may increase the severity of adverse effects when combined with Sertindole and Sertindole may increase the severity of adverse effects when combined with Levetiracetam
Dyclonine may increase the severity of adverse effects when combined with Gabapentin enacarbil and Gabapentin enacarbil may increase the severity of adverse effects when combined with Levetiracetam
Dyclonine may increase the severity of adverse effects when combined with Nitrazepam and Nitrazepam may increase the severity of adverse effects when combined with Levetiracetam
Dyclonine (Compound) resembles Haloperidol (Compound) and Haloperidol may increase the severity of adverse effects when combined with Levetiracetam
Dyclonine can increase the therapeutic efficacy of Pregabalin and Pregabalin may decrease the therapeutic efficacy of Levetiracetam
Dyclonine may increase the central nervous system depressant activities of Brimonidine and Brimonidine (Compound) causes Bronchitis (Side Effect) and Bronchitis (Side Effect) is caused by Levetiracetam (Compound)
|
DB00628
|
DB00263
| 335 | 575 |
Clorazepic acid
|
Sulfisoxazole
|
Clorazepic acid (clorazepate) is a water-soluble benzodiazepine with muscle-relaxant and anticonvulsant actions effective in the treatment of anxiety.[A957,L44788] Following administration, clorazepate is rapidly converted to nordiazepam (N-desmethyldiazepam), its active metabolite, before entering systemic circulation. Similar to other benzodiazepines, the active metabolite of clorazepate enhances the binding of gamma-aminobutyric acid (GABA) to the GABA type A (GABA-A) receptor, which promotes channel opening and neuronal hyperpolarization.[A256683,T883] The concomitant use of clorazepate and opioids may result in profound sedation, respiratory depression, coma, and death. Also, the use of clorazepate exposes users to users to the risks of abuse, misuse, and addiction
|
A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
|
The metabolism of Sulfisoxazole can be decreased when combined with Clorazepic acid.
| 46 |
[
[
[
335,
69,
575
]
],
[
[
335,
180,
177
],
[
177,
26,
575
]
],
[
[
335,
95,
191
],
[
191,
26,
575
]
],
[
[
335,
249,
142
],
[
142,
26,
575
]
],
[
[
335,
155,
169
],
[
169,
28,
575
]
],
[
[
335,
71,
320
],
[
320,
184,
575
]
],
[
[
335,
71,
63
],
[
63,
185,
575
]
],
[
[
335,
71,
175
],
[
175,
196,
575
]
],
[
[
335,
69,
528
],
[
528,
42,
575
]
],
[
[
335,
225,
245
],
[
245,
42,
575
]
]
] |
[
[
[
"Clorazepic acid",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
]
],
[
[
"Clorazepic acid",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Sulfisoxazole"
]
],
[
[
"Clorazepic acid",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} can increase the metabolism of {v}",
"Sulfisoxazole"
]
],
[
[
"Clorazepic acid",
"{u} may increase the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Sulfisoxazole"
]
],
[
[
"Clorazepic acid",
"{u} (Compound) resembles {v} (Compound)",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Sulfisoxazole"
]
],
[
[
"Clorazepic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thiopental"
],
[
"Thiopental",
"{u} can increase the therapeutic efficacy of {v}",
"Sulfisoxazole"
]
],
[
[
"Clorazepic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may increase the hypoglycemic activities of {v}",
"Sulfisoxazole"
]
],
[
[
"Clorazepic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} may increase the QTc prolonging activities of {v}",
"Sulfisoxazole"
]
],
[
[
"Clorazepic acid",
"{u} may decrease the metabolism of {v}",
"Telithromycin"
],
[
"Telithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Sulfisoxazole"
]
],
[
[
"Clorazepic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may increase the QTc prolonging activities of {v}",
"Sulfisoxazole"
]
]
] |
Clorazepic acid can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Sulfisoxazole
Clorazepic acid may increase the serum concentration of Aprepitant and Aprepitant can increase the metabolism of Sulfisoxazole
Clorazepic acid may increase the serum concentration of Phenytoin and Phenytoin can increase the metabolism of Sulfisoxazole
Clorazepic acid (Compound) resembles Phenindione (Compound) and Phenindione may increase the anticoagulant activities of Sulfisoxazole
Clorazepic acid may increase the severity of adverse effects when combined with Thiopental and Thiopental can increase the therapeutic efficacy of Sulfisoxazole
Clorazepic acid may increase the severity of adverse effects when combined with Tranylcypromine and Tranylcypromine may increase the hypoglycemic activities of Sulfisoxazole
Clorazepic acid may increase the severity of adverse effects when combined with Trazodone and Trazodone may increase the QTc prolonging activities of Sulfisoxazole
Clorazepic acid may decrease the metabolism of Telithromycin and Telithromycin may increase the QTc prolonging activities of Sulfisoxazole
Clorazepic acid may increase the severity of adverse effects when combined with Haloperidol and Haloperidol may increase the QTc prolonging activities of Sulfisoxazole
|
DB00370
|
DB00542
| 543 | 642 |
Mirtazapine
|
Benazepril
|
Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.
|
Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837]. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
|
The serum concentration of Benazepril can be increased when it is combined with Mirtazapine.
| 72 |
[
[
[
543,
95,
642
]
],
[
[
543,
196,
1318
],
[
1318,
1,
642
]
],
[
[
543,
95,
315
],
[
315,
225,
642
]
],
[
[
543,
38,
961
],
[
961,
1,
642
]
],
[
[
543,
95,
549
],
[
549,
236,
642
]
],
[
[
543,
95,
676
],
[
676,
1,
642
]
],
[
[
543,
21,
28847
],
[
28847,
175,
642
]
],
[
[
543,
38,
156
],
[
156,
26,
642
]
],
[
[
543,
213,
702
],
[
702,
32,
642
]
],
[
[
543,
38,
968
],
[
968,
206,
642
]
]
] |
[
[
[
"Mirtazapine",
"{u} may increase the serum concentration of {v}",
"Benazepril"
]
],
[
[
"Mirtazapine",
"{u} may increase the QTc prolonging activities of {v}",
"Propafenone"
],
[
"Propafenone",
"{u} (Compound) resembles {v} (Compound)",
"Benazepril"
]
],
[
[
"Mirtazapine",
"{u} may increase the serum concentration of {v}",
"Enalapril"
],
[
"Enalapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benazepril"
]
],
[
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Benazepril"
]
],
[
[
"Mirtazapine",
"{u} may increase the serum concentration of {v}",
"Spirapril"
],
[
"Spirapril",
"{u} may increase the hypotensive activities of {v}",
"Benazepril"
]
],
[
[
"Mirtazapine",
"{u} may increase the serum concentration of {v}",
"Lisinopril"
],
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Benazepril"
]
],
[
[
"Mirtazapine",
"{u} (Compound) causes {v} (Side Effect)",
"Erectile dysfunction"
],
[
"Erectile dysfunction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Benazepril"
]
],
[
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Benazepril"
]
],
[
[
"Mirtazapine",
"{u} may decrease the antihypertensive activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Benazepril"
]
],
[
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Benazepril"
]
]
] |
Mirtazapine may increase the QTc prolonging activities of Propafenone and Propafenone (Compound) resembles Benazepril (Compound)
Mirtazapine may increase the serum concentration of Enalapril and Enalapril may increase the severity of adverse effects when combined with Benazepril
Mirtazapine may increase the central nervous system depressant activities of Fentanyl and Fentanyl (Compound) resembles Benazepril (Compound)
Mirtazapine may increase the serum concentration of Spirapril and Spirapril may increase the hypotensive activities of Benazepril
Mirtazapine may increase the serum concentration of Lisinopril and Lisinopril (Compound) resembles Benazepril (Compound)
Mirtazapine (Compound) causes Erectile dysfunction (Side Effect) and Erectile dysfunction (Side Effect) is caused by Benazepril (Compound)
Mirtazapine may increase the central nervous system depressant activities of Carbamazepine and Carbamazepine can increase the metabolism of Benazepril
Mirtazapine may decrease the antihypertensive activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Benazepril
Mirtazapine may increase the central nervous system depressant activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Benazepril
|
DB00216
|
DB00283
| 558 | 41 |
Eletriptan
|
Clemastine
|
Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
|
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
|
The serum concentration of Clemastine can be increased when it is combined with Eletriptan.
| 72 |
[
[
[
558,
119,
41
]
],
[
[
558,
1,
1407
],
[
1407,
69,
41
]
],
[
[
558,
116,
990
],
[
990,
69,
41
]
],
[
[
558,
6,
4590
],
[
4590,
160,
41
]
],
[
[
558,
21,
28684
],
[
28684,
175,
41
]
],
[
[
558,
69,
31
],
[
31,
178,
41
]
],
[
[
558,
71,
42
],
[
42,
178,
41
]
],
[
[
558,
71,
543
],
[
543,
38,
41
]
],
[
[
558,
69,
414
],
[
414,
69,
41
]
],
[
[
558,
71,
221
],
[
221,
69,
41
]
]
] |
[
[
[
"Eletriptan",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the serum concentration of {v}",
"Clemastine"
]
],
[
[
"Eletriptan",
"{u} (Compound) resembles {v} (Compound)",
"Encainide"
],
[
"Encainide",
"{u} may decrease the metabolism of {v}",
"Clemastine"
]
],
[
[
"Eletriptan",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Mesoridazine"
],
[
"Mesoridazine",
"{u} may decrease the metabolism of {v}",
"Clemastine"
]
],
[
[
"Eletriptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clemastine"
]
],
[
[
"Eletriptan",
"{u} (Compound) causes {v} (Side Effect)",
"Euphoric mood"
],
[
"Euphoric mood",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clemastine"
]
],
[
[
"Eletriptan",
"{u} may decrease the metabolism of {v}",
"Minaprine"
],
[
"Minaprine",
"{u} may increase the anticholinergic activities of {v}",
"Clemastine"
]
],
[
[
"Eletriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isocarboxazid"
],
[
"Isocarboxazid",
"{u} may increase the anticholinergic activities of {v}",
"Clemastine"
]
],
[
[
"Eletriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Clemastine"
]
],
[
[
"Eletriptan",
"{u} may decrease the metabolism of {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Clemastine"
]
],
[
[
"Eletriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} may decrease the metabolism of {v}",
"Clemastine"
]
]
] |
Eletriptan (Compound) resembles Clemastine (Compound) and
Eletriptan (Compound) resembles Encainide (Compound) and Encainide may decrease the metabolism of Clemastine
Eletriptan (Compound) resembles Mesoridazine (Compound) and Eletriptan may increase the severity of adverse effects when combined with Mesoridazine and Mesoridazine may decrease the metabolism of Clemastine
Eletriptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clemastine (Compound)
Eletriptan (Compound) causes Euphoric mood (Side Effect) and Euphoric mood (Side Effect) is caused by Clemastine (Compound)
Eletriptan may decrease the metabolism of Minaprine and Minaprine may increase the anticholinergic activities of Clemastine
Eletriptan may increase the severity of adverse effects when combined with Isocarboxazid and Isocarboxazid may increase the anticholinergic activities of Clemastine
Eletriptan may increase the severity of adverse effects when combined with Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Clemastine
Eletriptan may decrease the metabolism of Cholecalciferol and Cholecalciferol may decrease the metabolism of Clemastine
Eletriptan may increase the severity of adverse effects when combined with Nortriptyline and Nortriptyline may decrease the metabolism of Clemastine
|
DB00898
|
DB09128
| 587 | 957 |
Ethanol
|
Brexpiprazole
|
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
|
Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor. It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. Currently approved for the treatment of depression, schizophrenia, and agitation
|
Ethanol may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
| 15 |
[
[
[
587,
38,
957
]
],
[
[
587,
38,
674
],
[
674,
30,
957
]
],
[
[
587,
38,
1257
],
[
1257,
192,
957
]
],
[
[
587,
192,
1083
],
[
1083,
38,
957
]
],
[
[
587,
192,
1264
],
[
1264,
192,
957
]
],
[
[
587,
54,
471
],
[
471,
208,
957
]
],
[
[
587,
38,
997
],
[
997,
57,
957
]
],
[
[
587,
38,
980
],
[
980,
58,
957
]
],
[
[
587,
38,
916
],
[
916,
71,
957
]
],
[
[
587,
71,
542
],
[
542,
71,
957
]
]
] |
[
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Brexpiprazole"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Brexpiprazole"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Brexpiprazole"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Brexpiprazole"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Brexpiprazole"
]
],
[
[
"Ethanol",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Brexpiprazole"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Brexpiprazole"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Amisulpride"
],
[
"Amisulpride",
"{u} may increase the antipsychotic activities of {v}",
"Brexpiprazole"
]
],
[
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Etomidate"
],
[
"Etomidate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brexpiprazole"
]
],
[
[
"Ethanol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zopiclone"
],
[
"Zopiclone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brexpiprazole"
]
]
] |
Ethanol may increase the central nervous system depressant activities of Pregabalin and Pregabalin can increase the therapeutic efficacy of Brexpiprazole
Ethanol may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Brexpiprazole
Ethanol may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Brexpiprazole
Ethanol may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Brexpiprazole
Ethanol may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Brexpiprazole
Ethanol may increase the central nervous system depressant activities of Lithium cation and Lithium cation may increase the neurotoxic activities of Brexpiprazole
Ethanol may increase the central nervous system depressant activities of Amisulpride and Amisulpride may increase the antipsychotic activities of Brexpiprazole
Ethanol may increase the central nervous system depressant activities of Etomidate and Etomidate may increase the severity of adverse effects when combined with Brexpiprazole
Ethanol may increase the severity of adverse effects when combined with Zopiclone and Zopiclone may increase the severity of adverse effects when combined with Brexpiprazole
|
DB06605
|
DB00675
| 632 | 568 |
Apixaban
|
Tamoxifen
|
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012.
|
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
|
The metabolism of Tamoxifen can be decreased when combined with Apixaban.
| 46 |
[
[
[
632,
69,
568
]
],
[
[
632,
28,
827
],
[
827,
1,
568
]
],
[
[
632,
97,
574
],
[
574,
1,
568
]
],
[
[
632,
249,
195
],
[
195,
155,
568
]
],
[
[
632,
6,
8607
],
[
8607,
160,
568
]
],
[
[
632,
21,
28498
],
[
28498,
175,
568
]
],
[
[
632,
180,
156
],
[
156,
26,
568
]
],
[
[
632,
251,
161
],
[
161,
26,
568
]
],
[
[
632,
182,
219
],
[
219,
28,
568
]
],
[
[
632,
225,
613
],
[
613,
33,
568
]
]
] |
[
[
[
"Apixaban",
"{u} may decrease the metabolism of {v}",
"Tamoxifen"
]
],
[
[
"Apixaban",
"{u} may increase the anticoagulant activities of {v}",
"Naftifine"
],
[
"Naftifine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Apixaban",
"{u} may decrease the serum concentration of {v}",
"Diethylstilbestrol"
],
[
"Diethylstilbestrol",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Apixaban",
"{u} may increase the serum concentration of {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Apixaban",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Apixaban",
"{u} (Compound) causes {v} (Side Effect)",
"Haemorrhage"
],
[
"Haemorrhage",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Apixaban",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Tamoxifen"
]
],
[
[
"Apixaban",
"{u} may decrease the serum concentration of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Tamoxifen"
]
],
[
[
"Apixaban",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Tamoxifen"
]
],
[
[
"Apixaban",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Tamoxifen"
]
]
] |
Apixaban may increase the anticoagulant activities of Naftifine and Naftifine (Compound) resembles Tamoxifen (Compound)
Apixaban may decrease the serum concentration of Diethylstilbestrol and Diethylstilbestrol (Compound) resembles Tamoxifen (Compound)
Apixaban may increase the serum concentration of Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Tamoxifen (Compound)
Apixaban (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Tamoxifen (Compound)
Apixaban (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Tamoxifen (Compound)
Apixaban can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Tamoxifen
Apixaban may decrease the serum concentration of Primidone and Primidone can increase the metabolism of Tamoxifen
Apixaban may increase the anticoagulant activities of Warfarin and Warfarin may increase the anticoagulant activities of Tamoxifen
Apixaban may increase the severity of adverse effects when combined with Ticlopidine and Ticlopidine may reduce the serum concentration of the active metabolites of Tamoxifen
|
DB01320
|
DB00253
| 150 | 101 |
Fosphenytoin
|
Medrysone
|
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
|
Medrysone is a corticosteroid used in ophthalmology.
|
The serum concentration of Medrysone can be decreased when it is combined with Fosphenytoin.
| 74 |
[
[
[
150,
97,
101
]
],
[
[
150,
97,
129
],
[
129,
155,
101
]
],
[
[
150,
97,
117
],
[
117,
1,
101
]
],
[
[
150,
92,
623
],
[
623,
155,
101
]
],
[
[
150,
26,
372
],
[
372,
155,
101
]
],
[
[
150,
21,
28580
],
[
28580,
175,
101
]
],
[
[
150,
39,
25
],
[
25,
198,
101
]
],
[
[
150,
26,
364
],
[
364,
71,
101
]
],
[
[
150,
97,
827
],
[
827,
71,
101
]
],
[
[
150,
246,
285
],
[
285,
225,
101
]
]
] |
[
[
[
"Fosphenytoin",
"{u} may decrease the serum concentration of {v}",
"Medrysone"
]
],
[
[
"Fosphenytoin",
"{u} may decrease the serum concentration of {v}",
"Fluocortolone"
],
[
"Fluocortolone",
"{u} (Compound) resembles {v} (Compound)",
"Medrysone"
]
],
[
[
"Fosphenytoin",
"{u} may decrease the serum concentration of {v}",
"Rimexolone"
],
[
"Rimexolone",
"{u} (Compound) resembles {v} (Compound)",
"Medrysone"
]
],
[
[
"Fosphenytoin",
"{u} may decrease the therapeutic efficacy of {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} (Compound) resembles {v} (Compound)",
"Medrysone"
]
],
[
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Finasteride"
],
[
"Finasteride",
"{u} (Compound) resembles {v} (Compound)",
"Medrysone"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Conjunctivitis"
],
[
"Conjunctivitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Medrysone"
]
],
[
[
"Fosphenytoin",
"{u} may decrease the neuromuscular blocking activities of {v}",
"Atracurium besylate"
],
[
"Atracurium besylate",
"{u} may increase the adverse neuromuscular activities of {v}",
"Medrysone"
]
],
[
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Etoricoxib"
],
[
"Etoricoxib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Medrysone"
]
],
[
[
"Fosphenytoin",
"{u} may decrease the serum concentration of {v}",
"Naftifine"
],
[
"Naftifine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Medrysone"
]
],
[
[
"Fosphenytoin",
"{u} may decrease the therapeutic efficacy of {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Medrysone"
]
]
] |
Fosphenytoin may decrease the serum concentration of Fluocortolone and Fluocortolone (Compound) resembles Medrysone (Compound)
Fosphenytoin may decrease the serum concentration of Rimexolone and Rimexolone (Compound) resembles Medrysone (Compound)
Fosphenytoin may decrease the therapeutic efficacy of Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) resembles Medrysone (Compound)
Fosphenytoin can increase the metabolism of Finasteride and Finasteride (Compound) resembles Medrysone (Compound)
Fosphenytoin (Compound) causes Conjunctivitis (Side Effect) and Conjunctivitis (Side Effect) is caused by Medrysone (Compound)
Fosphenytoin may decrease the neuromuscular blocking activities of Atracurium besylate and Atracurium besylate may increase the adverse neuromuscular activities of Medrysone
Fosphenytoin can increase the metabolism of Etoricoxib and Etoricoxib may increase the severity of adverse effects when combined with Medrysone
Fosphenytoin may decrease the serum concentration of Naftifine and Naftifine may increase the severity of adverse effects when combined with Medrysone
Fosphenytoin may decrease the therapeutic efficacy of Mefloquine and Mefloquine may increase the severity of adverse effects when combined with Medrysone
|
DB00633
|
DB08883
| 724 | 1,257 |
Dexmedetomidine
|
Perampanel
|
An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.
|
Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.
|
Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
| 15 |
[
[
[
724,
38,
1257
]
],
[
[
724,
71,
988
],
[
988,
38,
1257
]
],
[
[
724,
225,
639
],
[
639,
38,
1257
]
],
[
[
724,
192,
679
],
[
679,
38,
1257
]
],
[
[
724,
82,
453
],
[
453,
38,
1257
]
],
[
[
724,
249,
730
],
[
730,
38,
1257
]
],
[
[
724,
59,
195
],
[
195,
38,
1257
]
],
[
[
724,
236,
932
],
[
932,
38,
1257
]
],
[
[
724,
47,
911
],
[
911,
38,
1257
]
],
[
[
724,
52,
968
],
[
968,
38,
1257
]
]
] |
[
[
[
"Dexmedetomidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Melperone"
],
[
"Melperone",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the hypotensive activities of {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the serum concentration of {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Dexmedetomidine",
"{u} may decrease the antihypertensive activities of {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the hypotensive activities of {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
]
] |
Dexmedetomidine may increase the severity of adverse effects when combined with Melperone and Melperone may increase the central nervous system depressant activities of Perampanel
Dexmedetomidine may increase the severity of adverse effects when combined with Valproic acid and Valproic acid may increase the central nervous system depressant activities of Perampanel
Dexmedetomidine may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Perampanel
Dexmedetomidine may increase the hypotensive activities of Risperidone and Risperidone may increase the central nervous system depressant activities of Perampanel
Dexmedetomidine may increase the serum concentration of Tizanidine and Tizanidine may increase the central nervous system depressant activities of Perampanel
Dexmedetomidine may decrease the antihypertensive activities of Cyclobenzaprine and Cyclobenzaprine may increase the central nervous system depressant activities of Perampanel
Dexmedetomidine may increase the hypotensive activities of Aripiprazole and Aripiprazole may increase the central nervous system depressant activities of Perampanel
Dexmedetomidine may increase the atrioventricular blocking activities of Oxprenolol and Oxprenolol may increase the central nervous system depressant activities of Perampanel
Dexmedetomidine may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the central nervous system depressant activities of Perampanel
|
DB00454
|
DB09017
| 465 | 930 |
Meperidine
|
Brotizolam
|
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
|
Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects. Brotizolam has similar effects to short-acting benzodiazepines such as triazolam. Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours). Brotizolam is not approved for sale in the UK, United States or Canada but is sold in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan.
|
The risk or severity of adverse effects can be increased when Meperidine is combined with Brotizolam.
| 48 |
[
[
[
465,
71,
930
]
],
[
[
465,
184,
674
],
[
674,
30,
930
]
],
[
[
465,
38,
1264
],
[
1264,
192,
930
]
],
[
[
465,
192,
1083
],
[
1083,
38,
930
]
],
[
[
465,
54,
1365
],
[
1365,
208,
930
]
],
[
[
465,
225,
994
],
[
994,
71,
930
]
],
[
[
465,
71,
976
],
[
976,
225,
930
]
],
[
[
465,
71,
923
],
[
923,
71,
930
]
],
[
[
465,
251,
150
],
[
150,
225,
930
]
],
[
[
465,
69,
200
],
[
200,
71,
930
]
]
] |
[
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
],
[
[
"Meperidine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Brotizolam"
]
],
[
[
"Meperidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Brotizolam"
]
],
[
[
"Meperidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Brotizolam"
]
],
[
[
"Meperidine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Brotizolam"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butabarbital"
],
[
"Butabarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dimenhydrinate"
],
[
"Dimenhydrinate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Articaine"
],
[
"Articaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
],
[
[
"Meperidine",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
],
[
[
"Meperidine",
"{u} may decrease the metabolism of {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
]
]
] |
Meperidine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Brotizolam
Meperidine may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Brotizolam
Meperidine may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Brotizolam
Meperidine may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Brotizolam
Meperidine may increase the severity of adverse effects when combined with Butabarbital and Butabarbital may increase the severity of adverse effects when combined with Brotizolam
Meperidine may increase the severity of adverse effects when combined with Dimenhydrinate and Dimenhydrinate may increase the severity of adverse effects when combined with Brotizolam
Meperidine may increase the severity of adverse effects when combined with Articaine and Articaine may increase the severity of adverse effects when combined with Brotizolam
Meperidine may decrease the serum concentration of Fosphenytoin and Fosphenytoin may increase the severity of adverse effects when combined with Brotizolam
Meperidine may decrease the metabolism of Cocaine and Cocaine may increase the severity of adverse effects when combined with Brotizolam
|
DB00385
|
DB06736
| 895 | 148 |
Valrubicin
|
Aceclofenac
|
Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a chemotherapy drug commonly marketed under the trade name VALSTAR. It is a semisynthetic analog of the [doxorubicin], which is an anthracycline drug. Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder.
|
Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [A19667, A19668, A19670]. Aceclofenac potently inhibits the cyclo-oxygenase enzyme (COX) that is involved in the synthesis of prostaglandins, which are inflammatory mediators that cause pain, swelling, inflammation, and fever. Aceclofenac belongs to BCS Class II as it possesses poor aqueous solubility. It displays high permeability to penetrate into synovial joints where in patients with osteoarthritis and related conditions, the loss of articular cartilage in the area causes joint pain, tenderness, stiffness, crepitus,
|
Valrubicin may decrease the excretion rate of Aceclofenac which could result in a higher serum level.
| 71 |
[
[
[
895,
94,
148
]
],
[
[
895,
225,
893
],
[
893,
205,
148
]
],
[
[
895,
94,
582
],
[
582,
223,
148
]
],
[
[
895,
94,
793
],
[
793,
225,
148
]
],
[
[
895,
95,
1421
],
[
1421,
225,
148
]
],
[
[
895,
94,
478
],
[
478,
71,
148
]
],
[
[
895,
200,
1341
],
[
1341,
225,
148
]
],
[
[
895,
233,
198
],
[
198,
79,
148
]
],
[
[
895,
94,
768
],
[
768,
79,
148
]
],
[
[
895,
1,
207
],
[
207,
94,
148
]
]
] |
[
[
[
"Valrubicin",
"{u} may decrease the excretion rate {v}",
"Aceclofenac"
]
],
[
[
"Valrubicin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may decrease the diuretic activities of {v}",
"Aceclofenac"
]
],
[
[
"Valrubicin",
"{u} may decrease the excretion rate {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may decrease the metabolism of {v}",
"Aceclofenac"
]
],
[
[
"Valrubicin",
"{u} may decrease the excretion rate {v}",
"Salicylamide"
],
[
"Salicylamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceclofenac"
]
],
[
[
"Valrubicin",
"{u} may increase the serum concentration of {v}",
"Tenofovir disoproxil"
],
[
"Tenofovir disoproxil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceclofenac"
]
],
[
[
"Valrubicin",
"{u} may decrease the excretion rate {v}",
"Olopatadine"
],
[
"Olopatadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceclofenac"
]
],
[
[
"Valrubicin",
"{u} may increase the hypocalcemic activities of {v}",
"Alendronic acid"
],
[
"Alendronic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceclofenac"
]
],
[
[
"Valrubicin",
"{u} may increase the nephrotoxic activities of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the nephrotoxic activities of {v}",
"Aceclofenac"
]
],
[
[
"Valrubicin",
"{u} may decrease the excretion rate {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the nephrotoxic activities of {v}",
"Aceclofenac"
]
],
[
[
"Valrubicin",
"{u} (Compound) resembles {v} (Compound)",
"Idarubicin"
],
[
"Idarubicin",
"{u} may decrease the excretion rate {v}",
"Aceclofenac"
]
]
] |
Valrubicin may increase the severity of adverse effects when combined with Etacrynic acid and Etacrynic acid may decrease the diuretic activities of Aceclofenac
Valrubicin may decrease the excretion rate Leflunomide and Leflunomide may decrease the metabolism of Aceclofenac
Valrubicin may decrease the excretion rate Salicylamide and Salicylamide may increase the severity of adverse effects when combined with Aceclofenac
Valrubicin may increase the serum concentration of Tenofovir disoproxil and Tenofovir disoproxil may increase the severity of adverse effects when combined with Aceclofenac
Valrubicin may decrease the excretion rate Olopatadine and Olopatadine may increase the severity of adverse effects when combined with Aceclofenac
Valrubicin may increase the hypocalcemic activities of Alendronic acid and Alendronic acid may increase the severity of adverse effects when combined with Aceclofenac
Valrubicin may increase the nephrotoxic activities of Cyclosporine and Cyclosporine may increase the nephrotoxic activities of Aceclofenac
Valrubicin may decrease the excretion rate Olsalazine and Olsalazine may increase the nephrotoxic activities of Aceclofenac
Valrubicin (Compound) resembles Idarubicin (Compound) and Idarubicin may decrease the excretion rate Aceclofenac
|
DB00794
|
DB06212
| 161 | 1,437 |
Primidone
|
Tolvaptan
|
Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954.
|
Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
|
The serum concentration of Tolvaptan can be decreased when it is combined with Primidone.
| 74 |
[
[
[
161,
97,
1437
]
],
[
[
161,
26,
235
],
[
235,
249,
1437
]
],
[
[
161,
6,
4590
],
[
4590,
160,
1437
]
],
[
[
161,
21,
28622
],
[
28622,
175,
1437
]
],
[
[
161,
26,
510
],
[
510,
71,
1437
]
],
[
[
161,
225,
1012
],
[
1012,
71,
1437
]
],
[
[
161,
192,
1083
],
[
1083,
71,
1437
]
],
[
[
161,
26,
304
],
[
304,
78,
1437
]
],
[
[
161,
82,
1071
],
[
1071,
90,
1437
]
],
[
[
161,
26,
239
],
[
239,
90,
1437
]
]
] |
[
[
[
"Primidone",
"{u} may decrease the serum concentration of {v}",
"Tolvaptan"
]
],
[
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may increase the serum concentration of {v}",
"Tolvaptan"
]
],
[
[
"Primidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tolvaptan"
]
],
[
[
"Primidone",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tolvaptan"
]
],
[
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Sufentanil"
],
[
"Sufentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolvaptan"
]
],
[
[
"Primidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diamorphine"
],
[
"Diamorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolvaptan"
]
],
[
[
"Primidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolvaptan"
]
],
[
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Candesartan cilexetil"
],
[
"Candesartan cilexetil",
"{u} may increase the hypotensive effects when combined with {v}",
"Tolvaptan"
]
],
[
[
"Primidone",
"{u} may increase the hypotensive activities of {v}",
"Telmisartan"
],
[
"Telmisartan",
"{u} may increase the hyperkalemic activities of {v}",
"Tolvaptan"
]
],
[
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Valsartan"
],
[
"Valsartan",
"{u} may increase the hyperkalemic activities of {v}",
"Tolvaptan"
]
]
] |
Primidone can increase the metabolism of Zafirlukast and Zafirlukast may increase the serum concentration of Tolvaptan
Primidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tolvaptan (Compound)
Primidone (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Tolvaptan (Compound)
Primidone can increase the metabolism of Sufentanil and Sufentanil may increase the severity of adverse effects when combined with Tolvaptan
Primidone may increase the severity of adverse effects when combined with Diamorphine and Diamorphine may increase the severity of adverse effects when combined with Tolvaptan
Primidone may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the severity of adverse effects when combined with Tolvaptan
Primidone can increase the metabolism of Candesartan cilexetil and Candesartan cilexetil may increase the hypotensive effects when combined with Tolvaptan
Primidone may increase the hypotensive activities of Telmisartan and Telmisartan may increase the hyperkalemic activities of Tolvaptan
Primidone can increase the metabolism of Valsartan and Valsartan may increase the hyperkalemic activities of Tolvaptan
|
DB01100
|
DB00754
| 413 | 821 |
Pimozide
|
Ethotoin
|
A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
|
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used.
|
The risk or severity of adverse effects can be increased when Pimozide is combined with Ethotoin.
| 48 |
[
[
[
413,
71,
821
]
],
[
[
413,
180,
161
],
[
161,
155,
821
]
],
[
[
413,
71,
380
],
[
380,
71,
821
]
],
[
[
413,
6,
10999
],
[
10999,
160,
821
]
],
[
[
413,
18,
14599
],
[
14599,
172,
821
]
],
[
[
413,
21,
28463
],
[
28463,
175,
821
]
],
[
[
413,
192,
1266
],
[
1266,
38,
821
]
],
[
[
413,
38,
1264
],
[
1264,
192,
821
]
],
[
[
413,
54,
1046
],
[
1046,
208,
821
]
],
[
[
413,
225,
464
],
[
464,
71,
821
]
]
] |
[
[
[
"Pimozide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethotoin"
]
],
[
[
"Pimozide",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Ethotoin"
]
],
[
[
"Pimozide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Glutethimide"
],
[
"Glutethimide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethotoin"
]
],
[
[
"Pimozide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Ethotoin"
]
],
[
[
"Pimozide",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ethotoin"
]
],
[
[
"Pimozide",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ethotoin"
]
],
[
[
"Pimozide",
"{u} may increase the central nervous system depressant activities of {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethotoin"
]
],
[
[
"Pimozide",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethotoin"
]
],
[
[
"Pimozide",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Ethotoin"
]
],
[
[
"Pimozide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meprobamate"
],
[
"Meprobamate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethotoin"
]
]
] |
Pimozide can increase the metabolism of Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Pimozide may increase the severity of adverse effects when combined with Glutethimide and Glutethimide may increase the severity of adverse effects when combined with Ethotoin
Pimozide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ethotoin (Compound)
Pimozide (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Ethotoin (Compound)
Pimozide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Ethotoin (Compound)
Pimozide may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Ethotoin
Pimozide may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Ethotoin
Pimozide may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Ethotoin
Pimozide may increase the severity of adverse effects when combined with Meprobamate and Meprobamate may increase the severity of adverse effects when combined with Ethotoin
|
DB00381
|
DB00975
| 385 | 736 |
Amlodipine
|
Dipyridamole
|
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label].
|
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
|
The risk or severity of adverse effects can be increased when Amlodipine is combined with Dipyridamole.
| 48 |
[
[
[
385,
71,
736
]
],
[
[
385,
6,
8339
],
[
8339,
160,
736
]
],
[
[
385,
10,
17096
],
[
17096,
164,
736
]
],
[
[
385,
21,
28913
],
[
28913,
175,
736
]
],
[
[
385,
92,
597
],
[
597,
28,
736
]
],
[
[
385,
69,
613
],
[
613,
182,
736
]
],
[
[
385,
52,
828
],
[
828,
206,
736
]
],
[
[
385,
71,
1359
],
[
1359,
71,
736
]
],
[
[
385,
71,
426
],
[
426,
225,
736
]
],
[
[
385,
82,
1360
],
[
1360,
71,
736
]
]
] |
[
[
[
"Amlodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dipyridamole"
]
],
[
[
"Amlodipine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dipyridamole"
]
],
[
[
"Amlodipine",
"{u} (Compound) palliates {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u} (Disease) is palliated by {v} (Compound)",
"Dipyridamole"
]
],
[
[
"Amlodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Migraine"
],
[
"Migraine",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dipyridamole"
]
],
[
[
"Amlodipine",
"{u} may decrease the therapeutic efficacy of {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may increase the anticoagulant activities of {v}",
"Dipyridamole"
]
],
[
[
"Amlodipine",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may increase the anticoagulant activities of {v}",
"Dipyridamole"
]
],
[
[
"Amlodipine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Dipyridamole"
]
],
[
[
"Amlodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triamterene"
],
[
"Triamterene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dipyridamole"
]
],
[
[
"Amlodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dipyridamole"
]
],
[
[
"Amlodipine",
"{u} may increase the hypotensive activities of {v}",
"Amifostine"
],
[
"Amifostine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dipyridamole"
]
]
] |
Amlodipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dipyridamole (Compound)
Amlodipine (Compound) palliates coronary artery disease (Disease) and coronary artery disease (Disease) is palliated by Dipyridamole (Compound)
Amlodipine (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Dipyridamole (Compound)
Amlodipine may decrease the therapeutic efficacy of Clopidogrel and Clopidogrel may increase the anticoagulant activities of Dipyridamole
Amlodipine may decrease the metabolism of Ticlopidine and Ticlopidine may increase the anticoagulant activities of Dipyridamole
Amlodipine may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Dipyridamole
Amlodipine may increase the severity of adverse effects when combined with Triamterene and Triamterene may increase the severity of adverse effects when combined with Dipyridamole
Amlodipine may increase the severity of adverse effects when combined with Dapagliflozin and Dapagliflozin may increase the severity of adverse effects when combined with Dipyridamole
Amlodipine may increase the hypotensive activities of Amifostine and Amifostine may increase the severity of adverse effects when combined with Dipyridamole
|
DB00688
|
DB01155
| 620 | 863 |
Mycophenolate mofetil
|
Gemifloxacin
|
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995. In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis.[A180799,A180805] Previously, mycophenolic acid
|
Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
|
Mycophenolate mofetil may increase the neuroexcitatory activities of Gemifloxacin.
| 26 |
[
[
[
620,
49,
863
]
],
[
[
620,
49,
862
],
[
862,
1,
863
]
],
[
[
620,
49,
757
],
[
757,
155,
863
]
],
[
[
620,
21,
28515
],
[
28515,
175,
863
]
],
[
[
620,
182,
384
],
[
384,
28,
863
]
],
[
[
620,
69,
514
],
[
514,
31,
863
]
],
[
[
620,
191,
243
],
[
243,
37,
863
]
],
[
[
620,
69,
575
],
[
575,
196,
863
]
],
[
[
620,
251,
684
],
[
684,
196,
863
]
],
[
[
620,
56,
340
],
[
340,
196,
863
]
]
] |
[
[
[
"Mycophenolate mofetil",
"{u} may increase the neuroexcitatory activities of {v}",
"Gemifloxacin"
]
],
[
[
"Mycophenolate mofetil",
"{u} may increase the neuroexcitatory activities of {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gemifloxacin"
]
],
[
[
"Mycophenolate mofetil",
"{u} may increase the neuroexcitatory activities of {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gemifloxacin"
]
],
[
[
"Mycophenolate mofetil",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gemifloxacin"
]
],
[
[
"Mycophenolate mofetil",
"{u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Gemifloxacin"
]
],
[
[
"Mycophenolate mofetil",
"{u} may decrease the metabolism of {v}",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} may increase the hypoglycemic activities of {v}",
"Gemifloxacin"
]
],
[
[
"Mycophenolate mofetil",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Gemifloxacin"
]
],
[
[
"Mycophenolate mofetil",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the QTc prolonging activities of {v}",
"Gemifloxacin"
]
],
[
[
"Mycophenolate mofetil",
"{u} may decrease the serum concentration of {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may increase the QTc prolonging activities of {v}",
"Gemifloxacin"
]
],
[
[
"Mycophenolate mofetil",
"{u} may increase the immunosuppressive activities of {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may increase the QTc prolonging activities of {v}",
"Gemifloxacin"
]
]
] |
Mycophenolate mofetil may increase the neuroexcitatory activities of Trovafloxacin and Trovafloxacin (Compound) resembles Gemifloxacin (Compound)
Mycophenolate mofetil may increase the neuroexcitatory activities of Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin (Compound)
Mycophenolate mofetil (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Gemifloxacin (Compound)
Mycophenolate mofetil may increase the anticoagulant activities of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Gemifloxacin
Mycophenolate mofetil may decrease the metabolism of Rosiglitazone and Rosiglitazone may increase the hypoglycemic activities of Gemifloxacin
Mycophenolate mofetil may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Gemifloxacin
Mycophenolate mofetil may decrease the metabolism of Sulfisoxazole and Sulfisoxazole may increase the QTc prolonging activities of Gemifloxacin
Mycophenolate mofetil may decrease the serum concentration of Dabrafenib and Dabrafenib may increase the QTc prolonging activities of Gemifloxacin
Mycophenolate mofetil may increase the immunosuppressive activities of Fingolimod and Fingolimod may increase the QTc prolonging activities of Gemifloxacin
|
DB06616
|
DB01032
| 1,240 | 1,401 |
Bosutinib
|
Probenecid
|
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in
|
The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
|
The serum concentration of Probenecid can be increased when it is combined with Bosutinib.
| 72 |
[
[
[
1240,
95,
1401
]
],
[
[
1240,
95,
569
],
[
569,
1,
1401
]
],
[
[
1240,
6,
8339
],
[
8339,
160,
1401
]
],
[
[
1240,
21,
28721
],
[
28721,
175,
1401
]
],
[
[
1240,
95,
526
],
[
526,
65,
1401
]
],
[
[
1240,
249,
744
],
[
744,
95,
1401
]
],
[
[
1240,
95,
588
],
[
588,
95,
1401
]
],
[
[
1240,
95,
569
],
[
569,
1,
1528
],
[
1528,
1,
1401
]
],
[
[
1240,
6,
8339
],
[
8339,
160,
569
],
[
569,
1,
1401
]
],
[
[
1240,
6,
4590
],
[
4590,
160,
526
],
[
526,
65,
1401
]
]
] |
[
[
[
"Bosutinib",
"{u} may increase the serum concentration of {v}",
"Probenecid"
]
],
[
[
"Bosutinib",
"{u} may increase the serum concentration of {v}",
"Chlorpropamide"
],
[
"Chlorpropamide",
"{u} (Compound) resembles {v} (Compound)",
"Probenecid"
]
],
[
[
"Bosutinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Probenecid"
]
],
[
[
"Bosutinib",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema multiforme"
],
[
"Erythema multiforme",
"{u} (Side Effect) is caused by {v} (Compound)",
"Probenecid"
]
],
[
[
"Bosutinib",
"{u} may increase the serum concentration of {v}",
"Glyburide"
],
[
"Glyburide",
"{u} may decrease the protein binding of {v}",
"Probenecid"
]
],
[
[
"Bosutinib",
"{u} may increase the serum concentration of {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may increase the serum concentration of {v}",
"Probenecid"
]
],
[
[
"Bosutinib",
"{u} may increase the serum concentration of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may increase the serum concentration of {v}",
"Probenecid"
]
],
[
[
"Bosutinib",
"{u} may increase the serum concentration of {v}",
"Chlorpropamide"
],
[
"Chlorpropamide",
"{u} (Compound) resembles {v} (Compound)",
"Sulfacetamide"
],
[
"Sulfacetamide",
"{u} (Compound) resembles {v} (Compound)",
"Probenecid"
]
],
[
[
"Bosutinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Chlorpropamide"
],
[
"Chlorpropamide",
"{u} (Compound) resembles {v} (Compound)",
"Probenecid"
]
],
[
[
"Bosutinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Glyburide"
],
[
"Glyburide",
"{u} may decrease the protein binding of {v}",
"Probenecid"
]
]
] |
Bosutinib may increase the serum concentration of Chlorpropamide and Chlorpropamide (Compound) resembles Probenecid (Compound)
Bosutinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Probenecid (Compound)
Bosutinib (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Probenecid (Compound)
Bosutinib may increase the serum concentration of Glyburide and Glyburide may decrease the protein binding of Probenecid
Bosutinib may increase the serum concentration of Edoxaban and Edoxaban may increase the serum concentration of Probenecid
Bosutinib may increase the serum concentration of Chloroquine and Chloroquine may increase the serum concentration of Probenecid
Bosutinib may increase the serum concentration of Chlorpropamide and Chlorpropamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Probenecid (Compound)
Bosutinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Chlorpropamide (Compound) and Chlorpropamide (Compound) resembles Probenecid (Compound)
Bosutinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Glyburide (Compound) and Glyburide may decrease the protein binding of Probenecid
|
DB12161
|
DB09073
| 399 | 1,394 |
Deutetrabenazine
|
Palbociclib
|
Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated. The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound. This allows less frequent dosing and a lower daily dose with improvement in tolerability. Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine. Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction,
|
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
|
The serum concentration of Palbociclib can be increased when it is combined with Deutetrabenazine.
| 72 |
[
[
[
399,
95,
1394
]
],
[
[
399,
69,
610
],
[
610,
223,
1394
]
],
[
[
399,
69,
499
],
[
499,
95,
1394
]
],
[
[
399,
95,
1269
],
[
1269,
249,
1394
]
],
[
[
399,
95,
1098
],
[
1098,
95,
1394
]
],
[
[
399,
180,
173
],
[
173,
95,
1394
]
],
[
[
399,
69,
1099
],
[
1099,
249,
1394
]
],
[
[
399,
251,
225
],
[
225,
95,
1394
]
],
[
[
399,
249,
531
],
[
531,
95,
1394
]
],
[
[
399,
180,
171
],
[
171,
97,
1394
]
]
] |
[
[
[
"Deutetrabenazine",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may decrease the metabolism of {v}",
"Palbociclib"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Deutetrabenazine",
"{u} may increase the serum concentration of {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Deutetrabenazine",
"{u} may increase the serum concentration of {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Deutetrabenazine",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the serum concentration of {v}",
"Bosentan"
],
[
"Bosentan",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Deutetrabenazine",
"{u} may increase the serum concentration of {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Deutetrabenazine",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may decrease the serum concentration of {v}",
"Palbociclib"
]
]
] |
Deutetrabenazine may decrease the metabolism of Atomoxetine and Atomoxetine may decrease the metabolism of Palbociclib
Deutetrabenazine may decrease the metabolism of Clomipramine and Clomipramine may increase the serum concentration of Palbociclib
Deutetrabenazine may increase the serum concentration of Stiripentol and Stiripentol may increase the serum concentration of Palbociclib
Deutetrabenazine may increase the serum concentration of Panobinostat and Panobinostat may increase the serum concentration of Palbociclib
Deutetrabenazine can increase the metabolism of Nevirapine and Nevirapine may increase the serum concentration of Palbociclib
Deutetrabenazine may decrease the metabolism of Idelalisib and Idelalisib may increase the serum concentration of Palbociclib
Deutetrabenazine may decrease the serum concentration of Bosentan and Bosentan may increase the serum concentration of Palbociclib
Deutetrabenazine may increase the serum concentration of Conivaptan and Conivaptan may increase the serum concentration of Palbociclib
Deutetrabenazine can increase the metabolism of Pentobarbital and Pentobarbital may decrease the serum concentration of Palbociclib
|
DB08860
|
DB01124
| 598 | 297 |
Pitavastatin
|
Tolbutamide
|
Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those
|
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to
|
The metabolism of Tolbutamide can be decreased when combined with Pitavastatin.
| 46 |
[
[
[
598,
69,
297
]
],
[
[
598,
6,
7128
],
[
7128,
160,
297
]
],
[
[
598,
7,
9986
],
[
9986,
161,
297
]
],
[
[
598,
18,
13041
],
[
13041,
172,
297
]
],
[
[
598,
21,
28392
],
[
28392,
175,
297
]
],
[
[
598,
95,
177
],
[
177,
26,
297
]
],
[
[
598,
251,
150
],
[
150,
26,
297
]
],
[
[
598,
180,
164
],
[
164,
26,
297
]
],
[
[
598,
182,
169
],
[
169,
28,
297
]
],
[
[
598,
95,
53
],
[
53,
185,
297
]
]
] |
[
[
[
"Pitavastatin",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
]
],
[
[
"Pitavastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Pitavastatin",
"{u} (Compound) upregulates {v} (Gene)",
"PLCB3"
],
[
"PLCB3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Pitavastatin",
"{u} (Compound) downregulates {v} (Gene)",
"ATP6V0B"
],
[
"ATP6V0B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Pitavastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Pitavastatin",
"{u} may increase the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Tolbutamide"
]
],
[
[
"Pitavastatin",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Tolbutamide"
]
],
[
[
"Pitavastatin",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Tolbutamide"
]
],
[
[
"Pitavastatin",
"{u} may increase the anticoagulant activities of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Tolbutamide"
]
],
[
[
"Pitavastatin",
"{u} may increase the serum concentration of {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may increase the hypoglycemic activities of {v}",
"Tolbutamide"
]
]
] |
Pitavastatin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Tolbutamide (Compound)
Pitavastatin (Compound) upregulates PLCB3 (Gene) and PLCB3 (Gene) is upregulated by Tolbutamide (Compound)
Pitavastatin (Compound) downregulates ATP6V0B (Gene) and ATP6V0B (Gene) is downregulated by Tolbutamide (Compound)
Pitavastatin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Tolbutamide (Compound)
Pitavastatin may increase the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Tolbutamide
Pitavastatin may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Tolbutamide
Pitavastatin can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Tolbutamide
Pitavastatin may increase the anticoagulant activities of Phenindione and Phenindione may increase the anticoagulant activities of Tolbutamide
Pitavastatin may increase the serum concentration of Phenelzine and Phenelzine may increase the hypoglycemic activities of Tolbutamide
|
DB01337
|
DB00486
| 73 | 1,265 |
Pancuronium
|
Nabilone
|
A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.
|
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are
|
Pancuronium may increase the tachycardic activities of Nabilone.
| 84 |
[
[
[
73,
107,
1265
]
],
[
[
73,
107,
1261
],
[
1261,
1,
1265
]
],
[
[
73,
21,
28474
],
[
28474,
175,
1265
]
],
[
[
73,
43,
997
],
[
997,
38,
1265
]
],
[
[
73,
178,
18
],
[
18,
38,
1265
]
],
[
[
73,
71,
510
],
[
510,
38,
1265
]
],
[
[
73,
43,
405
],
[
405,
192,
1265
]
],
[
[
73,
225,
51
],
[
51,
38,
1265
]
],
[
[
73,
249,
1059
],
[
1059,
225,
1265
]
],
[
[
73,
193,
894
],
[
894,
225,
1265
]
]
] |
[
[
[
"Pancuronium",
"{u} may increase the tachycardic activities of {v}",
"Nabilone"
]
],
[
[
"Pancuronium",
"{u} may increase the tachycardic activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} (Compound) resembles {v} (Compound)",
"Nabilone"
]
],
[
[
"Pancuronium",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nabilone"
]
],
[
[
"Pancuronium",
"{u} may increase the neuromuscular blocking activities of {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
]
],
[
[
"Pancuronium",
"{u} may increase the anticholinergic activities of {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
]
],
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sufentanil"
],
[
"Sufentanil",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
]
],
[
[
"Pancuronium",
"{u} may increase the neuromuscular blocking activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
]
],
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
]
],
[
[
"Pancuronium",
"{u} may increase the serum concentration of {v}",
"Metolazone"
],
[
"Metolazone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nabilone"
]
],
[
[
"Pancuronium",
"{u} may decrease the neuromuscular blocking activities of {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nabilone"
]
]
] |
Pancuronium may increase the tachycardic activities of Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Pancuronium (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nabilone (Compound)
Pancuronium may increase the neuromuscular blocking activities of Lithium cation and Lithium cation may increase the central nervous system depressant activities of Nabilone
Pancuronium may increase the anticholinergic activities of Sulpiride and Sulpiride may increase the central nervous system depressant activities of Nabilone
Pancuronium may increase the severity of adverse effects when combined with Sufentanil and Sufentanil may increase the central nervous system depressant activities of Nabilone
Pancuronium may increase the neuromuscular blocking activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Nabilone
Pancuronium may increase the severity of adverse effects when combined with Scopolamine and Scopolamine may increase the central nervous system depressant activities of Nabilone
Pancuronium may increase the serum concentration of Metolazone and Metolazone may increase the severity of adverse effects when combined with Nabilone
Pancuronium may decrease the neuromuscular blocking activities of Furosemide and Furosemide may increase the severity of adverse effects when combined with Nabilone
|
DB06654
|
DB05521
| 646 | 1,092 |
Safinamide
|
Telaprevir
|
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
|
Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Telaprevir. Telaprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotype 1 [FDA Label]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B. The barrier for develoment of resistance to NS
|
The metabolism of Telaprevir can be decreased when combined with Safinamide.
| 46 |
[
[
[
646,
69,
1092
]
],
[
[
646,
69,
269
],
[
269,
223,
1092
]
],
[
[
646,
69,
381
],
[
381,
69,
1092
]
],
[
[
646,
69,
137
],
[
137,
225,
1092
]
],
[
[
646,
180,
156
],
[
156,
95,
1092
]
],
[
[
646,
95,
476
],
[
476,
249,
1092
]
],
[
[
646,
69,
1099
],
[
1099,
95,
1092
]
],
[
[
646,
69,
496
],
[
496,
249,
1092
]
],
[
[
646,
95,
764
],
[
764,
95,
1092
]
],
[
[
646,
251,
495
],
[
495,
249,
1092
]
]
] |
[
[
[
"Safinamide",
"{u} may decrease the metabolism of {v}",
"Telaprevir"
]
],
[
[
"Safinamide",
"{u} may decrease the metabolism of {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may decrease the metabolism of {v}",
"Telaprevir"
]
],
[
[
"Safinamide",
"{u} may decrease the metabolism of {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may decrease the metabolism of {v}",
"Telaprevir"
]
],
[
[
"Safinamide",
"{u} may decrease the metabolism of {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Telaprevir"
]
],
[
[
"Safinamide",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may increase the serum concentration of {v}",
"Telaprevir"
]
],
[
[
"Safinamide",
"{u} may increase the serum concentration of {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may increase the serum concentration of {v}",
"Telaprevir"
]
],
[
[
"Safinamide",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may increase the serum concentration of {v}",
"Telaprevir"
]
],
[
[
"Safinamide",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
],
[
"Ketoconazole",
"{u} may increase the serum concentration of {v}",
"Telaprevir"
]
],
[
[
"Safinamide",
"{u} may increase the serum concentration of {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may increase the serum concentration of {v}",
"Telaprevir"
]
],
[
[
"Safinamide",
"{u} may decrease the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the serum concentration of {v}",
"Telaprevir"
]
]
] |
Safinamide may decrease the metabolism of Nelfinavir and Nelfinavir may decrease the metabolism of Telaprevir
Safinamide may decrease the metabolism of Rucaparib and Rucaparib may decrease the metabolism of Telaprevir
Safinamide may decrease the metabolism of Amiodarone and Amiodarone may increase the severity of adverse effects when combined with Telaprevir
Safinamide can increase the metabolism of Carbamazepine and Carbamazepine may increase the serum concentration of Telaprevir
Safinamide may increase the serum concentration of Netupitant and Netupitant may increase the serum concentration of Telaprevir
Safinamide may decrease the metabolism of Idelalisib and Idelalisib may increase the serum concentration of Telaprevir
Safinamide may decrease the metabolism of Ketoconazole and Ketoconazole may increase the serum concentration of Telaprevir
Safinamide may increase the serum concentration of Dasatinib and Dasatinib may increase the serum concentration of Telaprevir
Safinamide may decrease the serum concentration of Vemurafenib and Vemurafenib may increase the serum concentration of Telaprevir
|
DB01174
|
DB00390
| 164 | 457 |
Phenobarbital
|
Digoxin
|
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
|
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.
|
The metabolism of Digoxin can be increased when combined with Phenobarbital.
| 3 |
[
[
[
164,
26,
457
]
],
[
[
164,
26,
232
],
[
232,
155,
457
]
],
[
[
164,
6,
10007
],
[
10007,
160,
457
]
],
[
[
164,
21,
28549
],
[
28549,
175,
457
]
],
[
[
164,
38,
142
],
[
142,
26,
457
]
],
[
[
164,
270,
171
],
[
171,
26,
457
]
],
[
[
164,
97,
657
],
[
657,
223,
457
]
],
[
[
164,
26,
143
],
[
143,
223,
457
]
],
[
[
164,
71,
41
],
[
41,
223,
457
]
],
[
[
164,
69,
1076
],
[
1076,
223,
457
]
]
] |
[
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Digoxin"
]
],
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
]
],
[
[
"Phenobarbital",
"{u} (Compound) binds {v} (Gene)",
"ABCB11"
],
[
"ABCB11",
"{u} (Gene) is bound by {v} (Compound)",
"Digoxin"
]
],
[
[
"Phenobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Digoxin"
]
],
[
[
"Phenobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Digoxin"
]
],
[
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Digoxin"
]
],
[
[
"Phenobarbital",
"{u} may decrease the serum concentration of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may decrease the metabolism of {v}",
"Digoxin"
]
],
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may decrease the metabolism of {v}",
"Digoxin"
]
],
[
[
"Phenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Digoxin"
]
],
[
[
"Phenobarbital",
"{u} may decrease the metabolism of {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may decrease the metabolism of {v}",
"Digoxin"
]
]
] |
Phenobarbital can increase the metabolism of Digitoxin and Digitoxin (Compound) resembles Digoxin (Compound)
Phenobarbital (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Digoxin (Compound)
Phenobarbital (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Digoxin (Compound)
Phenobarbital may increase the central nervous system depressant activities of Phenytoin and Phenytoin can increase the metabolism of Digoxin
Phenobarbital (Compound) resembles Pentobarbital (Compound) and Phenobarbital may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Digoxin
Phenobarbital may decrease the serum concentration of Voriconazole and Voriconazole may decrease the metabolism of Digoxin
Phenobarbital can increase the metabolism of Erythromycin and Erythromycin may decrease the metabolism of Digoxin
Phenobarbital may increase the severity of adverse effects when combined with Clemastine and Clemastine may decrease the metabolism of Digoxin
Phenobarbital may decrease the metabolism of Fluconazole and Fluconazole may decrease the metabolism of Digoxin
|
DB00688
|
DB00287
| 620 | 1,051 |
Mycophenolate mofetil
|
Travoprost
|
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995. In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis.[A180799,A180805] Previously, mycophenolic acid
|
Travoprost is a synthetic isopropyl ester prodrug of a prostaglandin F2alpha (F2α) analogue and selective FP prostanoid receptor agonist. It is used to decrease intraocular pressure in open-angle glaucoma and ocular hypertension. Unlike other prostaglandin analogues, travoprost demonstrates full agonism and high selectivity at the prostanoid receptor, reporting a higher efficacy in reducing intraocular pressure and a reduced risk for developing off-target side effects.
|
The therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolate mofetil.
| 69 |
[
[
[
620,
92,
1051
]
],
[
[
620,
92,
1537
],
[
1537,
155,
1051
]
],
[
[
620,
92,
1489
],
[
1489,
1,
1051
]
],
[
[
620,
21,
28463
],
[
28463,
175,
1051
]
],
[
[
620,
225,
1071
],
[
1071,
236,
1051
]
],
[
[
620,
213,
1037
],
[
1037,
82,
1051
]
],
[
[
620,
69,
461
],
[
461,
236,
1051
]
],
[
[
620,
92,
1045
],
[
1045,
236,
1051
]
],
[
[
620,
213,
911
],
[
911,
236,
1051
]
],
[
[
620,
225,
607
],
[
607,
82,
1051
]
]
] |
[
[
[
"Mycophenolate mofetil",
"{u} may decrease the therapeutic efficacy of {v}",
"Travoprost"
]
],
[
[
"Mycophenolate mofetil",
"{u} may decrease the therapeutic efficacy of {v}",
"Dinoprost tromethamine"
],
[
"Dinoprost tromethamine",
"{u} (Compound) resembles {v} (Compound)",
"Travoprost"
]
],
[
[
"Mycophenolate mofetil",
"{u} may decrease the therapeutic efficacy of {v}",
"Carboprost tromethamine"
],
[
"Carboprost tromethamine",
"{u} (Compound) resembles {v} (Compound)",
"Travoprost"
]
],
[
[
"Mycophenolate mofetil",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Travoprost"
]
],
[
[
"Mycophenolate mofetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Telmisartan"
],
[
"Telmisartan",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
],
[
[
"Mycophenolate mofetil",
"{u} may decrease the antihypertensive activities of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
],
[
[
"Mycophenolate mofetil",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
],
[
[
"Mycophenolate mofetil",
"{u} may decrease the therapeutic efficacy of {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
],
[
[
"Mycophenolate mofetil",
"{u} may decrease the antihypertensive activities of {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
],
[
[
"Mycophenolate mofetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ramipril"
],
[
"Ramipril",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
]
] |
Mycophenolate mofetil may decrease the therapeutic efficacy of Dinoprost tromethamine and Dinoprost tromethamine (Compound) resembles Travoprost (Compound)
Mycophenolate mofetil may decrease the therapeutic efficacy of Carboprost tromethamine and Carboprost tromethamine (Compound) resembles Travoprost (Compound)
Mycophenolate mofetil (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Travoprost (Compound)
Mycophenolate mofetil may increase the severity of adverse effects when combined with Telmisartan and Telmisartan may increase the hypotensive activities of Travoprost
Mycophenolate mofetil may decrease the antihypertensive activities of Betaxolol and Betaxolol may increase the hypotensive activities of Travoprost
Mycophenolate mofetil may decrease the metabolism of Diltiazem and Diltiazem may increase the hypotensive activities of Travoprost
Mycophenolate mofetil may decrease the therapeutic efficacy of Trichlormethiazide and Trichlormethiazide may increase the hypotensive activities of Travoprost
Mycophenolate mofetil may decrease the antihypertensive activities of Oxprenolol and Oxprenolol may increase the hypotensive activities of Travoprost
Mycophenolate mofetil may increase the severity of adverse effects when combined with Ramipril and Ramipril may increase the hypotensive activities of Travoprost
|
DB00955
|
DB08880
| 905 | 814 |
Netilmicin
|
Teriflunomide
|
Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.
|
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
|
Netilmicin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.
| 71 |
[
[
[
905,
94,
814
]
],
[
[
905,
225,
557
],
[
557,
205,
814
]
],
[
[
905,
94,
375
],
[
375,
69,
814
]
],
[
[
905,
94,
826
],
[
826,
71,
814
]
],
[
[
905,
200,
421
],
[
421,
225,
814
]
],
[
[
905,
94,
810
],
[
810,
225,
814
]
],
[
[
905,
95,
1421
],
[
1421,
225,
814
]
],
[
[
905,
94,
768
],
[
768,
79,
814
]
],
[
[
905,
233,
198
],
[
198,
79,
814
]
],
[
[
905,
155,
900
],
[
900,
94,
814
]
]
] |
[
[
[
"Netilmicin",
"{u} may decrease the excretion rate {v}",
"Teriflunomide"
]
],
[
[
"Netilmicin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may decrease the diuretic activities of {v}",
"Teriflunomide"
]
],
[
[
"Netilmicin",
"{u} may decrease the excretion rate {v}",
"Mefenamic acid"
],
[
"Mefenamic acid",
"{u} may decrease the metabolism of {v}",
"Teriflunomide"
]
],
[
[
"Netilmicin",
"{u} may decrease the excretion rate {v}",
"Oxyphenbutazone"
],
[
"Oxyphenbutazone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Teriflunomide"
]
],
[
[
"Netilmicin",
"{u} may increase the hypocalcemic activities of {v}",
"Risedronic acid"
],
[
"Risedronic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Teriflunomide"
]
],
[
[
"Netilmicin",
"{u} may decrease the excretion rate {v}",
"Loxoprofen"
],
[
"Loxoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Teriflunomide"
]
],
[
[
"Netilmicin",
"{u} may increase the serum concentration of {v}",
"Tenofovir disoproxil"
],
[
"Tenofovir disoproxil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Teriflunomide"
]
],
[
[
"Netilmicin",
"{u} may decrease the excretion rate {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the nephrotoxic activities of {v}",
"Teriflunomide"
]
],
[
[
"Netilmicin",
"{u} may increase the nephrotoxic activities of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the nephrotoxic activities of {v}",
"Teriflunomide"
]
],
[
[
"Netilmicin",
"{u} (Compound) resembles {v} (Compound)",
"Gentamicin"
],
[
"Gentamicin",
"{u} may decrease the excretion rate {v}",
"Teriflunomide"
]
]
] |
Netilmicin may increase the severity of adverse effects when combined with Torasemide and Torasemide may decrease the diuretic activities of Teriflunomide
Netilmicin may decrease the excretion rate Mefenamic acid and Mefenamic acid may decrease the metabolism of Teriflunomide
Netilmicin may decrease the excretion rate Oxyphenbutazone and Oxyphenbutazone may increase the severity of adverse effects when combined with Teriflunomide
Netilmicin may increase the hypocalcemic activities of Risedronic acid and Risedronic acid may increase the severity of adverse effects when combined with Teriflunomide
Netilmicin may decrease the excretion rate Loxoprofen and Loxoprofen may increase the severity of adverse effects when combined with Teriflunomide
Netilmicin may increase the serum concentration of Tenofovir disoproxil and Tenofovir disoproxil may increase the severity of adverse effects when combined with Teriflunomide
Netilmicin may decrease the excretion rate Olsalazine and Olsalazine may increase the nephrotoxic activities of Teriflunomide
Netilmicin may increase the nephrotoxic activities of Cyclosporine and Cyclosporine may increase the nephrotoxic activities of Teriflunomide
Netilmicin (Compound) resembles Gentamicin (Compound) and Gentamicin may decrease the excretion rate Teriflunomide
|
DB00701
|
DB00544
| 431 | 233 |
Amprenavir
|
Fluorouracil
|
Amprenavir is a protease inhibitor used to treat HIV infection.
|
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
|
The metabolism of Fluorouracil can be decreased when combined with Amprenavir.
| 46 |
[
[
[
431,
69,
233
]
],
[
[
431,
6,
12846
],
[
12846,
160,
233
]
],
[
[
431,
21,
28440
],
[
28440,
175,
233
]
],
[
[
431,
180,
156
],
[
156,
26,
233
]
],
[
[
431,
71,
243
],
[
243,
37,
233
]
],
[
[
431,
69,
613
],
[
613,
223,
233
]
],
[
[
431,
69,
284
],
[
284,
69,
233
]
],
[
[
431,
249,
598
],
[
598,
69,
233
]
],
[
[
431,
180,
173
],
[
173,
69,
233
]
],
[
[
431,
97,
639
],
[
639,
69,
233
]
]
] |
[
[
[
"Amprenavir",
"{u} may decrease the metabolism of {v}",
"Fluorouracil"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Fluorouracil"
]
],
[
[
"Amprenavir",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fluorouracil"
]
],
[
[
"Amprenavir",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Fluorouracil"
]
],
[
[
"Amprenavir",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Fluorouracil"
]
],
[
[
"Amprenavir",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may decrease the metabolism of {v}",
"Fluorouracil"
]
],
[
[
"Amprenavir",
"{u} may decrease the metabolism of {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may decrease the metabolism of {v}",
"Fluorouracil"
]
],
[
[
"Amprenavir",
"{u} may increase the serum concentration of {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may decrease the metabolism of {v}",
"Fluorouracil"
]
],
[
[
"Amprenavir",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may decrease the metabolism of {v}",
"Fluorouracil"
]
],
[
[
"Amprenavir",
"{u} may decrease the serum concentration of {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may decrease the metabolism of {v}",
"Fluorouracil"
]
]
] |
Amprenavir (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Fluorouracil (Compound)
Amprenavir (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Fluorouracil (Compound)
Amprenavir can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Fluorouracil
Amprenavir may increase the severity of adverse effects when combined with Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Fluorouracil
Amprenavir may decrease the metabolism of Ticlopidine and Ticlopidine may decrease the metabolism of Fluorouracil
Amprenavir may decrease the metabolism of Sulfadiazine and Sulfadiazine may decrease the metabolism of Fluorouracil
Amprenavir may increase the serum concentration of Pitavastatin and Pitavastatin may decrease the metabolism of Fluorouracil
Amprenavir can increase the metabolism of Nevirapine and Nevirapine may decrease the metabolism of Fluorouracil
Amprenavir may decrease the serum concentration of Valproic acid and Valproic acid may decrease the metabolism of Fluorouracil
|
DB01045
|
DB01124
| 147 | 297 |
Rifampicin
|
Tolbutamide
|
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
|
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to
|
The serum concentration of Tolbutamide can be decreased when it is combined with Rifampicin.
| 74 |
[
[
[
147,
97,
297
]
],
[
[
147,
97,
473
],
[
473,
155,
297
]
],
[
[
147,
97,
326
],
[
326,
69,
297
]
],
[
[
147,
6,
7128
],
[
7128,
160,
297
]
],
[
[
147,
180,
177
],
[
177,
26,
297
]
],
[
[
147,
97,
150
],
[
150,
26,
297
]
],
[
[
147,
71,
429
],
[
429,
26,
297
]
],
[
[
147,
26,
169
],
[
169,
28,
297
]
],
[
[
147,
97,
1027
],
[
1027,
185,
297
]
],
[
[
147,
26,
519
],
[
519,
185,
297
]
]
] |
[
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Tolbutamide"
]
],
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Tolbutamide"
]
],
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Tolbutamide"
]
],
[
[
"Rifampicin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} can increase the metabolism of {v}",
"Tolbutamide"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Tolbutamide"
]
],
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the hypoglycemic activities of {v}",
"Tolbutamide"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Celiprolol"
],
[
"Celiprolol",
"{u} may increase the hypoglycemic activities of {v}",
"Tolbutamide"
]
]
] |
Rifampicin may decrease the serum concentration of Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Rifampicin may decrease the serum concentration of Glipizide and Glipizide may decrease the metabolism of Tolbutamide
Rifampicin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Tolbutamide (Compound)
Rifampicin can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Tolbutamide
Rifampicin may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Tolbutamide
Rifampicin may increase the severity of adverse effects when combined with Lopinavir and Lopinavir can increase the metabolism of Tolbutamide
Rifampicin can increase the metabolism of Phenindione and Phenindione may increase the anticoagulant activities of Tolbutamide
Rifampicin may decrease the serum concentration of Sotalol and Sotalol may increase the hypoglycemic activities of Tolbutamide
Rifampicin can increase the metabolism of Celiprolol and Celiprolol may increase the hypoglycemic activities of Tolbutamide
|
DB00850
|
DB00801
| 525 | 972 |
Perphenazine
|
Halazepam
|
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
|
Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]
|
The risk or severity of adverse effects can be increased when Perphenazine is combined with Halazepam.
| 48 |
[
[
[
525,
71,
972
]
],
[
[
525,
225,
335
],
[
335,
71,
972
]
],
[
[
525,
95,
371
],
[
371,
71,
972
]
],
[
[
525,
71,
1270
],
[
1270,
1,
972
]
],
[
[
525,
71,
586
],
[
586,
71,
972
]
],
[
[
525,
184,
674
],
[
674,
30,
972
]
],
[
[
525,
38,
1264
],
[
1264,
192,
972
]
],
[
[
525,
192,
543
],
[
543,
38,
972
]
],
[
[
525,
122,
1262
],
[
1262,
192,
972
]
],
[
[
525,
54,
471
],
[
471,
208,
972
]
]
] |
[
[
[
"Perphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halazepam"
]
],
[
[
"Perphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clorazepic acid"
],
[
"Clorazepic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halazepam"
]
],
[
[
"Perphenazine",
"{u} may increase the serum concentration of {v}",
"Quazepam"
],
[
"Quazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halazepam"
]
],
[
[
"Perphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fludiazepam"
],
[
"Fludiazepam",
"{u} (Compound) resembles {v} (Compound)",
"Halazepam"
]
],
[
[
"Perphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triazolam"
],
[
"Triazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halazepam"
]
],
[
[
"Perphenazine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Halazepam"
]
],
[
[
"Perphenazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Halazepam"
]
],
[
[
"Perphenazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Halazepam"
]
],
[
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Halazepam"
]
],
[
[
"Perphenazine",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Halazepam"
]
]
] |
Perphenazine may increase the severity of adverse effects when combined with Clorazepic acid and Clorazepic acid may increase the severity of adverse effects when combined with Halazepam
Perphenazine may increase the serum concentration of Quazepam and Quazepam may increase the severity of adverse effects when combined with Halazepam
Perphenazine may increase the severity of adverse effects when combined with Fludiazepam and Fludiazepam (Compound) resembles Halazepam (Compound)
Perphenazine may increase the severity of adverse effects when combined with Triazolam and Triazolam may increase the severity of adverse effects when combined with Halazepam
Perphenazine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Halazepam
Perphenazine may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Halazepam
Perphenazine may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Halazepam
Perphenazine (Compound) resembles Hydroxyzine (Compound) and Perphenazine may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Halazepam
Perphenazine may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Halazepam
|
DB09038
|
DB04576
| 953 | 877 |
Empagliflozin
|
Fleroxacin
|
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues
|
Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.
|
Empagliflozin may increase the hypoglycemic activities of Fleroxacin.
| 8 |
[
[
[
953,
31,
877
]
],
[
[
953,
185,
284
],
[
284,
31,
877
]
],
[
[
953,
225,
426
],
[
426,
31,
877
]
],
[
[
953,
31,
768
],
[
768,
49,
877
]
],
[
[
953,
246,
119
],
[
119,
71,
877
]
],
[
[
953,
185,
284
],
[
284,
223,
498
],
[
498,
28,
877
]
],
[
[
953,
185,
874
],
[
874,
182,
498
],
[
498,
28,
877
]
],
[
[
953,
225,
426
],
[
426,
69,
284
],
[
284,
31,
877
]
],
[
[
953,
185,
1019
],
[
1019,
249,
498
],
[
498,
28,
877
]
],
[
[
953,
185,
423
],
[
423,
31,
481
],
[
481,
31,
877
]
]
] |
[
[
[
"Empagliflozin",
"{u} may increase the hypoglycemic activities of {v}",
"Fleroxacin"
]
],
[
[
"Empagliflozin",
"{u} may increase the hypoglycemic activities of {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may increase the hypoglycemic activities of {v}",
"Fleroxacin"
]
],
[
[
"Empagliflozin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may increase the hypoglycemic activities of {v}",
"Fleroxacin"
]
],
[
[
"Empagliflozin",
"{u} may increase the hypoglycemic activities of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the neuroexcitatory activities of {v}",
"Fleroxacin"
]
],
[
[
"Empagliflozin",
"{u} may decrease the therapeutic efficacy of {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fleroxacin"
]
],
[
[
"Empagliflozin",
"{u} may increase the hypoglycemic activities of {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may decrease the metabolism of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Fleroxacin"
]
],
[
[
"Empagliflozin",
"{u} may increase the hypoglycemic activities of {v}",
"Tolazamide"
],
[
"Tolazamide",
"{u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Fleroxacin"
]
],
[
[
"Empagliflozin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may decrease the metabolism of {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may increase the hypoglycemic activities of {v}",
"Fleroxacin"
]
],
[
[
"Empagliflozin",
"{u} may increase the hypoglycemic activities of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Fleroxacin"
]
],
[
[
"Empagliflozin",
"{u} may increase the hypoglycemic activities of {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may increase the hypoglycemic activities of {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may increase the hypoglycemic activities of {v}",
"Fleroxacin"
]
]
] |
Empagliflozin may increase the hypoglycemic activities of Sulfadiazine and Sulfadiazine may increase the hypoglycemic activities of Fleroxacin
Empagliflozin may increase the severity of adverse effects when combined with Dapagliflozin and Dapagliflozin may increase the hypoglycemic activities of Fleroxacin
Empagliflozin may increase the hypoglycemic activities of Olsalazine and Olsalazine may increase the neuroexcitatory activities of Fleroxacin
Empagliflozin may decrease the therapeutic efficacy of Dexamethasone and Dexamethasone may increase the severity of adverse effects when combined with Fleroxacin
Empagliflozin may increase the hypoglycemic activities of Sulfadiazine and Sulfadiazine may decrease the metabolism of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Fleroxacin
Empagliflozin may increase the hypoglycemic activities of Tolazamide and Tolazamide may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Fleroxacin
Empagliflozin may increase the severity of adverse effects when combined with Dapagliflozin and Dapagliflozin may decrease the metabolism of Sulfadiazine and Sulfadiazine may increase the hypoglycemic activities of Fleroxacin
Empagliflozin may increase the hypoglycemic activities of Mifepristone and Mifepristone may increase the serum concentration of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Fleroxacin
Empagliflozin may increase the hypoglycemic activities of Repaglinide and Repaglinide may increase the hypoglycemic activities of Sitagliptin and Sitagliptin may increase the hypoglycemic activities of Fleroxacin
|
DB01184
|
DB06697
| 370 | 539 |
Domperidone
|
Artemether
|
A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
|
Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
|
The metabolism of Artemether can be decreased when combined with Domperidone.
| 46 |
[
[
[
370,
69,
539
]
],
[
[
370,
6,
18777
],
[
18777,
160,
539
]
],
[
[
370,
95,
173
],
[
173,
33,
539
]
],
[
[
370,
180,
171
],
[
171,
33,
539
]
],
[
[
370,
42,
158
],
[
158,
196,
539
]
],
[
[
370,
95,
1076
],
[
1076,
196,
539
]
],
[
[
370,
209,
1027
],
[
1027,
55,
539
]
],
[
[
370,
42,
417
],
[
417,
55,
539
]
],
[
[
370,
55,
1007
],
[
1007,
55,
539
]
],
[
[
370,
302,
413
],
[
413,
55,
539
]
]
] |
[
[
[
"Domperidone",
"{u} may decrease the metabolism of {v}",
"Artemether"
]
],
[
[
"Domperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Artemether"
]
],
[
[
"Domperidone",
"{u} may increase the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artemether"
]
],
[
[
"Domperidone",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artemether"
]
],
[
[
"Domperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Domperidone",
"{u} may increase the serum concentration of {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may increase the QTc prolonging activities of {v}",
"Artemether"
]
],
[
[
"Domperidone",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artemether"
]
],
[
[
"Domperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Primaquine"
],
[
"Primaquine",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artemether"
]
],
[
[
"Domperidone",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artemether"
]
],
[
[
"Domperidone",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of QTc prolonging effects when combined with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Artemether"
]
]
] |
Domperidone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Artemether (Compound)
Domperidone may increase the serum concentration of Nevirapine and Nevirapine may reduce the serum concentration of the active metabolites of Artemether
Domperidone can increase the metabolism of Pentobarbital and Pentobarbital may reduce the serum concentration of the active metabolites of Artemether
Domperidone may increase the QTc prolonging activities of Nicardipine and Nicardipine may increase the QTc prolonging activities of Artemether
Domperidone may increase the serum concentration of Fluconazole and Fluconazole may increase the QTc prolonging activities of Artemether
Domperidone may increase the severity of QTc prolonging effects when combined with Sotalol and Sotalol may increase the severity of QTc prolonging effects when combined with Artemether
Domperidone may increase the QTc prolonging activities of Primaquine and Primaquine may increase the severity of QTc prolonging effects when combined with Artemether
Domperidone may increase the severity of QTc prolonging effects when combined with Paliperidone and Paliperidone may increase the severity of QTc prolonging effects when combined with Artemether
Domperidone (Compound) resembles Pimozide (Compound) and Domperidone may increase the severity of QTc prolonging effects when combined with Pimozide and Pimozide may increase the severity of QTc prolonging effects when combined with Artemether
|
DB00843
|
DB00908
| 209 | 59 |
Donepezil
|
Quinidine
|
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
|
Quinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication.[A38016,A250050] Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute conversion of atrial fibrillation to normal sinus rhythm. It prolongs cellular action potential by blocking sodium and potassium currents. A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug. Due to its side effects and increased risk of mortality, the use of quinidine was reduced over the next few decades. However, it continues to be used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation.
|
The metabolism of Quinidine can be decreased when combined with Donepezil.
| 46 |
[
[
[
209,
69,
59
]
],
[
[
209,
69,
640
],
[
640,
1,
59
]
],
[
[
209,
6,
7128
],
[
7128,
160,
59
]
],
[
[
209,
21,
28671
],
[
28671,
175,
59
]
],
[
[
209,
92,
20
],
[
20,
24,
59
]
],
[
[
209,
180,
171
],
[
171,
26,
59
]
],
[
[
209,
69,
438
],
[
438,
196,
59
]
],
[
[
209,
76,
1030
],
[
1030,
196,
59
]
],
[
[
209,
230,
264
],
[
264,
196,
59
]
],
[
[
209,
92,
44
],
[
44,
196,
59
]
]
] |
[
[
[
"Donepezil",
"{u} may decrease the metabolism of {v}",
"Quinidine"
]
],
[
[
"Donepezil",
"{u} may decrease the metabolism of {v}",
"Quinine"
],
[
"Quinine",
"{u} (Compound) resembles {v} (Compound)",
"Quinidine"
]
],
[
[
"Donepezil",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Quinidine"
]
],
[
[
"Donepezil",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quinidine"
]
],
[
[
"Donepezil",
"{u} may decrease the therapeutic efficacy of {v}",
"Umeclidinium"
],
[
"Umeclidinium",
"{u} may increase the anticholinergic activities of {v}",
"Quinidine"
]
],
[
[
"Donepezil",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Quinidine"
]
],
[
[
"Donepezil",
"{u} may decrease the metabolism of {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may increase the QTc prolonging activities of {v}",
"Quinidine"
]
],
[
[
"Donepezil",
"{u} may increase the bradycardic activities of {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may increase the QTc prolonging activities of {v}",
"Quinidine"
]
],
[
[
"Donepezil",
"{u} may increase the bradycardic activities of {v}",
"Galantamine"
],
[
"Galantamine",
"{u} may increase the QTc prolonging activities of {v}",
"Quinidine"
]
],
[
[
"Donepezil",
"{u} may decrease the therapeutic efficacy of {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may increase the QTc prolonging activities of {v}",
"Quinidine"
]
]
] |
Donepezil may decrease the metabolism of Quinine and Quinine (Compound) resembles Quinidine (Compound)
Donepezil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Quinidine (Compound)
Donepezil (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Quinidine (Compound)
Donepezil may decrease the therapeutic efficacy of Umeclidinium and Umeclidinium may increase the anticholinergic activities of Quinidine
Donepezil can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Quinidine
Donepezil may decrease the metabolism of Imipramine and Imipramine may increase the QTc prolonging activities of Quinidine
Donepezil may increase the bradycardic activities of Pasireotide and Pasireotide may increase the QTc prolonging activities of Quinidine
Donepezil may increase the bradycardic activities of Galantamine and Galantamine may increase the QTc prolonging activities of Quinidine
Donepezil may decrease the therapeutic efficacy of Tolterodine and Tolterodine may increase the QTc prolonging activities of Quinidine
|
DB01626
|
DB00217
| 75 | 1,061 |
Pargyline
|
Bethanidine
|
Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
|
A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.
|
Pargyline may increase the hypotensive activities of Bethanidine.
| 59 |
[
[
[
75,
123,
1061
]
],
[
[
75,
247,
718
],
[
718,
155,
1061
]
],
[
[
75,
1,
1335
],
[
1335,
155,
1061
]
],
[
[
75,
236,
39
],
[
39,
155,
1061
]
],
[
[
75,
155,
16882
],
[
16882,
1,
1061
]
],
[
[
75,
236,
42
],
[
42,
82,
1061
]
],
[
[
75,
1,
53
],
[
53,
82,
1061
]
],
[
[
75,
186,
344
],
[
344,
32,
1061
]
],
[
[
75,
82,
519
],
[
519,
201,
1061
]
],
[
[
75,
240,
193
],
[
193,
213,
1061
]
]
] |
[
[
[
"Pargyline",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the hypotensive activities of {v}",
"Bethanidine"
]
],
[
[
"Pargyline",
"{u} may increase the hypertensive activities of {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} (Compound) resembles {v} (Compound)",
"Bethanidine"
]
],
[
[
"Pargyline",
"{u} (Compound) resembles {v} (Compound)",
"Phentermine"
],
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound)",
"Bethanidine"
]
],
[
[
"Pargyline",
"{u} may increase the hypotensive activities of {v}",
"Selegiline"
],
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound)",
"Bethanidine"
]
],
[
[
"Pargyline",
"{u} (Compound) resembles {v} (Compound)",
"Fenproporex"
],
[
"Fenproporex",
"{u} (Compound) resembles {v} (Compound)",
"Bethanidine"
]
],
[
[
"Pargyline",
"{u} may increase the hypotensive activities of {v}",
"Isocarboxazid"
],
[
"Isocarboxazid",
"{u} may increase the hypotensive activities of {v}",
"Bethanidine"
]
],
[
[
"Pargyline",
"{u} (Compound) resembles {v} (Compound)",
"Phenelzine"
],
[
"Phenelzine",
"{u} may increase the hypotensive activities of {v}",
"Bethanidine"
]
],
[
[
"Pargyline",
"{u} may increase the antihypertensive activities of {v}",
"Udenafil"
],
[
"Udenafil",
"{u} may increase the antihypertensive activities of {v}",
"Bethanidine"
]
],
[
[
"Pargyline",
"{u} may increase the hypotensive activities of {v}",
"Celiprolol"
],
[
"Celiprolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Bethanidine"
]
],
[
[
"Pargyline",
"{u} may increase the serotonergic activities of {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may decrease the antihypertensive activities of {v}",
"Bethanidine"
]
]
] |
Pargyline (Compound) resembles Bethanidine (Compound) and
Pargyline may increase the hypertensive activities of Pseudoephedrine and Pseudoephedrine (Compound) resembles Bethanidine (Compound)
Pargyline (Compound) resembles Phentermine (Compound) and Phentermine (Compound) resembles Bethanidine (Compound)
Pargyline may increase the hypotensive activities of Selegiline and Selegiline (Compound) resembles Bethanidine (Compound)
Pargyline (Compound) resembles Fenproporex (Compound) and Fenproporex (Compound) resembles Bethanidine (Compound)
Pargyline may increase the hypotensive activities of Isocarboxazid and Isocarboxazid may increase the hypotensive activities of Bethanidine
Pargyline (Compound) resembles Phenelzine (Compound) and Phenelzine may increase the hypotensive activities of Bethanidine
Pargyline may increase the antihypertensive activities of Udenafil and Udenafil may increase the antihypertensive activities of Bethanidine
Pargyline may increase the hypotensive activities of Celiprolol and Celiprolol may increase the atrioventricular blocking activities of Bethanidine
Pargyline may increase the serotonergic activities of Levomilnacipran and Levomilnacipran may decrease the antihypertensive activities of Bethanidine
|
DB00696
|
DB01242
| 563 | 499 |
Ergotamine
|
Clomipramine
|
A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
|
Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic ser
|
Ergotamine may decrease the antihypertensive activities of Clomipramine.
| 36 |
[
[
[
563,
59,
499
]
],
[
[
563,
71,
964
],
[
964,
71,
499
]
],
[
[
563,
71,
270
],
[
270,
69,
499
]
],
[
[
563,
71,
1379
],
[
1379,
225,
499
]
],
[
[
563,
59,
221
],
[
221,
71,
499
]
],
[
[
563,
71,
967
],
[
967,
155,
499
]
],
[
[
563,
6,
8339
],
[
8339,
160,
499
]
],
[
[
563,
21,
28613
],
[
28613,
175,
499
]
],
[
[
563,
180,
161
],
[
161,
26,
499
]
],
[
[
563,
71,
568
],
[
568,
187,
499
]
]
] |
[
[
[
"Ergotamine",
"{u} may decrease the antihypertensive activities of {v}",
"Clomipramine"
]
],
[
[
"Ergotamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triflupromazine"
],
[
"Triflupromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clomipramine"
]
],
[
[
"Ergotamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may decrease the metabolism of {v}",
"Clomipramine"
]
],
[
[
"Ergotamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Periciazine"
],
[
"Periciazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clomipramine"
]
],
[
[
"Ergotamine",
"{u} may decrease the antihypertensive activities of {v}",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clomipramine"
]
],
[
[
"Ergotamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorprothixene"
],
[
"Chlorprothixene",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
]
],
[
[
"Ergotamine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clomipramine"
]
],
[
[
"Ergotamine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clomipramine"
]
],
[
[
"Ergotamine",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Clomipramine"
]
],
[
[
"Ergotamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Clomipramine"
]
]
] |
Ergotamine may increase the severity of adverse effects when combined with Triflupromazine and Triflupromazine may increase the severity of adverse effects when combined with Clomipramine
Ergotamine may increase the severity of adverse effects when combined with Prochlorperazine and Prochlorperazine may decrease the metabolism of Clomipramine
Ergotamine may increase the severity of adverse effects when combined with Periciazine and Periciazine may increase the severity of adverse effects when combined with Clomipramine
Ergotamine may decrease the antihypertensive activities of Nortriptyline and Nortriptyline may increase the severity of adverse effects when combined with Clomipramine
Ergotamine may increase the severity of adverse effects when combined with Chlorprothixene and Chlorprothixene (Compound) resembles Clomipramine (Compound)
Ergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clomipramine (Compound)
Ergotamine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Clomipramine (Compound)
Ergotamine can increase the metabolism of Primidone and Primidone can increase the metabolism of Clomipramine
Ergotamine may increase the severity of adverse effects when combined with Tamoxifen and Tamoxifen may reduce the serum concentration of the active metabolites of Clomipramine
|
DB06589
|
DB00346
| 437 | 278 |
Pazopanib
|
Alfuzosin
|
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
|
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.
|
Pazopanib may increase the QTc-prolonging activities of Alfuzosin.
| 19 |
[
[
[
437,
42,
278
]
],
[
[
437,
6,
4590
],
[
4590,
160,
278
]
],
[
[
437,
7,
4671
],
[
4671,
161,
278
]
],
[
[
437,
21,
28499
],
[
28499,
175,
278
]
],
[
[
437,
251,
173
],
[
173,
26,
278
]
],
[
[
437,
95,
156
],
[
156,
26,
278
]
],
[
[
437,
95,
563
],
[
563,
181,
278
]
],
[
[
437,
42,
705
],
[
705,
181,
278
]
],
[
[
437,
42,
1313
],
[
1313,
42,
278
]
],
[
[
437,
196,
1007
],
[
1007,
42,
278
]
]
] |
[
[
[
"Pazopanib",
"{u} may increase the QTc prolonging activities of {v}",
"Alfuzosin"
]
],
[
[
"Pazopanib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Alfuzosin"
]
],
[
[
"Pazopanib",
"{u} (Compound) upregulates {v} (Gene)",
"SERPINA3"
],
[
"SERPINA3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Alfuzosin"
]
],
[
[
"Pazopanib",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alfuzosin"
]
],
[
[
"Pazopanib",
"{u} may decrease the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Alfuzosin"
]
],
[
[
"Pazopanib",
"{u} may increase the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Alfuzosin"
]
],
[
[
"Pazopanib",
"{u} may increase the serum concentration of {v}",
"Ergotamine"
],
[
"Ergotamine",
"{u} may decrease the vasoconstricting activities of {v}",
"Alfuzosin"
]
],
[
[
"Pazopanib",
"{u} may increase the QTc prolonging activities of {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may decrease the vasoconstricting activities of {v}",
"Alfuzosin"
]
],
[
[
"Pazopanib",
"{u} may increase the QTc prolonging activities of {v}",
"Perflutren"
],
[
"Perflutren",
"{u} may increase the QTc prolonging activities of {v}",
"Alfuzosin"
]
],
[
[
"Pazopanib",
"{u} may increase the QTc prolonging activities of {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Alfuzosin"
]
]
] |
Pazopanib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alfuzosin (Compound)
Pazopanib (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is upregulated by Alfuzosin (Compound)
Pazopanib (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Alfuzosin (Compound)
Pazopanib may decrease the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Alfuzosin
Pazopanib may increase the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Alfuzosin
Pazopanib may increase the serum concentration of Ergotamine and Ergotamine may decrease the vasoconstricting activities of Alfuzosin
Pazopanib may increase the QTc prolonging activities of Salbutamol and Salbutamol may decrease the vasoconstricting activities of Alfuzosin
Pazopanib may increase the QTc prolonging activities of Perflutren and Perflutren may increase the QTc prolonging activities of Alfuzosin
Pazopanib may increase the QTc prolonging activities of Paliperidone and Paliperidone may increase the QTc prolonging activities of Alfuzosin
|
DB00517
|
DB00921
| 19 | 491 |
Anisotropine methylbromide
|
Buprenorphine
|
Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion.
|
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.[A186283,A186292] It is also commonly used as an alternative to [methadone] for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid receptor antagonist. Combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist effects of buprenorphine if injected intravenously.[A186289,L46571] Buprenorphine has poor gastrointestinal absorption and is therefore formulated as a sublingual tablet. Buprenorphine has a
|
The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Buprenorphine.
| 48 |
[
[
[
19,
71,
491
]
],
[
[
19,
71,
1012
],
[
1012,
192,
491
]
],
[
[
19,
107,
1261
],
[
1261,
192,
491
]
],
[
[
19,
225,
51
],
[
51,
192,
491
]
],
[
[
19,
71,
237
],
[
237,
223,
491
]
],
[
[
19,
71,
44
],
[
44,
71,
491
]
],
[
[
19,
225,
37
],
[
37,
71,
491
]
],
[
[
19,
249,
1049
],
[
1049,
225,
491
]
],
[
[
19,
246,
31
],
[
31,
225,
491
]
],
[
[
19,
71,
327
],
[
327,
276,
491
]
]
] |
[
[
[
"Anisotropine methylbromide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Buprenorphine"
]
],
[
[
"Anisotropine methylbromide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diamorphine"
],
[
"Diamorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
]
],
[
[
"Anisotropine methylbromide",
"{u} may increase the tachycardic activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
]
],
[
[
"Anisotropine methylbromide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
]
],
[
[
"Anisotropine methylbromide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may decrease the metabolism of {v}",
"Buprenorphine"
]
],
[
[
"Anisotropine methylbromide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Buprenorphine"
]
],
[
[
"Anisotropine methylbromide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxyphenonium"
],
[
"Oxyphenonium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Buprenorphine"
]
],
[
[
"Anisotropine methylbromide",
"{u} may increase the serum concentration of {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Buprenorphine"
]
],
[
[
"Anisotropine methylbromide",
"{u} may decrease the therapeutic efficacy of {v}",
"Minaprine"
],
[
"Minaprine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Buprenorphine"
]
],
[
[
"Anisotropine methylbromide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxymorphone"
],
[
"Oxymorphone",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
]
]
] |
Anisotropine methylbromide may increase the severity of adverse effects when combined with Diamorphine and Diamorphine may increase the central nervous system depressant activities of Buprenorphine
Anisotropine methylbromide may increase the tachycardic activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Buprenorphine
Anisotropine methylbromide may increase the severity of adverse effects when combined with Scopolamine and Scopolamine may increase the central nervous system depressant activities of Buprenorphine
Anisotropine methylbromide may increase the severity of adverse effects when combined with Mirabegron and Mirabegron may decrease the metabolism of Buprenorphine
Anisotropine methylbromide may increase the severity of adverse effects when combined with Tolterodine and Tolterodine may increase the severity of adverse effects when combined with Buprenorphine
Anisotropine methylbromide may increase the severity of adverse effects when combined with Oxyphenonium and Oxyphenonium may increase the severity of adverse effects when combined with Buprenorphine
Anisotropine methylbromide may increase the serum concentration of Bendroflumethiazide and Bendroflumethiazide may increase the severity of adverse effects when combined with Buprenorphine
Anisotropine methylbromide may decrease the therapeutic efficacy of Minaprine and Minaprine may increase the severity of adverse effects when combined with Buprenorphine
Anisotropine methylbromide may increase the severity of adverse effects when combined with Oxymorphone and Oxymorphone (Compound) resembles Buprenorphine (Compound) and Oxymorphone may increase the central nervous system depressant activities of Buprenorphine
|
DB00169
|
DB00619
| 414 | 637 |
Cholecalciferol
|
Imatinib
|
Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-derived form, vitamin D2 (ergocalciferol), are considered the main forms of vitamin d and are found in various types of food for daily intake. Structurally, ergocalciferol differs from cholecalciferol in that it possesses a double bond between C22 and C23 and has an additional methyl group at C24. Finally, ergocalciferol is pharmacologically less potent than cholecalciferol, which makes vitamin D3 the preferred agent for medical use. Appropriate levels of vitamin D must be upheld in the body in order to maintain calcium and phosphorus levels in a
|
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
|
The metabolism of Imatinib can be decreased when combined with Cholecalciferol.
| 46 |
[
[
[
414,
69,
637
]
],
[
[
414,
223,
675
],
[
675,
155,
637
]
],
[
[
414,
6,
10999
],
[
10999,
160,
637
]
],
[
[
414,
223,
219
],
[
219,
28,
637
]
],
[
[
414,
223,
680
],
[
680,
187,
637
]
],
[
[
414,
223,
186
],
[
186,
204,
637
]
],
[
[
414,
223,
1389
],
[
1389,
210,
637
]
],
[
[
414,
223,
206
],
[
206,
69,
637
]
],
[
[
414,
223,
639
],
[
639,
223,
637
]
],
[
[
414,
33,
568
],
[
568,
69,
637
]
]
] |
[
[
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Imatinib"
]
],
[
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} (Compound) resembles {v} (Compound)",
"Imatinib"
]
],
[
[
"Cholecalciferol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Imatinib"
]
],
[
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Imatinib"
]
],
[
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Imatinib"
]
],
[
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may increase the dermatologic adverse activities of {v}",
"Imatinib"
]
],
[
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may increase the immunosuppressive activities of {v}",
"Imatinib"
]
],
[
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may decrease the metabolism of {v}",
"Imatinib"
]
],
[
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may decrease the metabolism of {v}",
"Imatinib"
]
],
[
[
"Cholecalciferol",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may decrease the metabolism of {v}",
"Imatinib"
]
]
] |
Cholecalciferol may decrease the metabolism of Ponatinib and Ponatinib (Compound) resembles Imatinib (Compound)
Cholecalciferol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Imatinib (Compound)
Cholecalciferol may decrease the metabolism of Warfarin and Warfarin may increase the anticoagulant activities of Imatinib
Cholecalciferol may decrease the metabolism of Ifosfamide and Ifosfamide may reduce the serum concentration of the active metabolites of Imatinib
Cholecalciferol may decrease the metabolism of Lansoprazole and Lansoprazole may increase the dermatologic adverse activities of Imatinib
Cholecalciferol may decrease the metabolism of Tofacitinib and Tofacitinib may increase the immunosuppressive activities of Imatinib
Cholecalciferol may decrease the metabolism of Lapatinib and Lapatinib may decrease the metabolism of Imatinib
Cholecalciferol may decrease the metabolism of Valproic acid and Valproic acid may decrease the metabolism of Imatinib
Cholecalciferol may reduce the serum concentration of the active metabolites of Tamoxifen and Tamoxifen may decrease the metabolism of Imatinib
|
DB01082
|
DB00314
| 897 | 1,331 |
Streptomycin
|
Capreomycin
|
Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.
|
Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.
|
Streptomycin may increase the neuromuscular blocking activities of Capreomycin.
| 20 |
[
[
[
897,
43,
1331
]
],
[
[
897,
21,
29013
],
[
29013,
175,
1331
]
],
[
[
897,
216,
1286
],
[
1286,
43,
1331
]
],
[
[
897,
1,
896
],
[
896,
43,
1331
]
],
[
[
897,
197,
45
],
[
45,
43,
1331
]
],
[
[
897,
92,
1572
],
[
1572,
246,
1331
]
],
[
[
897,
21,
29013
],
[
29013,
175,
892
],
[
892,
43,
1331
]
],
[
[
897,
216,
1286
],
[
1286,
62,
901
],
[
901,
43,
1331
]
],
[
[
897,
216,
939
],
[
939,
21,
28463
],
[
28463,
175,
1331
]
],
[
[
897,
1,
896
],
[
896,
21,
29099
],
[
29099,
175,
1331
]
]
] |
[
[
[
"Streptomycin",
"{u} may increase the neuromuscular blocking activities of {v}",
"Capreomycin"
]
],
[
[
"Streptomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Renal impairment"
],
[
"Renal impairment",
"{u} (Side Effect) is caused by {v} (Compound)",
"Capreomycin"
]
],
[
[
"Streptomycin",
"{u} may increase the respiratory depressant activities of {v}",
"Pyrantel"
],
[
"Pyrantel",
"{u} may increase the neuromuscular blocking activities of {v}",
"Capreomycin"
]
],
[
[
"Streptomycin",
"{u} (Compound) resembles {v} (Compound)",
"Kanamycin"
],
[
"Kanamycin",
"{u} may increase the neuromuscular blocking activities of {v}",
"Capreomycin"
]
],
[
[
"Streptomycin",
"{u} may increase the neuromuscular blocking activities of {v}",
"Mecamylamine"
],
[
"Mecamylamine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Capreomycin"
]
],
[
[
"Streptomycin",
"{u} may decrease the therapeutic efficacy of {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Capreomycin"
]
],
[
[
"Streptomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Renal impairment"
],
[
"Renal impairment",
"{u} (Side Effect) is caused by {v} (Compound)",
"Epirubicin"
],
[
"Epirubicin",
"{u} may increase the neuromuscular blocking activities of {v}",
"Capreomycin"
]
],
[
[
"Streptomycin",
"{u} may increase the respiratory depressant activities of {v}",
"Pyrantel"
],
[
"Pyrantel",
"{u} may increase the respiratory depressant activities of {v}",
"Streptozocin"
],
[
"Streptozocin",
"{u} may increase the neuromuscular blocking activities of {v}",
"Capreomycin"
]
],
[
[
"Streptomycin",
"{u} may increase the respiratory depressant activities of {v}",
"Succinylcholine"
],
[
"Succinylcholine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Capreomycin"
]
],
[
[
"Streptomycin",
"{u} (Compound) resembles {v} (Compound)",
"Kanamycin"
],
[
"Kanamycin",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by {v} (Compound)",
"Capreomycin"
]
]
] |
Streptomycin (Compound) causes Renal impairment (Side Effect) and Renal impairment (Side Effect) is caused by Capreomycin (Compound)
Streptomycin may increase the respiratory depressant activities of Pyrantel and Pyrantel may increase the neuromuscular blocking activities of Capreomycin
Streptomycin (Compound) resembles Kanamycin (Compound) and Kanamycin may increase the neuromuscular blocking activities of Capreomycin
Streptomycin may increase the neuromuscular blocking activities of Mecamylamine and Mecamylamine may increase the neuromuscular blocking activities of Capreomycin
Streptomycin may decrease the therapeutic efficacy of Picosulfuric acid and Picosulfuric acid may decrease the therapeutic efficacy of Capreomycin
Streptomycin (Compound) causes Renal impairment (Side Effect) and Renal impairment (Side Effect) is caused by Epirubicin (Compound) and Epirubicin may increase the neuromuscular blocking activities of Capreomycin
Streptomycin may increase the respiratory depressant activities of Pyrantel and Pyrantel may increase the respiratory depressant activities of Streptozocin and Streptozocin may increase the neuromuscular blocking activities of Capreomycin
Streptomycin may increase the respiratory depressant activities of Succinylcholine and Succinylcholine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Capreomycin (Compound)
Streptomycin (Compound) resembles Kanamycin (Compound) and Kanamycin (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Capreomycin (Compound)
|
DB00455
|
DB00705
| 401 | 508 |
Loratadine
|
Delavirdine
|
Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
|
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
|
The metabolism of Delavirdine can be decreased when combined with Loratadine.
| 46 |
[
[
[
401,
69,
508
]
],
[
[
401,
6,
10999
],
[
10999,
160,
508
]
],
[
[
401,
21,
28515
],
[
28515,
175,
508
]
],
[
[
401,
180,
161
],
[
161,
26,
508
]
],
[
[
401,
225,
371
],
[
371,
69,
508
]
],
[
[
401,
69,
307
],
[
307,
69,
508
]
],
[
[
401,
95,
137
],
[
137,
223,
508
]
],
[
[
401,
69,
1086
],
[
1086,
223,
508
]
],
[
[
401,
192,
587
],
[
587,
69,
508
]
],
[
[
401,
71,
434
],
[
434,
69,
508
]
]
] |
[
[
[
"Loratadine",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Loratadine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Delavirdine"
]
],
[
[
"Loratadine",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Delavirdine"
]
],
[
[
"Loratadine",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Loratadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quazepam"
],
[
"Quazepam",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Loratadine",
"{u} may decrease the metabolism of {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Loratadine",
"{u} may increase the serum concentration of {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Loratadine",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Loratadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Loratadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunarizine"
],
[
"Flunarizine",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
]
] |
Loratadine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Delavirdine (Compound)
Loratadine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Delavirdine (Compound)
Loratadine can increase the metabolism of Primidone and Primidone can increase the metabolism of Delavirdine
Loratadine may increase the severity of adverse effects when combined with Quazepam and Quazepam may decrease the metabolism of Delavirdine
Loratadine may decrease the metabolism of Fluvastatin and Fluvastatin may decrease the metabolism of Delavirdine
Loratadine may increase the serum concentration of Amiodarone and Amiodarone may decrease the metabolism of Delavirdine
Loratadine may decrease the metabolism of Clotrimazole and Clotrimazole may decrease the metabolism of Delavirdine
Loratadine may increase the central nervous system depressant activities of Ethanol and Ethanol may decrease the metabolism of Delavirdine
Loratadine may increase the severity of adverse effects when combined with Flunarizine and Flunarizine may decrease the metabolism of Delavirdine
|
DB00697
|
DB01580
| 730 | 911 |
Tizanidine
|
Oxprenolol
|
Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
|
A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
|
Tizanidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
| 24 |
[
[
[
730,
47,
911
]
],
[
[
730,
47,
1026
],
[
1026,
82,
911
]
],
[
[
730,
225,
1005
],
[
1005,
225,
911
]
],
[
[
730,
21,
28512
],
[
28512,
175,
911
]
],
[
[
730,
246,
674
],
[
674,
30,
911
]
],
[
[
730,
192,
587
],
[
587,
38,
911
]
],
[
[
730,
59,
543
],
[
543,
38,
911
]
],
[
[
730,
95,
491
],
[
491,
38,
911
]
],
[
[
730,
38,
1257
],
[
1257,
192,
911
]
],
[
[
730,
93,
1303
],
[
1303,
41,
911
]
]
] |
[
[
[
"Tizanidine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Oxprenolol"
]
],
[
[
"Tizanidine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may increase the hypotensive activities of {v}",
"Oxprenolol"
]
],
[
[
"Tizanidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methocarbamol"
],
[
"Methocarbamol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxprenolol"
]
],
[
[
"Tizanidine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxprenolol"
]
],
[
[
"Tizanidine",
"{u} may decrease the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Oxprenolol"
]
],
[
[
"Tizanidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Oxprenolol"
]
],
[
[
"Tizanidine",
"{u} may decrease the antihypertensive activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Oxprenolol"
]
],
[
[
"Tizanidine",
"{u} may increase the serum concentration of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Oxprenolol"
]
],
[
[
"Tizanidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Oxprenolol"
]
],
[
[
"Tizanidine",
"{u} may increase the hypertensive activities of {v}",
"Methylergometrine"
],
[
"Methylergometrine",
"{u} may increase the vasoconstricting activities of {v}",
"Oxprenolol"
]
]
] |
Tizanidine may increase the atrioventricular blocking activities of Acebutolol and Acebutolol may increase the hypotensive activities of Oxprenolol
Tizanidine may increase the severity of adverse effects when combined with Methocarbamol and Methocarbamol may increase the severity of adverse effects when combined with Oxprenolol
Tizanidine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Oxprenolol (Compound)
Tizanidine may decrease the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Oxprenolol
Tizanidine may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the central nervous system depressant activities of Oxprenolol
Tizanidine may decrease the antihypertensive activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Oxprenolol
Tizanidine may increase the serum concentration of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Oxprenolol
Tizanidine may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Oxprenolol
Tizanidine may increase the hypertensive activities of Methylergometrine and Methylergometrine may increase the vasoconstricting activities of Oxprenolol
|
DB00589
|
DB01012
| 308 | 547 |
Lisuride
|
Cinacalcet
|
An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).
|
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
|
The metabolism of Cinacalcet can be decreased when combined with Lisuride.
| 46 |
[
[
[
308,
69,
547
]
],
[
[
308,
69,
828
],
[
828,
95,
547
]
],
[
[
308,
6,
18777
],
[
18777,
160,
547
]
],
[
[
308,
21,
28742
],
[
28742,
175,
547
]
],
[
[
308,
180,
171
],
[
171,
26,
547
]
],
[
[
308,
69,
245
],
[
245,
69,
547
]
],
[
[
308,
71,
599
],
[
599,
69,
547
]
],
[
[
308,
69,
564
],
[
564,
223,
547
]
],
[
[
308,
71,
1119
],
[
1119,
223,
547
]
],
[
[
308,
95,
1095
],
[
1095,
223,
547
]
]
] |
[
[
[
"Lisuride",
"{u} may decrease the metabolism of {v}",
"Cinacalcet"
]
],
[
[
"Lisuride",
"{u} may decrease the metabolism of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the serum concentration of {v}",
"Cinacalcet"
]
],
[
[
"Lisuride",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Cinacalcet"
]
],
[
[
"Lisuride",
"{u} (Compound) causes {v} (Side Effect)",
"Cough"
],
[
"Cough",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cinacalcet"
]
],
[
[
"Lisuride",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Cinacalcet"
]
],
[
[
"Lisuride",
"{u} may decrease the metabolism of {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may decrease the metabolism of {v}",
"Cinacalcet"
]
],
[
[
"Lisuride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may decrease the metabolism of {v}",
"Cinacalcet"
]
],
[
[
"Lisuride",
"{u} may decrease the metabolism of {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may decrease the metabolism of {v}",
"Cinacalcet"
]
],
[
[
"Lisuride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zucapsaicin"
],
[
"Zucapsaicin",
"{u} may decrease the metabolism of {v}",
"Cinacalcet"
]
],
[
[
"Lisuride",
"{u} may increase the serum concentration of {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may decrease the metabolism of {v}",
"Cinacalcet"
]
]
] |
Lisuride may decrease the metabolism of Duloxetine and Duloxetine may increase the serum concentration of Cinacalcet
Lisuride (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Cinacalcet (Compound)
Lisuride (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Cinacalcet (Compound)
Lisuride can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Cinacalcet
Lisuride may decrease the metabolism of Haloperidol and Haloperidol may decrease the metabolism of Cinacalcet
Lisuride may increase the severity of adverse effects when combined with Ranitidine and Ranitidine may decrease the metabolism of Cinacalcet
Lisuride may decrease the metabolism of Atazanavir and Atazanavir may decrease the metabolism of Cinacalcet
Lisuride may increase the severity of adverse effects when combined with Zucapsaicin and Zucapsaicin may decrease the metabolism of Cinacalcet
Lisuride may increase the serum concentration of Cobicistat and Cobicistat may decrease the metabolism of Cinacalcet
|
DB00697
|
DB00679
| 730 | 653 |
Tizanidine
|
Thioridazine
|
Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
|
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
|
The serum concentration of Thioridazine can be increased when it is combined with Tizanidine.
| 72 |
[
[
[
730,
95,
653
]
],
[
[
730,
196,
288
],
[
288,
249,
653
]
],
[
[
730,
225,
970
],
[
970,
249,
653
]
],
[
[
730,
225,
270
],
[
270,
69,
653
]
],
[
[
730,
225,
973
],
[
973,
155,
653
]
],
[
[
730,
225,
940
],
[
940,
1,
653
]
],
[
[
730,
95,
1014
],
[
1014,
155,
653
]
],
[
[
730,
95,
525
],
[
525,
249,
653
]
],
[
[
730,
6,
2914
],
[
2914,
160,
653
]
],
[
[
730,
18,
13061
],
[
13061,
161,
653
]
]
] |
[
[
[
"Tizanidine",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
]
],
[
[
"Tizanidine",
"{u} may increase the QTc prolonging activities of {v}",
"Promazine"
],
[
"Promazine",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
]
],
[
[
"Tizanidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thiothixene"
],
[
"Thiothixene",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
]
],
[
[
"Tizanidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may decrease the metabolism of {v}",
"Thioridazine"
]
],
[
[
"Tizanidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceprometazine"
],
[
"Aceprometazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
]
],
[
[
"Tizanidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
]
],
[
[
"Tizanidine",
"{u} may increase the serum concentration of {v}",
"Fluphenazine"
],
[
"Fluphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
]
],
[
[
"Tizanidine",
"{u} may increase the serum concentration of {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
]
],
[
[
"Tizanidine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2A"
],
[
"ADRA2A",
"{u} (Gene) is bound by {v} (Compound)",
"Thioridazine"
]
],
[
[
"Tizanidine",
"{u} (Compound) downregulates {v} (Gene)",
"MTHFD2"
],
[
"MTHFD2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Thioridazine"
]
]
] |
Tizanidine may increase the QTc prolonging activities of Promazine and Promazine may increase the serum concentration of Thioridazine
Tizanidine may increase the severity of adverse effects when combined with Thiothixene and Thiothixene may increase the serum concentration of Thioridazine
Tizanidine may increase the severity of adverse effects when combined with Prochlorperazine and Prochlorperazine may decrease the metabolism of Thioridazine
Tizanidine may increase the severity of adverse effects when combined with Aceprometazine and Aceprometazine (Compound) resembles Thioridazine (Compound)
Tizanidine may increase the severity of adverse effects when combined with Trifluoperazine and Trifluoperazine (Compound) resembles Thioridazine (Compound)
Tizanidine may increase the serum concentration of Fluphenazine and Fluphenazine (Compound) resembles Thioridazine (Compound)
Tizanidine may increase the serum concentration of Perphenazine and Perphenazine may increase the serum concentration of Thioridazine
Tizanidine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Thioridazine (Compound)
Tizanidine (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Thioridazine (Compound)
|
DB00237
|
DB00391
| 994 | 18 |
Butabarbital
|
Sulpiride
|
Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.[A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.[A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines. Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.
|
Sulpiride first appeared in published literature in 1967. Clinical studies show a greater effect on treating the negative symptoms of schizophrenia rather than positive symptoms at low doses, though the effects are more equal at higher doses. Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.
|
The risk or severity of adverse effects can be increased when Butabarbital is combined with Sulpiride.
| 48 |
[
[
[
994,
71,
18
]
],
[
[
994,
71,
920
],
[
920,
71,
18
]
],
[
[
994,
184,
674
],
[
674,
30,
18
]
],
[
[
994,
192,
587
],
[
587,
38,
18
]
],
[
[
994,
38,
1265
],
[
1265,
192,
18
]
],
[
[
994,
54,
471
],
[
471,
208,
18
]
],
[
[
994,
71,
1003
],
[
1003,
212,
18
]
],
[
[
994,
71,
926
],
[
926,
225,
18
]
],
[
[
994,
225,
1267
],
[
1267,
71,
18
]
],
[
[
994,
116,
977
],
[
977,
225,
18
]
]
] |
[
[
[
"Butabarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
]
],
[
[
"Butabarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Remoxipride"
],
[
"Remoxipride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
]
],
[
[
"Butabarbital",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Sulpiride"
]
],
[
[
"Butabarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Sulpiride"
]
],
[
[
"Butabarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Sulpiride"
]
],
[
[
"Butabarbital",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Sulpiride"
]
],
[
[
"Butabarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lurasidone"
],
[
"Lurasidone",
"{u} may increase the antipsychotic activities of {v}",
"Sulpiride"
]
],
[
[
"Butabarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Proparacaine"
],
[
"Proparacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
]
],
[
[
"Butabarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lorazepam"
],
[
"Lorazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
]
],
[
[
"Butabarbital",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
]
]
] |
Butabarbital may increase the severity of adverse effects when combined with Remoxipride and Remoxipride may increase the severity of adverse effects when combined with Sulpiride
Butabarbital can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Sulpiride
Butabarbital may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the central nervous system depressant activities of Sulpiride
Butabarbital may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Sulpiride
Butabarbital may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Sulpiride
Butabarbital may increase the severity of adverse effects when combined with Lurasidone and Lurasidone may increase the antipsychotic activities of Sulpiride
Butabarbital may increase the severity of adverse effects when combined with Proparacaine and Proparacaine may increase the severity of adverse effects when combined with Sulpiride
Butabarbital may increase the severity of adverse effects when combined with Lorazepam and Lorazepam may increase the severity of adverse effects when combined with Sulpiride
Butabarbital (Compound) resembles Butalbital (Compound) and Butabarbital may increase the severity of adverse effects when combined with Butalbital and Butalbital may increase the severity of adverse effects when combined with Sulpiride
|
DB04871
|
DB00503
| 578 | 244 |
Lorcaserin
|
Ritonavir
|
Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride. In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets, 20 mg) to voluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug. This decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients
|
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
|
The metabolism of Ritonavir can be decreased when combined with Lorcaserin.
| 46 |
[
[
[
578,
69,
244
]
],
[
[
578,
69,
429
],
[
429,
223,
244
]
],
[
[
578,
180,
171
],
[
171,
26,
244
]
],
[
[
578,
223,
1083
],
[
1083,
187,
244
]
],
[
[
578,
223,
1322
],
[
1322,
42,
244
]
],
[
[
578,
95,
1019
],
[
1019,
196,
244
]
],
[
[
578,
69,
575
],
[
575,
42,
244
]
],
[
[
578,
71,
1007
],
[
1007,
42,
244
]
],
[
[
578,
225,
324
],
[
324,
42,
244
]
],
[
[
578,
223,
165
],
[
165,
69,
244
]
]
] |
[
[
[
"Lorcaserin",
"{u} may decrease the metabolism of {v}",
"Ritonavir"
]
],
[
[
"Lorcaserin",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} may decrease the metabolism of {v}",
"Ritonavir"
]
],
[
[
"Lorcaserin",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Ritonavir"
]
],
[
[
"Lorcaserin",
"{u} may decrease the metabolism of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Ritonavir"
]
],
[
[
"Lorcaserin",
"{u} may decrease the metabolism of {v}",
"Procainamide"
],
[
"Procainamide",
"{u} may increase the QTc prolonging activities of {v}",
"Ritonavir"
]
],
[
[
"Lorcaserin",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Ritonavir"
]
],
[
[
"Lorcaserin",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the QTc prolonging activities of {v}",
"Ritonavir"
]
],
[
[
"Lorcaserin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Ritonavir"
]
],
[
[
"Lorcaserin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may increase the QTc prolonging activities of {v}",
"Ritonavir"
]
],
[
[
"Lorcaserin",
"{u} may decrease the metabolism of {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may decrease the metabolism of {v}",
"Ritonavir"
]
]
] |
Lorcaserin may decrease the metabolism of Lopinavir and Lopinavir may decrease the metabolism of Ritonavir
Lorcaserin can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Ritonavir
Lorcaserin may decrease the metabolism of Hydrocodone and Hydrocodone may reduce the serum concentration of the active metabolites of Ritonavir
Lorcaserin may decrease the metabolism of Procainamide and Procainamide may increase the QTc prolonging activities of Ritonavir
Lorcaserin may increase the serum concentration of Mifepristone and Mifepristone may increase the QTc prolonging activities of Ritonavir
Lorcaserin may decrease the metabolism of Sulfisoxazole and Sulfisoxazole may increase the QTc prolonging activities of Ritonavir
Lorcaserin may increase the severity of adverse effects when combined with Paliperidone and Paliperidone may increase the QTc prolonging activities of Ritonavir
Lorcaserin may increase the severity of adverse effects when combined with Escitalopram and Escitalopram may increase the QTc prolonging activities of Ritonavir
Lorcaserin may decrease the metabolism of Brompheniramine and Brompheniramine may decrease the metabolism of Ritonavir
|
DB00771
|
DB04908
| 941 | 929 |
Clidinium
|
Flibanserin
|
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
|
Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
|
The risk or severity of adverse effects can be increased when Clidinium is combined with Flibanserin.
| 48 |
[
[
[
941,
71,
929
]
],
[
[
941,
38,
1262
],
[
1262,
192,
929
]
],
[
[
941,
192,
1083
],
[
1083,
38,
929
]
],
[
[
941,
54,
1046
],
[
1046,
208,
929
]
],
[
[
941,
225,
980
],
[
980,
71,
929
]
],
[
[
941,
71,
989
],
[
989,
71,
929
]
],
[
[
941,
155,
918
],
[
918,
71,
929
]
],
[
[
941,
71,
196
],
[
196,
225,
929
]
],
[
[
941,
270,
961
],
[
961,
71,
929
]
],
[
[
941,
192,
587
],
[
587,
82,
929
]
]
] |
[
[
[
"Clidinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Clidinium",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Flibanserin"
]
],
[
[
"Clidinium",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Flibanserin"
]
],
[
[
"Clidinium",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Flibanserin"
]
],
[
[
"Clidinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amisulpride"
],
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Clidinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound)",
"Difenoxin"
],
[
"Difenoxin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Clidinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flibanserin"
]
],
[
[
"Clidinium",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the hypotensive activities of {v}",
"Flibanserin"
]
]
] |
Clidinium may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Flibanserin
Clidinium may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Flibanserin
Clidinium may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Flibanserin
Clidinium may increase the severity of adverse effects when combined with Amisulpride and Amisulpride may increase the severity of adverse effects when combined with Flibanserin
Clidinium may increase the severity of adverse effects when combined with Cyclizine and Cyclizine may increase the severity of adverse effects when combined with Flibanserin
Clidinium (Compound) resembles Difenoxin (Compound) and Difenoxin may increase the severity of adverse effects when combined with Flibanserin
Clidinium may increase the severity of adverse effects when combined with Iloperidone and Iloperidone may increase the severity of adverse effects when combined with Flibanserin
Clidinium (Compound) resembles Fentanyl (Compound) and Clidinium may increase the severity of adverse effects when combined with Fentanyl and Fentanyl may increase the severity of adverse effects when combined with Flibanserin
Clidinium may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the hypotensive activities of Flibanserin
|
DB00831
|
DB00358
| 940 | 285 |
Trifluoperazine
|
Mefloquine
|
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
|
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196
|
The serum concentration of Mefloquine can be increased when it is combined with Trifluoperazine.
| 72 |
[
[
[
940,
95,
285
]
],
[
[
940,
6,
8339
],
[
8339,
160,
285
]
],
[
[
940,
7,
5785
],
[
5785,
161,
285
]
],
[
[
940,
18,
5353
],
[
5353,
172,
285
]
],
[
[
940,
21,
28448
],
[
28448,
175,
285
]
],
[
[
940,
225,
171
],
[
171,
26,
285
]
],
[
[
940,
69,
173
],
[
173,
26,
285
]
],
[
[
940,
71,
1007
],
[
1007,
42,
285
]
],
[
[
940,
69,
645
],
[
645,
42,
285
]
],
[
[
940,
82,
1027
],
[
1027,
42,
285
]
]
] |
[
[
[
"Trifluoperazine",
"{u} may increase the serum concentration of {v}",
"Mefloquine"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) upregulates {v} (Gene)",
"NPC1"
],
[
"NPC1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Mefloquine"
]
],
[
[
"Trifluoperazine",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Mefloquine"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Mefloquine"
]
],
[
[
"Trifluoperazine",
"{u} may decrease the metabolism of {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Mefloquine"
]
],
[
[
"Trifluoperazine",
"{u} may increase the hypotensive activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Mefloquine"
]
]
] |
Trifluoperazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mefloquine (Compound)
Trifluoperazine (Compound) upregulates NPC1 (Gene) and NPC1 (Gene) is upregulated by Mefloquine (Compound)
Trifluoperazine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Mefloquine (Compound)
Trifluoperazine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Mefloquine (Compound)
Trifluoperazine may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Mefloquine
Trifluoperazine may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Mefloquine
Trifluoperazine may increase the severity of adverse effects when combined with Paliperidone and Paliperidone may increase the QTc prolonging activities of Mefloquine
Trifluoperazine may decrease the metabolism of Azithromycin and Azithromycin may increase the QTc prolonging activities of Mefloquine
Trifluoperazine may increase the hypotensive activities of Sotalol and Sotalol may increase the QTc prolonging activities of Mefloquine
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.